fzmd-10q_20170930.htm

0001564590-17-022672.txt : 20171108 0001564590-17-022672.hdr.sgml : 20171108 20171108152259 ACCESSION NUMBER: 0001564590-17-022672 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171108 DATE AS OF CHANGE: 20171108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fuse Medical, Inc. CENTRAL INDEX KEY: 0000319016 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 591224913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-10093 FILM NUMBER: 171186364 BUSINESS ADDRESS: STREET 1: 1565 NORTH CENTRAL EXPRESSWAY STREET 2: SUITE 220 CITY: RICHARDSON STATE: TX ZIP: 75080 BUSINESS PHONE: 469-862-3030 MAIL ADDRESS: STREET 1: 1565 NORTH CENTRAL EXPRESSWAY STREET 2: SUITE 220 CITY: RICHARDSON STATE: TX ZIP: 75080 FORMER COMPANY: FORMER CONFORMED NAME: GOLF ROUNDS COM INC DATE OF NAME CHANGE: 19991126 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN METALS SERVICE INC DATE OF NAME CHANGE: 19920703 10-Q 1 fzmd-10q_20170930.htm 10-Q fzmd-10q_20170930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-10093

Fuse Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware		59-1224913
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1565 N. Central Expressway, Suite 220, Richardson, TX		75080
(Address of principal executive offices)		(Zip Code)

(469) 862-3030

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☐	(Do not check if smaller reporting company)	Smaller reporting company	☒
Emerging growth company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new of revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Indicate the number of shares outstanding of each of the registrant’s classes of Common Stock, as of the latest practicable date: As of November 6, 2017, 18,215,808 shares of the registrant’s Common Stock were outstanding.

FUSE MEDICAL, INC.

FORM 10-Q

INDEX

			PAGE
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements		F-1
	Condensed Balance Sheets at September 30, 2017 (Unaudited) and December 31, 2016		F-1
	Condensed (Unaudited) Statements of Operations for the Three-months and Nine-months Ended September 30, 2017 and 2016		F-2
	Condensed (Unaudited) Statement of Changes in Stockholders' Equity for the Nine-months Ended September 30, 2017		F-3
	Condensed (Unaudited) Statements of Cash Flows for the Nine-months Ended September 30, 2017 and 2016		F-4
	Notes to Condensed (Unaudited) Financial Statements		F-5
Item 2.		Management's Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3.		Quantitative and Qualitative Disclosures About Market Risk	8
Item 4.		Controls and Procedures	8
PART II. OTHER INFORMATION
Item 1.		Legal Proceedings	9
Item 1A.		Risk Factors	9
Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds	9
Item 3.		Defaults upon Senior Securities	9
Item 4.		Mine Safety Disclosures	9
Item 5.		Other Information	9
Item 6.		Exhibits	9
Signatures			11

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

FUSE MEDICAL, INC.

CONDENSED BALANCE SHEETS

	September 30, 2017			December 31, 2016
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	472,246		$	667,475
Accounts receivable		285,463			58,065
Inventories		8,493			25,326
Prepaid expenses and other current assets		24,704			3,528
Total current assets		790,906			754,394
Property and equipment, net		2,029			8,931
Security deposit		3,822			3,822
Total assets	$	796,757		$	767,147
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	61,764		$	83,410
Accounts payable - related parties		110,626			77,178
Accrued expenses		95,104			5,097
Note payable - related parties		150,000			150,000
Deferred rent - short term		-			160
Total current liabilities		417,494			315,845
Deferred rent - long term		-			687
Total liabilities		417,494			316,532
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding		-			-
Common stock, $0.01 par value; 100,000,000 shares authorized, 18,215,808 and 15,890,808 shares issued and outstanding		162,158			158,908
Additional paid-in capital		3,210,560			3,192,686
Accumulated deficit		(2,993,455	)		(2,900,979	)
Total stockholders' equity		379,263			450,615
Total liabilities and stockholders' equity	$	796,757		$	767,147

The accompanying notes are an integral part of these condensed financial statements.

F-1

FUSE MEDICAL, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

(Amounts in dollars, except per share data)	For the Three-months Ended September 30, 2017			For the Three-months Ended September 30, 2016			For the Nine- months Ended September 30, 2017			For the Nine- months Ended September 30, 2016
Revenues	$	428,204		$	107,584		$	911,033		$	421,170
Cost of revenues (primarily from related party, see note 8)		169,817			42,536			333,119			144,654
Gross profit		258,387			65,048			577,914			276,516
Operating expenses:
General, administrative and other		216,874			178,633			686,902			590,147
Loss on disposal of property and equipment		3,058			-			3,365			1,580
Depreciation		384			3,501			3,237			10,666
Total operating expenses		220,316			182,134			693,504			602,393
Operating income (loss)		38,071			(117,086	)		(115,590	)		(325,877	)

Interest expense		(6,806	)		(31,824	)		(20,194	)		(35,324	)
Extinguishment of debt		-			35,517			43,308			35,517

Net income (loss)	$	31,265		$	(113,393	)	$	(92,476	)	$	(325,684	)
Net income (loss) per common share - basic	$	0.00		$	(0.02	)	$	(0.01	)	$	(0.05	)
Net income (loss) per common share - diluted	$	0.00		$	-		$	-		$	-
Weighted average number of common shares outstanding - basic		15,890,808			6,890,808			15,890,808			6,890,808
Weighted average number of common shares outstanding - diluted		17,047,291			-			-			-

The accompanying notes are an integral part of these condensed financial statements.

F-2

FUSE MEDICAL, INC.

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(Unaudited)

	Common Stock				Additional Paid-In		Accumulated
(Amounts in dollars, except per share data)	Shares		Amount		Capital		Deficit			Total
Balance, December 31, 2016		15,890,808	$	158,908	$	3,192,686	$	(2,900,979	)	$	450,615
Issuance of restricted stock for services		2,325,000		3,250		17,874		-			21,124
Net loss		-		-		-		(92,476	)		(92,476	)
Balance, September 30, 2017		18,215,808	$	162,158	$	3,210,560	$	(2,993,455	)	$	379,263

The accompanying notes are an integral part of these condensed financial statements.

F-3

FUSE MEDICAL, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Nine- months Ended September 30, 2017			For the Nine- months Ended September 30, 2016
Cash flows from operating activities
Net loss	$	(92,476	)	$	(325,684	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt discount		-			28,499
Depreciation		3,237			10,666
Loss on disposal of property and equipment		3,365			1,580
Extinguishment of debt		(43,308	)		(35,517	)
Stock-based compensation		21,124			-
Changes in operating assets and liabilities
Accounts receivable		(227,398	)		275,683
Inventories		16,833			49,618
Prepaid expenses and other receivables		(21,176	)		13,604
Accounts payable		21,662			(146,096	)
Accounts payable - related parties		33,448			(13,604	)
Accrued expenses		88,312			2,170
Deferred revenues		-			91,534
Deferred rent		848			824
Net cash (used in) provided by operating activities		(195,529	)		(46,723	)
Cash flows from investing activities
Proceeds from the disposal of property and equipment		300			300
Net cash provided by investing activities		300			300
Cash flows from financing activities
Proceeds from issuance of promissory notes to related parties		-			100,000
Net cash provided by financing activities		-			100,000
Net (decrease) increase in cash and cash equivalents		(195,229	)		53,577
Cash and cash equivalents - beginning of period		667,475			8,157
Cash and cash equivalents - end of period	$	472,246		$	61,734
Supplemental disclosure of cash flow information:
Interest Paid	$	-		$	5,250

The accompanying notes are an integral part of these condensed financial statements.

F-4

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTHS ENDED SEPTEMBER 30, 2017
(Unaudited)

Note 1. Nature of Operations

Overview

The Company was initially incorporated in 1968 as Golf Rounds.com, Inc., a Delaware corporation. Effective May 28, 2014, the Company amended its certificate of incorporation to change its name from “GolfRounds.com, Inc.” to “Fuse Medical, Inc.” (the “Company”). Then, also on May 28, 2014, the Company merged with and into Fuse Medical, LLC, with Fuse Medical, LLC surviving as a wholly owned subsidiary of Fuse Medical, Inc (“Legacy Fuse”). The transaction was accounted for as a reverse merger with Fuse Medical, Inc. deemed the legal acquirer, and Fuse Medical, LLC deemed the accounting acquirer. During 2015, Certificates of Termination were filed for Fuse Medical, LLC and its two subsidiaries.

On December 19, 2016 (the “Closing Date”), the Company entered into a definitive Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), and Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg (“RMI” and, together with NC 143, the “Investors”), pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. The closing of the Purchase Agreement resulted in a change in control of the Company whereby the Investors acquired a majority interest in the Company. Effective as of the Closing Date, Mark W. Brooks became the Chairman of the Board of Directors and Christopher C. Reeg became the Chief Executive Officer of the Company.

The Company distributes a broad portfolio of orthopedic implants including internal and external fixation products, upper and lower extremity plating and total joint reconstruction, soft tissue fixation and augmentation for sports medicine procedures, and full spinal implants for trauma, degenerative disc disease and deformity indications (“Orthopedic Implants”). The Company also supports its broad portfolio of Orthopedic Implants with human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”). The Company’s principal supplier is CPM Medical Consultants, LLC (“CPM”) a company owned and controlled by the Company’s Chairman of the Board of Directors. The Company strives to provide cost savings and quality products to its customers, which include hospitals and medical facilities.

Basis of Presentation

The interim condensed financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading.

The condensed balance sheet information as of December 31, 2016, was derived from the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 20, 2017 (“2016 Annual Report”). These condensed financial statements should be read in conjunction with the 2016 Annual Report.

The results of operations for the three and nine-months ended September 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period.

F-5

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTHS ENDED SEPTEMBER 30, 2017
(Unaudited)

Going Concern

The accompanying condensed financial statements have been prepared as if the Company will continue as a going concern. For the nine-month period ended September 30, 2017, the Company used cash in operations of $195,529, of which $92,476 represented a net loss. The Company’s ability to continue as a going concern is dependent upon the ability of the Company’s management to successfully execute its restructuring and rebranding strategies while increasing revenue growth and profitability. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s 2016 audited financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern.

The Company’s management expects to fund its future business development activities and its working capital needs largely from improved future operations and other traditional financing sources, such as a revolving line of credit facility, term notes, or additional private placements until such time sufficient funds are provided by operations. There can be no assurance the Company’s financing efforts will be successful, or if the Company’s management will be able to achieve sufficient revenue and profitability growth from operations. Additional financing, may include restrictions on the Company’s operations, or with equity financing may result in the Company’s stockholders’ ownership being diluted.

The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2. Significant Accounting Policies

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the condensed financial statements. Actual results could differ from those estimates. Significant estimates in the accompanying condensed financial statements may include allowance for doubtful accounts, valuation of inventories, the estimates of fixed assets useful lives, the valuation of property and equipment, the valuation allowance on deferred tax assets, and the fair value calculation of stock-based awards.

Net Income (Loss) Per Common Share

Basic net income (loss) per common share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. As of September 30, 2016, 604,788 outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive.

Fair Value Measurements

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets,

Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities, and

F-6

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTHS ENDED SEPTEMBER 30, 2017
(Unaudited)

Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded value of notes payable approximates their fair value based upon their effective interest rates.

Reclassifications

Certain amounts in the accompanying condensed financial statements as of September 30, 2016, and for the three-months and nine-months then ended, have been reclassified to conform to the presentation of September 30, 2017 condensed financial statements for the three-months and nine-months then ended. These include deferred rent and depreciation expense, previously reported as a component of accrued expenses and general, administrative and other expenses, respectively.

Cash and Cash Equivalents

The Company considers highly liquid investments with maturities of three-months or less at the time of purchase to be cash equivalents. There were no cash equivalents at September 30, 2017 and 2016. The Company maintains its cash in a financial institution demand deposit account that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through September 30, 2017. As of September 30, 2017, and December 31, 2016, there were deposits of $231,498 and $421,636, respectively, greater than federally insured limits.

Accounts Receivable and Allowance for Doubtful Accounts Receivable

Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. Payment trends and receivable amounts outstanding for an extended period beyond contractual terms are examples of these indicators. Accounts deemed uncollectible are written off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. The Company’s Management has determined that no allowance for doubtful accounts was necessary at September 30, 2017 and December 31, 2016.

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market. Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit.

Income Taxes

The Company uses the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company has deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are subject to periodic recoverability assessments. Realization of the deferred tax assets, net of deferred tax liabilities, is principally dependent upon achievement of projected future taxable income.

The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. As of September 30, 2017, the Company had no liabilities for uncertain tax positions. The Company's policy is to recognize interest and penalties related to income tax matters as a component of income tax expense. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

Revenue Recognition

F-7

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTHS ENDED SEPTEMBER 30, 2017
(Unaudited)

The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) the fees are fixed or determinable, (iii) no significant Company obligations remain, and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs).

Stock-Based Compensation

The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s Statement of Operations. The Company estimates the fair value of restricted stock awards (“RSA”) to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s Statements of Operations. The Company accounts for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management do not believe that this guidance will have a material impact on its financial statements and disclosures.

All other ASUs issued and not yet effective for the nine-months ended September 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position of results of operations.

F-8

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTHS ENDED SEPTEMBER 30, 2017
(Unaudited)

Note 3. Property and Equipment

Property and equipment consisted of the following at September 30, 2017 and December 31, 2016:

	September 30, 2017			December 31, 2016
Computer equipment	$	-		$	29,290
Furniture and fixtures		5,047			6,347
Leasehold improvements		-			6,728
Office equipment		1,580			1,580
		6,627			43,945
Less: accumulated depreciation		(4,598	)		(35,014	)
Property and equipment, net	$	2,029		$	8,931

Depreciation expense for the three-months ended September 30, 2017 and 2016 was $384 and $3,501, respectively. Depreciation expense for the nine-months ended September 30, 2017 and 2016 was $3,237 and $10,666, respectively. During the nine-months ended September 30, 2017 the Company disposed of furniture and fixtures with a net book value of $3,665 for proceeds of $300, resulting in a loss of $3,365 on disposal of property and equipment.

Note 4. Notes Payable – Related Parties

During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. This resulted in a beneficial conversion feature in the aggregate amount of $117,500, which was treated as a discount to each of the promissory notes and amortized over the term of each respective promissory note, maturing on December 31, 2016, the date in which the beneficial conversion feature was fully amortized.

During the three-months ended September 30, 2017 and 2016, interest expense of $6,806 and $1,750, respectively, was recognized on outstanding notes payable – related parties and are reflected within interest expense on the accompanying condensed statements of operations. During the nine-months ended September 30, 2017 and 2016, interest expense of $20,194 and $5,250, respectively, was recognized on outstanding notes payable – related parties and are reflected within interest expense on the accompanying condensed statements of operations. As of September 30, 2017, and December 31, 2016, accrued interest payable was $25,290 and $5,096, respectively, which is included in accrued expenses on the accompanying condensed balance sheets.

Note 5. Commitments and Contingencies

Legal Matters

On January 27, 2014, M. Richard Cutler and Cutler Law Group, P.C. (the “Plaintiffs”) filed a complaint in the District Court of Harris County, Texas, 2014-03355, against Legacy Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc. (the “Defendants”). On April 21, 2014, the complaint was dismissed for “want of prosecution.” On September 18, 2015, Plaintiffs refiled a complaint in the District Court of Harris County, Texas, Cause No. 2015-55652 and added PH Squared, LLC as an additional Plaintiff, as more fully described in “Legal Matters” included in Note 6 in the Company’s 2016 Annual Report, which is herein incorporated by reference. During April 2017, one of the named individuals in the complaint filed for bankruptcy protection. There is currently no trial date set.

The Company’s management continues to believe that the lawsuit is completely without merit and will vigorously contest it and protect the Company’s interests.

F-9

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTHS ENDED SEPTEMBER 30, 2017
(Unaudited)

Accounts Payable

During the nine-months ended September 30, 2017, the Company recorded a gain of $43,308 on extinguishment of long-aged outstanding payables owed to a former law firm for $32,052 and liabilities aggregating $11,256 owed to the Company’s beneficial owners for services provided to the Company and is reflected within extinguishment of debt on the accompanying condensed statements of operations. The Company’s management believes if these items were contested, the probable outcome would be favorable primarily due to statute of limitations.

Note 6. Stockholders' Equity

Stock Incentive Plans

The Company has a stock-based compensation plan which provides for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors; the 2017 Equity Incentive Plan of Fuse Medical, Inc. (the “2017 Plan”), which was adopted by the Company’s Board of Directors (the “Board”) on April 5, 2017. The awards are subject to a vesting schedule as set forth in individual agreements.

On September 21, 2017, the Board approved an amendment to the 2017 Plan to increase the number of shares of common stock authorized for issuance under the Plan from 1,500,000 shares of common stock to 2,500,000 shares of common stock.

The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the nine-months ended September 30, 2017 is presented below:

	No. of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Balance outstanding at December 31, 2016		1,304,788		$	0.22		4.3	$	35,000
Granted		-			-		-		-
Exercised		-			-		-		-
Forfeited		-			-		-		-
Expired		(2,736	)		-		-		-
Balance outstanding at September 30, 2017		1,302,052		$	0.20		3.5	$	3,277,000
Exercisable at September 30, 2017		1,302,052		$	0.20		3.5	$	3,277,000

Restricted Common Stock

On September 21, 2017, the Board voted to award an aggregate of 325,000 shares of common stock of the Company, par value $0.01 per share, through the granting of RSAs pursuant to the 2017 Plan, to the members of the Board as annual compensation for services rendered to the Company as Board members. Each member of the Board was granted an RSA constituting 65,000 shares of common stock. The common stock within each RSA had an aggregate fair market value of $0.78 per share on the date of grant ($253,500 in the aggregate) and each RSA will fully vest upon the one year anniversary of the date of grant or September 21, 2018. As of September 30, 2017, the Company had amortized $21,124 relating to the vesting of these shares which is included in general and administrative expenses, and $232,376 which will be recognized as an expense in future periods as the shares vest.

Also on September 21, 2017, the Board awarded an aggregate of 2,000,000 shares of common stock through the granting of RSAs pursuant to the 2017 Plan to the Company’s independent Board of Directors (“Independent Members”) as special services compensation. The Independent Members were each granted an RSA constituting 1,000,000 shares of common stock. The common stock within each RSA had a fair market value of $0.78 on the date of grant, ($1,560,000 in the aggregate) and each RSA will fully vest upon the earlier of a change in control of the Company or the Company’s listing on a national securities exchange. As of September 30, 2017, the Company had not amortized any amounts relating to the vesting of these shares due to the uncertainty of meeting these milestones.

The following table summarizes restricted common stock activity:

F-10

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTHS ENDED SEPTEMBER 30, 2017
(Unaudited)

	Number of Shares		Fair Value		Weighted Average Grant Date Fair Value
Non-vested, December 31, 2016		-	$	-	$	-
Granted		2,325,000		1,813,500		0.78
Vested		-		-		-
Forfeited		-		-		-
Non-vested, September 30, 2017		2,325,000	$	1,813,500	$	0.82

Note 7. Concentrations

Concentration of Revenues, Accounts Receivable and Suppliers

For the three-months and nine-months ended September 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:

	For the Three-months Ended September 30, 2017			For the Three-months Ended September 30, 2016			For the Nine-months Ended September 30, 2017			For the Nine-months Ended September 30, 2016
Customer 1		40.5	%		0.0	%		39.3	%		0.0	%
Customer 2		22.5	%		0.0	%		23.6	%		0.0	%
Customer 3		22.1	%		0.0	%		15.2	%		0.0	%
Customer 4		13.9	%		0.0	%		19.0	%		0.0	%
Totals		99.0	%		0.0	%		97.1	%		0.0	%

At September 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:

	September 30, 2017			December 31, 2016
Customer 1		48.3	%		0.0	%
Customer 2		21.0	%		0.0	%
Customer 3		20.4	%		10.3	%
Totals		89.7	%		10.3	%

The Company’s principal supplier is CPM (see Note 8) and provided 10% or greater of the Company’s goods purchased for the periods presented below:

	For the Three-months Ended September 30, 2017			For the Three-months Ended September 30, 2016			For the Nine-months Ended September 30, 2017			For the Nine-months Ended September 30, 2016
Supplier 1 - related party		99.6	%		88.3	%		98.9	%		38.1	%
Supplier 2		0.0	%		11.7	%		0.9	%		33.3	%
Supplier 3		0.0	%		0.0	%		0.0	%		28.6	%
Totals		99.6	%		100.0	%		99.8	%		100.0	%

Note 8. Related Party Transactions

The Company entered into a distributor agreement with CPM effective August 2, 2012, pursuant to which the Company acts as a non-exclusive distributor of certain amniotic membrane products. The term of the agreement is one year and renews on each annual

F-11

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND NINE-MONTHS ENDED SEPTEMBER 30, 2017
(Unaudited)

anniversary date for successive one-year terms unless it is terminated in writing by either party. Effective January 1, 2017, this agreement was amended to expand and include Orthopedic Implants and a broader assortment of Biologics. (See Note 1)

During the three-months ended September 30, 2017 and 2016 the Company sold $169,799 and $35,420, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the nine-months ended September 30, 2017 and 2016 the Company sold $327,381 and $48,420, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations.

During the three-months ended September 30, 2017 and 2016 the Company purchased $173,456 and $39,600, respectively, of its products from CPM. During the nine-months ended September 30, 2017 and 2016 the Company purchased $331,564 and $52,800, respectively, of its products from CPM. The balance due to CPM at September 30, 2017 and December 31, 2016 was $110,626 and $77,178, respectively, and are reflected within accounts payable – related parties on the accompanying condensed balance sheets.

During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. The balance of the notes payable at September 30, 2017 and December 31, 2016 was $150,000.

On December 19, 2016, the Company entered into the Purchase Agreement by and among the Company, NC 143, and RMI, pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. (See Note 1)

During the three-months and nine-months ended September 30, 2017, CPM provided shared services for back-office functions such as accounting, finance, supply chain management, and sales support. In addition, the Company’s Chief Executive Officer and Interim Chief Financial Officer provided services at no charge to the Company. The financial statements do not reflect an estimate of fair value of these services.

Effective January 1, 2017 the Company engaged AmBio Staffing, LLC, a Texas licensed professional employment organization to provide payroll processing, employee benefit administration, and related human capital services. AmBio Staffing, LLC is controlled by the Company’s Chairman of the Board of Directors. There was no balance due to AmBio Staffing at September 30, 2017 and December 31, 2016. For the three-months and nine-months ended September 30, 2017, $371 and $7,248 of fees were paid to AmBio Staffing, LLC for such services, respectively and are reflected within general, administrative and other expenses on the accompanying condensed statements of operations.

On July 19, 2017, the Company entered into a commercial property lease agreement for its new office space located at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080, dated to be effective July 14, 2017, by and between the Company and 1565 North Central Expressway, LP—an entity controlled by the Company’s Chairman of the Board of Directors. The Lease provides that the Company will pay rent of $4,000 per month and the initial term of the Lease begins on July 14, 2017 and ends December 31, 2017.

Note 9. Subsequent Events

On October 4, 2017, the Board approved an additional amendment to the 2017 Plan to increase the number of shares of common stock authorized for issuance under the 2017 Plan from 2,500,000 shares of common stock to 4,500,000 shares of common stock.

F-12

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Explanatory Note

As used in this report on Form 10-Q, “we”, “us”, “our”, and the “Company” refer to Fuse Medical, Inc.

Overview

We are an emerging national medical device distributor providing a broad portfolio of orthopedic implants including internal and external fixation products, upper and lower extremity plating and total joint reconstruction, soft tissue fixation and augmentation for sports medicine procedures, full spinal implants for trauma, degenerative disc disease and deformity indications, (“Orthopedic Implants”), and human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”) to support orthopedic surgeries and wound care. Our Biologics include:

•

Osteo Biologics – Cellular bone allografts, synthetics.

•

Tendon and Tissue – Ligaments, tendons, dermal graft.

•

Regenerative tissues – Amniotic membrane (dry), amniotic membrane (injectable), and amniotic fluids (frozen).

•

Autologous products – Platelet Rich Plasma, and Bone Marrow Aspirate concentration systems.

Medical device companies such as ours typically experience seasonality between the first two quarters compared to the last two quarters of the year. We believe this is in part the result of patient annual healthcare deductibles being met during the last two quarters of the calendar year compared to the first two quarters of the calendar year.

As more fully described in our Annual Report on Form 10-K for the year ended December 31, 2016, as filed on March 20, 2017 (the “2016 Annual Report”), during December 2016 the change in control over a majority of our issued and outstanding voting common stock resulted in new executive leadership.

Our results-oriented leadership has the following strategic objectives:

•

Scalable cost-effective infrastructure.

•

Broaden and expand product offerings.

•

Migrate sales model from fixed cost to variable cost.

•

Acquire strategic independent distributors.

During the nine-months ended September 30, 2017, we have successfully executed the following milestones:

•

Expanded product offerings from two manufacturers to over forty.

•

Effective January 1, 2017 all supply-chain, finance, sales support and other related functions were outsourced to a shared service platform providing scalability. We believe the shift to a shared service platform will result in a strengthening of our internal controls.

•

Payroll and human capital functions were outsourced to a licensed Texas professional employment organization which is controlled by our Chairman of the Board of Directors.

•

Legacy sales management was replaced with established independent contractors who contribute existing books of business with strong revenue and significant industry experience which we believe provides us with improved cost effectiveness with respect to distribution.

•

Fixed costs contracts with third-party service providers have been renegotiated for more favorable terms or terminated.

•

Conducted formalized initiatives:

To identify synergistic acquisition targets;

Vertical supply chain integration opportunities, and

Strategic high value new vendor relationships.

We continue to believe our comprehensive selection of Orthopedic Implants and Biologics products will prove pivotal in our ability to acquire new customers and increase revenues and profitability as demonstrated by our three months-ended March 31, 2017, June 30, 2017, and September 30, 2017 results of operations over the prior year. We expect to offer compensation and other valuable long-term incentives to key distributors, executive leadership and key employees as we continue to expand our strategic partnerships and network arrangements.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the U.S., (or “GAAP”), requires our management to make judgments, assumptions and estimates that affect the amounts of revenue,

expenses, income, assets and liabilities, reported in our condensed financial statements and accompanying notes. Understanding our accounting policies and the extent to which our management uses judgment, assumptions and estimates in applying these policies is integral to understanding our financial statements.

We describe our most significant accounting policies in Note 2, “Significant Accounting Policies” of our condensed notes to the financial statements beginning on page F-1 and found elsewhere in this report, and in our 2016 Annual Report. These policies are considered critical because they may result in fluctuations in our reported results from period to period due to the significant judgments, estimates and assumptions about highly complex and inherently uncertain matters and because the use of different judgments, assumptions or estimates could have a material impact on our financial condition or results of operations. We evaluate our critical accounting estimates and judgments required by our policies on an ongoing basis and update them as appropriate based on changing conditions.

There have been no material changes to our critical accounting policies during the period covered by this report.

Recent Accounting Pronouncements

We describe recent accounting pronouncements in Note 2, “Recent Accounting Pronouncements” of our condensed notes to the financial statements beginning of page F-1.

Results of Operations

The following table sets forth certain financial information from our condensed statements of operations along with a percentage of net revenue and should be read in conjunction with the condensed financial statements and related notes included in this report.

	For the Three-months Ended September 30, 2017			(%)		For the Three-months Ended September 30, 2016			(%)		For the Nine-months Ended September 30, 2017			(%)		For the Nine-months Ended September 30, 2016			(%)
Revenues	$	428,204			100%	$	107,584			100%	$	911,033			100%	$	421,170			100%
Cost of revenues		169,817			40%		42,536			40%		333,119			37%		144,654			34%
Gross profit		258,387			60%		65,048			60%		577,914			63%		276,516			66%
Operating expenses:
General, administrative and other		216,874			51%		178,633			166%		686,902			75%		590,147			140%
Loss on disposal of property and equipment		3,058			1%		-			0%		3,365			0%		1,580			0%
Depreciation		384			0%		3,501			3%		3,237			0%		10,666			3%
Total operating expenses		220,316			51%		182,134			169%		693,504			76%		602,393			143%
Operating income (loss)		38,071			9%		(117,086	)		-109%		(115,590	)		-13%		(325,877	)		-77%

Interest expense		(6,806	)		-2%		(31,824	)		-30%		(20,194	)		-2%		(35,324	)		-8%
Extinguishment of debt		-			0%		35,517			33%		43,308			5%		35,517			8%

Net income (loss)	$	31,265			7%	$	(113,393	)		-105%	$	(92,476	)		-10%	$	(325,684	)		-77%

Three-months Ended September 30, 2017 Compared to Three-months Ended September 30, 2016

Revenues

For the three-months ended September 30, 2017, revenues were $428,204 compared to $107,584 for the three-months ended September 30, 2016, an increase of $320,620, or approximately 298%. The increase in revenues is primarily a result of an approximate 84% increase in the medical cases in which our products are used (“Cases,” and each a “Case”) and an approximate 214% increase in average price per Case. We gained five new customers, offset, by three customers becoming inactive.

Cost of Revenues

For the three-months ended September 30, 2017, our cost of revenues was $169,817, compared to $42,536 for the three-months ended September 30, 2016, representing an increase of $127,281, or approximately 299%. The increase in cost of revenues is primarily attributable to an approximate 84% increase in revenue that resulted from an increase in the number of Cases and a shift from Cases in which we supplied Biologics to Cases in which we supplied Orthopedic Implants, which carry a higher average cost per Case

compared to Biologics, offset, in part, by productivity improvements in supply chain operations. These productivity improvements include the integration of a perpetual inventory system having FDA tracking capabilities as well as transitioning our product fulfillment and delivery model to a just in time approach. For the three-months ended September 30, 2017 and 2016, Orthopedic Implants represented 84% and 3% of revenues, respectively.

Gross Profit

For the three-months ended September 30, 2017, we generated a gross profit of $258,387, compared to $65,048 for the three-months ended September 30, 2016, an increase of $193,339, or approximately 297%. As a percentage of revenue, gross profit was approximately 60% for both the three-months ended September 30, 2017 and 2016, respectively.

General, Administrative and Other Expenses

For the three-months ended September 30, 2017, general, administrative and other operating expenses increased to $216,874 from $178,633 for the three-months ended September 30, 2016, representing an increase of $38,241, or approximately 21%. As a percentage of revenue, general, administrative and other operating expenses were approximately 51% and 166% for the three-months ended September 30, 2017 and 2016, respectively. The decrease as a percentage of revenues is approximately 115% and is primarily the result of a decrease of approximately 89% for payroll and benefit costs, a decrease of approximately 25% in professional fees, a 21% reduction in other corporate expenses, approximately 2% of savings from our exit of sponsorship programs, offset, in part, by an approximate 15% increase in legal and valuation study costs relating to our corporate restructuring and rebranding strategies, and an approximately 7% increase in commission expense.

Depreciation Expense

For the three-months ended September 30, 2017, depreciation expense decreased to $384 from $3,501 for the three-months ended September 30, 2016, representing a decrease of $3,117 or approximately 89%. The decrease is primarily related to a reduction in fixed assets.

Interest Expense

For the three-months ended September 30, 2017, interest expense decreased to $6,806 from $31,824 for the three-months ended September 30, 2016. The $25,018 decrease in interest expense is primarily driven by a $28,499 reduction in beneficial ownership discount amortization, a $1,750 reduction in interest expense related to a note payable with a beneficial owner, offset by an increase in interest expense of $5,230 related to the notes payables – related parties.

Extinguishment of Debt

For the three-months ended September 30, 2016 we recorded $35,517 on extinguishment of debt relating to settlement of outstanding accounts payable owed to our former legal counsel for $25,000. For the three-months ended September 30, 2017, we did not record any amount with respect to the extinguishment of debt.

Net Loss

For the three-months ended September 30, 2017, we had a net income of $31,265 compared to a net loss of $113,393 for the three-months ended September 30, 2016, representing an increase in profitability by $144,658, an increase of approximately 128%. The increase in profitability as a percentage of revenues was approximately 112% and is primarily a result of a (i) reduction of approximately 115% in general, administrative and other operating expenses, (ii) a reduction in depreciation expense of approximately 3% and (iii) a decrease in interest expense of approximately 28%. The increase in profitability as percentage of revenues was offset, in part, by approximately a 33% decrease in extinguishment of debt and an approximately 1% increase in loss on disposal of property and fixed assets.

Nine-months Ended September 30, 2017 Compared to Nine-months Ended September 30, 2016

Revenues

For the nine-months ended September 30, 2017, revenues were $911,033, compared to $421,170 for the nine-months ended September 30, 2016, an increase of $489,863, or approximately 116%. The increase in revenues is primarily a result of an approximate 34% increase in the number of Cases and an approximate 82% increase in average price per Case. We gained six new customers, offset, by six customers becoming inactive.

Cost of Revenues

For the nine-months ended September 30, 2017, our cost of revenues was $333,119, compared to $144,654 for the nine-months ended September 30, 2016, representing an increase of $188,465, or approximately 130%. The increase in cost of revenues is primarily attributable to an approximate 34% increase in the number of Cases and a shift from Cases in which we supplied Biologics to Cases in which we supplied Orthopedic Implants which carry a higher average cost per Case compared to Biologics, offset, in part, by productivity improvements in supply chain operations. The increase as a percentage of revenues is approximately 3% and is primarily a result of our strategy to increase Orthopedic Implants Case volume, offset, in part, by productivity improvements in supply chain operations. These productivity improvements include the integration of a perpetual inventory system having FDA tracking capabilities as well as transitioning our product fulfillment and delivery model to a just in time approach. For the nine-months ended September 30, 2017 and 2016, Orthopedic Implants represented 79% and 4% of revenues, respectively.

Gross Profit

For the nine-months ended September 30, 2017, we generated a gross profit of $577,914, compared to $276,516 for the nine-months ended September 30, 2016, an increase of $301,398, or approximately 109%. As a percentage of revenue, gross profit was approximately 63% and 66% for the nine-months ended September 30, 2017 and 2016, respectively.

General, Administrative and Other Expenses

For the nine-months ended September 30, 2017, general, administrative and other operating expenses increased to $686,902 from $590,147 for the nine-months ended September 30, 2016, representing an increase of $96,755, or approximately 16%. As a percentage of revenue, general, administrative and other was approximately 75% and 140% for the nine-months ended September 30, 2017 and 2016, respectively. This decrease as a percentage of revenues is approximately 65% and is primarily the result of a reduction of approximately 55% for payroll and benefit costs, approximately 16% for professional fees, approximately 12% for other corporate fixed costs, approximately 4% of savings from our exit of sponsorship programs, offset, in part, by an approximately 20% increase in legal and valuation study costs relating to our corporate restructuring and rebranding initiatives and approximately 2% increase in commission expense.

Depreciation Expense

For the nine-months ended September 30, 2017, depreciation expense decreased to $3,237 from $10,666 for the nine-months ended September 30, 2016, representing a decrease of $7,429 or approximately 70%. The decrease is primarily related to a reduction in fixed assets.

Interest Expense

For the nine-months ended September 30, 2017, interest expense decreased to $20,194 from $35,324 for the nine-months ended September 30, 2016. The $15,130 decrease in interest expense is primarily driven by a $28,499 reduction in beneficial ownership discount amortization, a $5,250 reduction in interest expense related to a note payable with a beneficial owner, offset by an increase in interest expense of $18,619 related to the notes payable – related parties.

Extinguishment of Debt

For the nine-months ended September 30, 2017 and 2016, we recorded $43,308 and $35,517, respectively, for extinguishment of debt. During the nine-months ended September 30, 2017, the extinguishment of debt primarily related to long-aged outstanding payables owed to a former law firm for $32,052 and liabilities aggregating $11,256 owed to the Company’s beneficial owners for services provided to the Company. During the nine-months ended September 30, 2016, our recording for the extinguishment of debt primarily resulted from the settlement of outstanding accounts payable of $60,517, owed to our former legal counsel for a payment of $25,000.

Net Loss

For the nine-months ended September 30, 2017, we generated a net loss of $92,476 compared to a net loss of $325,684 for the nine-months ended September 30, 2016, representing an increase in profitability by $233,208, an increase of approximately 72%. The increase in profitability as a percentage of revenues is approximately 68% and is primarily due to (i) an approximate 65% reduction of general, administrative and other costs, (ii) an approximate 3% reduction in depreciation expense and (iii) an approximate 6% reduction in interest expense. The increase in profitability as a percentage of revenue was offset, in part, by approximately 3% extinguishment of debt and approximately 3% reduction of gross profit.

Liquidity and Capital Resources

A summary of our cash flows is as follows:

	Nine Months Ended September 30,
	2017			2016
Net cash used in operating activities	$	(195,529	)	$	(46,723	)
Net cash provided by investing activities		300			300
Net cash provided by financing activities		-			100,000
Net (decrease) increase in cash and cash equivalents	$	(195,229	)	$	53,577

Net Cash (Used in) Provided by Operating Activities

Net cash used in operating activities during the nine-months ended September 30, 2017 resulted primarily from a net loss of $92,476, a $227,398 increase in accounts receivable, a $21,176 increase in prepaid expenses and other receivables, $15,582 of adjustments in stock-based compensation, depreciation expense and other non-cash items, net, offset in part, by $21,662 increase in accounts payable, $33,448 increase in accounts payable-related parties, $88,312 increase in accrued expenses, $16,833 reduction in inventories, and $848 increase in deferred rent.

Net Cash Provided by Investing Activities

Net cash provided by investing activities for the nine-months ended September 30, 2017 resulted cash proceeds from the disposal of property and equipment of $300.

Liquidity

At September 30, 2017, we had working capital of $373,412, including $472,246 in cash and cash equivalents. As of November 6, 2017, we had approximately $517,000 in available cash. Our cash is concentrated in a large financial institution. We believe our ability to continue as a going concern is dependent, in part, on our ability to successfully execute our restructuring and rebranding strategies, as well as expansion of our network of independent distributors, which we believe will increase our revenue growth and profitability. We believe these strategies, along with our current cash balance and anticipated cash generated by increasingly profitable operations will be enough to sustain operations through September 30, 2018.

The accompanying condensed financial statements have been prepared as if we will continue as a going concern. For the nine-month period ended September 30, 2017, we had net cash used in operations of $195,529, of which $92,476 represented a net loss. We expect to fund our future business development activities and working capital needs largely from improved future operations and other traditional financing sources, such as a revolving line of credit facility, term notes, or additional private placements until such time sufficient funds are provided by operations. There can be no assurance our financing efforts will be successful, or if we will be able to achieve sufficient revenue and profitability growth from operations. Additional financing, may include restrictions on our operations, or with equity financing may result in our stockholders’ ownership being diluted.

The estimated costs of operations while we work to increase our revenues are substantially greater than the amount of funds we have on hand. Our existence is dependent upon our ability to execute our restructuring and rebranding strategies and have accessibility to adequate funding as required. There can be no assurance that our efforts will result in profitable operations or provide resolution of our liquidity challenges. See Risk Factors, Item 1A, in our 2016 Annual Report.

In our 2016 Annual Report, our independent registered public accounting firm included an emphasis-of-matter paragraph with respect to our financial statements concerning our assumption that we will continue as a going concern.

Capital Expenditures

For the nine-months ended September 30, 2017, we had no material capital expenditures. We have no material commitments for capital expenditures as of September 30, 2017. These capital expenditures will be allocated across business development initiatives, including investment in inventories and scalable infrastructure.

Cautionary Note Regarding Forward-Looking Statements

This report includes forward-looking statements including statements regarding liquidity.

The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

The results anticipated by any or all of these forward-looking statements might not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include the condition of the capital markets, particularly for smaller companies, willingness of doctors and facilities to purchase the products that we sell and regulatory issues adversely affecting our margins, insurance companies denying reimbursement to facilities who use the products that we sell and/or our ability to sell products. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this item.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Based upon the evaluation required by Section 13a-13(b) of the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and Chief Financial Officer, with the participation of our Board of Directors, continue to believe based on changes we have been making, since our year ended December 31, 2016 that our disclosure controls and procedures, as of September 30, 2017, are significantly improved since December 31, 2016.

Our management is responsible for establishing and maintaining adequate internal controls over our financial reporting. With the new executive leadership team, including the Chief Executive Officer and the Chief Financial Officer, and the significant restructuring and rebranding efforts deemed necessary by our Board of Directors, our management was unable to complete their full assessment regarding the establishment and maintenance of adequate internal controls over our financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control — Integrated Framework. Due to the inability to properly complete this process, we are unable to conclude that internal controls over financial reporting were effective as of that date. Our Board of Directors, Chief Executive Officer, and Chief Financial Officer have engaged an independent third-party to assist in establishing a sustainable framework and processes to ensure adequate internal controls over financial reporting.

Changes in Internal Controls Over Financial Reporting

During the nine-months ended September 30, 2017, we out-sourced our supply chain management, finance, sales support, and other related functions, including payroll processing, employee benefit administration, and related human capital services to companies owned and controlled by our Chairman of the Board of Directors. We believe these arrangements have significantly improved internal controls over financial reporting and have provided us scalability for anticipated growth and expansion, while driving down fixed costs per transaction.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

On January 27, 2014, M. Richard Cutler and Cutler Law Group, P.C. (the “Plaintiffs”) filed a complaint in the District Court of Harris County, Texas, 2014-03355, against Legacy Fuse (See Note 1, “Nature of Operations and liquidity” of our interim condensed notes to the financial statements beginning on page F-1 and found elsewhere in this report), Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc. (the “Defendants”). On April 21, 2014, the complaint was dismissed for “want of prosecution.” On September 18, 2015, Plaintiffs refiled a complaint in the District Court of Harris County, Texas, Cause No. 2015-55652 and added PH Squared, LLC as an additional Plaintiff, as more fully described in “Legal Matters” included in Note 6 in our 2016 Annual Report, which is herein incorporated by reference. During April 2017, one of the named individuals in the complaint filed for bankruptcy protection. There is currently no trial date set.

Our management continues to believe that the lawsuit is completely without merit and will vigorously contest it and protect our interests.

ITEM 1A. RISK FACTORS.

As a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

See the exhibits listed in the accompanying “Exhibit Index”.

EXHIBIT INDEX

Exhibit No.		Description


3.1		Amended and Restated Certificate of Incorporation of the Company (filed as Exhibit 3.1 to the Company’s Form 8-K, filed on September 15, 2014, and incorporated herein by reference).

3.2		Amendment to the Amended and Restated Certificate of Incorporation of the Company (filed as Annex A to the Company’s Information Statement, filed on December 4, 2015, and incorporated herein by reference).


3.3		Bylaws (filed as Exhibit 3.2 to the Company’s Current Report Form 8-K, filed on May 29, 2014, and incorporated herein by reference).


3.4		Certificate of Merger, as filed with the Secretary of State of the State of Delaware on May 28, 2014 (filed as Exhibit 3.3 to the Company’s Form 8-K filed on May 29, 2014, and incorporated herein by reference).


3.5		Amendment No. 1 to the Bylaws (filed as Exhibit 3.1 to the Company’s Form 8-K, filed on December 19, 2016, and incorporated herein by reference).

4.1		2017 Equity Incentive Plan of Fuse Medical, Inc. dated April 5, 2017 (filed as Exhibit 99.2 to the Company’s Form 8-K filed April 6, 2017, and incorporated herein by reference).

4.2		Amendment Number 1 to the 2017 Equity Incentive Plan of Fuse Medical, Inc. dated September 21, 2017 (filed as Exhibit 4.1 to the Company’s Form 8-K/A filed November 6, 2017, and incorporated herein by reference.)

4.3		Amendment Number 2 to the 2017 Equity Incentive Plan of Fuse Medical, Inc. dated October 4, 2017 (filed as Exhibit 4.2 to the Company’s Form 8-K/A filed November 6, 2017, and incorporated herein by reference.)

10.1		Commercial Property Lease Agreement dated July 19, 2017 by and between Fuse Medical, Inc. and 1565 North Central Expressway, LP (filed as Exhibit 10.1 to the Company’s Form 8-K, filed on July 19, 2017, and incorporated herein by reference).

10.2		Assignment of Sublease and Consent, dated July 17, 2017, by and between (i) PBIII-SOP, LP, (ii) PHILLIP GALYEN, PC, d/b/a Bailey & Galyen, (iii) Fuse Medical, Inc., and (iv) LawConnect, Inc. d/b/a GetLegal.com (filed as Exhibit 10.2 to the Company’s Form 8-K, filed on July 19, 2017, and incorporated herein by reference).

10.3		Form of Restricted Stock Award for Board Compensation of Fuse Medical, Inc. (filed as Exhibit 10.1 to the Company’s Form 8-K filed October 10, 2017, and incorporated herein by reference).

10.4		Form of Restricted Stock Award for Special Board Compensation of Fuse Medical, Inc. (filed as Exhibit 10.2 to the Company’s Form 8-K filed October 10, 2017, and incorporated herein by reference).

31.1*		Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


31.2*		Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


32.1**		Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


101.INS *		XBRL Instance Document

101.SCH *		XBRL Taxonomy Extension Schema Document


101.CAL *		XBRL Taxonomy Extension Calculation Linkbase Document


101.DEF *		XBRL Taxonomy Extension Definition Linkbase Document


101.LAB *		XBRL Taxonomy Extension Label Linkbase Document


101.PRE *		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith.

**	Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	FUSE MEDICAL, INC.

Date: November 8, 2017	By:	/s/ Christopher C. Reeg
		Christopher C. Reeg
		Chief Executive Officer and Director (Principal Executive Officer)

Date: November 8, 2017

By:

/s/ William E. McLaughlin, III

William E. McLaughlin, III

Interim Chief Financial Officer and Director

(Principal Financial Officer)

EX-31.1 2 fzmd-ex311_7.htm EX-31.1 fzmd-ex311_7.htm

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Christopher C. Reeg, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Fuse Medical, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 8, 2017	By:	/s/ Christopher C. Reeg
		Christopher C. Reeg
		Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 fzmd-ex312_6.htm EX-31.2 fzmd-ex312_6.htm

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, William E. McLaughlin, III, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Fuse Medical, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 8, 2017	By:	/s/ William E. McLaughlin, III
		William E. McLaughlin, III
		Interim Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 fzmd-ex321_8.htm EX-32.1 fzmd-ex321_8.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Fuse Medical, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, Christopher C. Reeg, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 8, 2017	By:	/s/ Christopher C. Reeg
		Christopher C. Reeg
		Chief Executive Officer (Principal Executive Officer)

In connection with the quarterly report of Fuse Medical, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, William E. McLaughlin, III, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 8, 2017	By:	/s/ William E. McLaughlin, III
		William E. McLaughlin, III
		Interim Chief Financial Officer (Principal Financial Officer)

EX-101.INS 5 fzmd-20170930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure 0000319016 2017-01-01 2017-09-30 0000319016 2017-11-06 0000319016 2017-09-30 0000319016 2016-12-31 0000319016 2017-06-30 0000319016 2017-07-01 2017-09-30 0000319016 2016-07-01 2016-09-30 0000319016 2016-01-01 2016-09-30 0000319016 us-gaap:CommonStockMember 2016-12-31 0000319016 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000319016 us-gaap:RetainedEarningsMember 2016-12-31 0000319016 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0000319016 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0000319016 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0000319016 us-gaap:CommonStockMember 2017-09-30 0000319016 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000319016 us-gaap:RetainedEarningsMember 2017-09-30 0000319016 2015-12-31 0000319016 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember 2017-01-01 2017-09-30 0000319016 us-gaap:AccountsReceivableMember 2017-01-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember 2017-01-01 2017-09-30 0000319016 fzmd:NC143FamilyHoldingsLimitedPartnershipMember 2016-12-19 2016-12-19 0000319016 fzmd:ReegMedicalIndustriesIncorporationMember 2016-12-19 2016-12-19 0000319016 us-gaap:InvestorMember 2016-12-19 2016-12-19 0000319016 us-gaap:ComputerEquipmentMember 2016-12-31 0000319016 us-gaap:FurnitureAndFixturesMember 2017-09-30 0000319016 us-gaap:FurnitureAndFixturesMember 2016-12-31 0000319016 us-gaap:LeaseholdImprovementsMember 2016-12-31 0000319016 us-gaap:OfficeEquipmentMember 2017-09-30 0000319016 us-gaap:OfficeEquipmentMember 2016-12-31 0000319016 us-gaap:FurnitureAndFixturesMember 2017-01-01 2017-09-30 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2016-10-31 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2016-07-01 2016-10-31 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2017-01-01 2017-09-30 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2017-09-30 0000319016 us-gaap:InvestorMember 2017-01-01 2017-09-30 0000319016 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2017-09-30 0000319016 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2016-12-31 0000319016 us-gaap:AccountsPayableMember 2017-01-01 2017-09-30 0000319016 fzmd:FormerLawFirmMember us-gaap:AccountsPayableMember 2017-01-01 2017-09-30 0000319016 us-gaap:BeneficialOwnerMember us-gaap:AccountsPayableMember 2017-01-01 2017-09-30 0000319016 fzmd:TwentySeventeenPlanMember us-gaap:CommonStockMember 2017-04-05 0000319016 fzmd:TwentySeventeenPlanMember us-gaap:CommonStockMember 2017-09-21 0000319016 2016-01-01 2016-12-31 0000319016 us-gaap:CommonStockMember fzmd:TwentySeventeenPlanMember us-gaap:RestrictedStockMember 2017-09-21 0000319016 us-gaap:CommonStockMember fzmd:MembersOfBoardMember fzmd:TwentySeventeenPlanMember us-gaap:RestrictedStockMember 2017-09-20 2017-09-21 0000319016 us-gaap:CommonStockMember fzmd:MembersOfBoardMember fzmd:TwentySeventeenPlanMember us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000319016 us-gaap:CommonStockMember fzmd:MembersOfBoardMember fzmd:TwentySeventeenPlanMember us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-09-30 0000319016 us-gaap:CommonStockMember fzmd:MembersOfBoardMember fzmd:TwentySeventeenPlanMember us-gaap:RestrictedStockMember 2017-09-30 0000319016 us-gaap:CommonStockMember fzmd:TwentySeventeenPlanMember us-gaap:RestrictedStockMember 2017-09-20 2017-09-21 0000319016 us-gaap:CommonStockMember fzmd:TwentySeventeenPlanMember us-gaap:RestrictedStockMember fzmd:IndependentBoardOfDirectorsMember 2017-09-20 2017-09-21 0000319016 us-gaap:CommonStockMember fzmd:TwentySeventeenPlanMember us-gaap:RestrictedStockMember fzmd:IndependentBoardOfDirectorsMember 2017-01-01 2017-09-30 0000319016 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000319016 us-gaap:RestrictedStockMember 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer1Member 2017-07-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer1Member 2016-07-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer1Member 2017-01-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer1Member 2016-01-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer2Member 2017-07-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer2Member 2016-07-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer2Member 2017-01-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer2Member 2016-01-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer3Member 2017-07-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer3Member 2016-07-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer3Member 2017-01-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer3Member 2016-01-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer4Member 2017-07-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer4Member 2016-07-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer4Member 2017-01-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer4Member 2016-01-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-07-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2016-07-01 2016-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-09-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2016-01-01 2016-09-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer1Member 2017-01-01 2017-09-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer1Member 2016-01-01 2016-12-31 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer2Member 2017-01-01 2017-09-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer2Member 2016-01-01 2016-12-31 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer3Member 2017-01-01 2017-09-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer3Member 2016-01-01 2016-12-31 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-09-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2016-01-01 2016-12-31 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier1Member fzmd:CPMMedicalConsultantsLLCMember 2017-07-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier1Member fzmd:CPMMedicalConsultantsLLCMember 2016-07-01 2016-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier1Member fzmd:CPMMedicalConsultantsLLCMember 2017-01-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier1Member fzmd:CPMMedicalConsultantsLLCMember 2016-01-01 2016-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier2Member 2017-07-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier2Member 2016-07-01 2016-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier2Member 2017-01-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier2Member 2016-01-01 2016-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier3Member 2017-07-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier3Member 2016-07-01 2016-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier3Member 2017-01-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier3Member 2016-01-01 2016-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2017-07-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2016-07-01 2016-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2017-01-01 2017-09-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2016-01-01 2016-09-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2017-01-01 2017-09-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2017-07-01 2017-09-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2016-07-01 2016-09-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2016-01-01 2016-09-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2017-09-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2016-12-31 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2016-12-31 0000319016 fzmd:AmBioStaffingLLCMember fzmd:PayrollProcessingEmployeeBenefitAdministrationAndRelatedHumanCapitalServicesMember 2017-09-30 0000319016 fzmd:AmBioStaffingLLCMember fzmd:PayrollProcessingEmployeeBenefitAdministrationAndRelatedHumanCapitalServicesMember 2016-12-31 0000319016 fzmd:AmBioStaffingLLCMember fzmd:PayrollProcessingEmployeeBenefitAdministrationAndRelatedHumanCapitalServicesMember 2017-07-01 2017-09-30 0000319016 fzmd:AmBioStaffingLLCMember fzmd:PayrollProcessingEmployeeBenefitAdministrationAndRelatedHumanCapitalServicesMember 2017-01-01 2017-09-30 0000319016 2017-07-19 0000319016 2017-07-18 2017-07-19 0000319016 us-gaap:SubsequentEventMember fzmd:TwentySeventeenPlanMember us-gaap:CommonStockMember 2017-10-04 Fuse Medical, Inc. 0000319016 10-Q 2017-09-30 false --12-31 No No Yes Smaller Reporting Company 18215808 Q3 2017 FZMD

472246

667475

285463

58065

8493

25326

24704

3528

790906

754394

2029

8931

3822

796757

767147

61764

83410

110626

77178

95104

5097

150000

160

417494

315845

687

417494

316532

162158

158908

3210560

3192686

-2993455

-2900979

379263

450615

796757

767147

0.01

20000000

0.01

100000000

18215808

15890808

18215808

15890808

428204

107584

911033

421170

169817

42536

333119

144654

258387

65048

577914

276516

216874

178633

686902

590147

-3058

-3365

-1580

384

3501

3237

10666

220316

182134

693504

602393

38071

-117086

-115590

-325877

6806

31824

20194

35324

35517

43308

35517

31265

-113393

-92476

-325684

0.00

-0.02

-0.01

-0.05

0.00

15890808

6890808

15890808

6890808

17047291

15890808

158908

3192686

-2900979

2325000

3250

17874

21124

-92476

18215808

162158

3210560

-2993455

28499

21124

227398

-275683

-16833

-49618

21176

-13604

21662

-146096

33448

-13604

88312

2170

91534

-848

-824

-195529

-46723

300

100000

-195229

53577

8157

61734

5250

<div> Note 1. Nature of Operations Overview The Company was initially incorporated in 1968 as Golf Rounds.com, Inc., a Delaware corporation.  Effective May 28, 2014, the Company amended its certificate of incorporation to change its name from “GolfRounds.com, Inc.” to “Fuse Medical, Inc.” (the “Company”).  Then, also on May 28, 2014, the Company merged with and into Fuse Medical, LLC, with Fuse Medical, LLC surviving as a wholly owned subsidiary of Fuse Medical, Inc (“Legacy Fuse”).  The transaction was accounted for as a reverse merger with Fuse Medical, Inc. deemed the legal acquirer, and Fuse Medical, LLC deemed the accounting acquirer.  During 2015, Certificates of Termination were filed for Fuse Medical, LLC and its two subsidiaries. On December 19, 2016 (the “Closing Date”), the Company entered into a definitive Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), and Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg (“RMI” and, together with NC 143, the “Investors”), pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date.  As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391.  The closing of the Purchase Agreement resulted in a change in control of the Company whereby the Investors acquired a majority interest in the Company. Effective as of the Closing Date, Mark W. Brooks became the Chairman of the Board of Directors and Christopher C. Reeg became the Chief Executive Officer of the Company. The Company distributes a broad portfolio of orthopedic implants including internal and external fixation products, upper and lower extremity plating and total joint reconstruction, soft tissue fixation and augmentation for sports medicine procedures, and full spinal implants for trauma, degenerative disc disease and deformity indications (“Orthopedic Implants”). The Company also supports its broad portfolio of Orthopedic Implants with human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”). The Company’s principal supplier is CPM Medical Consultants, LLC (“CPM”) a company owned and controlled by the Company’s Chairman of the Board of Directors. The Company strives to provide cost savings and quality products to its customers, which include hospitals and medical facilities. Basis of Presentation The interim condensed financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading. The condensed balance sheet information as of December 31, 2016, was derived from the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 20, 2017 (“2016 Annual Report”). These condensed financial statements should be read in conjunction with the 2016 Annual Report. The results of operations for the three and nine-months ended September 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period. Going Concern The accompanying condensed financial statements have been prepared as if the Company will continue as a going concern. For the nine-month period ended September 30, 2017, the Company used cash in operations of $195,529, of which $92,476 represented a net loss. The Company’s ability to continue as a going concern is dependent upon the ability of the Company’s management to successfully execute its restructuring and rebranding strategies while increasing revenue growth and profitability. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s 2016 audited financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. The Company’s management expects to fund its future business development activities and its working capital needs largely from improved future operations and other traditional financing sources, such as a revolving line of credit facility, term notes, or additional private placements until such time sufficient funds are provided by operations. There can be no assurance the Company’s financing efforts will be successful, or if the Company’s management will be able to achieve sufficient revenue and profitability growth from operations. Additional financing, may include restrictions on the Company’s operations, or with equity financing may result in the Company’s stockholders’ ownership being diluted. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</div>

<div> Note 6. Stockholders' Equity Stock Incentive Plans The Company has a stock-based compensation plan which provides for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors; the 2017 Equity Incentive Plan of Fuse Medical, Inc. (the “2017 Plan”), which was adopted by the Company’s Board of Directors (the “Board”) on April 5, 2017. The awards are subject to a vesting schedule as set forth in individual agreements. On September 21, 2017, the Board approved an amendment to the 2017 Plan to increase the number of shares of common stock authorized for issuance under the Plan from 1,500,000 shares of common stock to 2,500,000 shares of common stock.   The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the nine-months ended September 30, 2017 is presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No. of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding at December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304,788</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.22</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,736</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding at September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,302,052</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,302,052</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Restricted Common Stock On September 21, 2017, the Board voted to award an aggregate of 325,000 shares of common stock of the Company, par value $0.01 per share, through the granting of RSAs pursuant to the 2017 Plan, to the members of the Board as annual compensation for services rendered to the Company as Board members. Each member of the Board was granted an RSA constituting 65,000 shares of common stock. The common stock within each RSA had an aggregate fair market value of $0.78 per share on the date of grant ($253,500 in the aggregate) and each RSA will fully vest upon the one year anniversary of the date of grant or September 21, 2018. As of September 30, 2017, the Company had amortized $21,124 relating to the vesting of these shares which is included in general and administrative expenses, and $232,376 which will be recognized as an expense in future periods as the shares vest. Also on September 21, 2017, the Board awarded an aggregate of 2,000,000 shares of common stock through the granting of RSAs pursuant to the 2017 Plan to the Company’s independent Board of Directors (“Independent Members”) as special services compensation. The Independent Members were each granted an RSA constituting 1,000,000 shares of common stock. The common stock within each RSA had a fair market value of $0.78 on the date of grant, ($1,560,000 in the aggregate) and each RSA will fully vest upon the earlier of a change in control of the Company or the Company’s listing on a national securities exchange. As of September 30, 2017, the Company had not amortized any amounts relating to the vesting of these shares due to the uncertainty of meeting these milestones. The following table summarizes restricted common stock activity:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Grant Date Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested, December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,325,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-vested, September 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,325,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,813,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.82</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Note 7. Concentrations Concentration of Revenues, Accounts Receivable and Suppliers For the three-months and nine-months ended September 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   At September 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   The Company’s principal supplier is CPM (see Note 8) and provided 10% or greater of the Company’s goods purchased for the periods presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplier 1 - related party</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplier 2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplier 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> Note 8. Related Party Transactions The Company entered into a distributor agreement with CPM effective August 2, 2012, pursuant to which the Company acts as a non-exclusive distributor of certain amniotic membrane products. The term of the agreement is one year and renews on each annual anniversary date for successive one-year terms unless it is terminated in writing by either party. Effective January 1, 2017, this agreement was amended to expand and include Orthopedic Implants and a broader assortment of Biologics. (See Note 1) During the three-months ended September 30, 2017 and 2016 the Company sold $169,799 and $35,420, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the nine-months ended September 30, 2017 and 2016 the Company sold $327,381 and $48,420, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the three-months ended September 30, 2017 and 2016 the Company purchased $173,456 and $39,600, respectively, of its products from CPM. During the nine-months ended September 30, 2017 and 2016 the Company purchased $331,564 and $52,800, respectively, of its products from CPM. The balance due to CPM at September 30, 2017 and December 31, 2016 was $110,626 and $77,178, respectively, and are reflected within accounts payable – related parties on the accompanying condensed balance sheets. During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. The balance of the notes payable at September 30, 2017 and December 31, 2016 was $150,000. On December 19, 2016, the Company entered into the Purchase Agreement by and among the Company, NC 143, and RMI, pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. (See Note 1) During the three-months and nine-months ended September 30, 2017, CPM provided shared services for back-office functions such as accounting, finance, supply chain management, and sales support. In addition, the Company’s Chief Executive Officer and Interim Chief Financial Officer provided services at no charge to the Company. The financial statements do not reflect an estimate of fair value of these services. Effective January 1, 2017 the Company engaged AmBio Staffing, LLC, a Texas licensed professional employment organization to provide payroll processing, employee benefit administration, and related human capital services. AmBio Staffing, LLC is controlled by the Company’s Chairman of the Board of Directors. There was no balance due to AmBio Staffing at September 30, 2017 and December 31, 2016. For the three-months and nine-months ended September 30, 2017, $371 and $7,248 of fees were paid to AmBio Staffing, LLC for such services, respectively and are reflected within general, administrative and other expenses on the accompanying condensed statements of operations.   On July 19, 2017, the Company entered into a commercial property lease agreement for its new office space located at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080, dated to be effective July 14, 2017, by and between the Company and 1565 North Central Expressway, LP—an entity controlled by the Company’s Chairman of the Board of Directors. The Lease provides that the Company will pay rent of $4,000 per month and the initial term of the Lease begins on July 14, 2017 and ends December 31, 2017.  </div>

<div>   Note 9. Subsequent Events   On October 4, 2017, the Board approved an additional amendment to the 2017 Plan to increase the number of shares of common stock authorized for issuance under the 2017 Plan from 2,500,000 shares of common stock to 4,500,000 shares of common stock.                  <p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</div>

<div> Use of Estimates The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the condensed financial statements. Actual results could differ from those estimates.  Significant estimates in the accompanying condensed financial statements may include allowance for doubtful accounts, valuation of inventories, the estimates of fixed assets useful lives, the valuation of property and equipment, the valuation allowance on deferred tax assets, and the fair value calculation of stock-based awards.</div>

<div>   Net Income (Loss) Per Common Share <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net income (loss) per common share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method.  As of September 30, 2016, 604,788 outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive. </div>

<div> Reclassifications Certain amounts in the accompanying condensed financial statements as of September 30, 2016, and for the three-months and nine-months then ended, have been reclassified to conform to the presentation of September 30, 2017 condensed financial statements for the three-months and nine-months then ended. These include deferred rent and depreciation expense, previously reported as a component of accrued expenses and general, administrative and other expenses, respectively.</div>

<div> Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three-months or less at the time of purchase to be cash equivalents.  There were no cash equivalents at September 30, 2017 and 2016. The Company maintains its cash in a financial institution demand deposit account that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through September 30, 2017. As of September 30, 2017, and December 31, 2016, there were deposits of $231,498 and $421,636, respectively, greater than federally insured limits.</div>

<div> Accounts Receivable and Allowance for Doubtful Accounts Receivable Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. Payment trends and receivable amounts outstanding for an extended period beyond contractual terms are examples of these indicators. Accounts deemed uncollectible are written off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. The Company’s Management has determined that no allowance for doubtful accounts was necessary at September 30, 2017 and December 31, 2016.</div>

<div> Inventories Inventories are stated at the lower of cost (first-in, first-out) or market.  Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics.  The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit.</div>

<div> Revenue Recognition The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) the fees are fixed or determinable, (iii) no significant Company obligations remain, and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs).</div>

<div> Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management do not believe that this guidance will have a material impact on its financial statements and disclosures.  All other ASUs issued and not yet effective for the nine-months ended September 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position of results of operations.</div>

<div> Property and equipment consisted of the following at September 30, 2017 and December 31, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,290</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,047</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,347</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,728</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,627</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,945</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,598</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,029</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,931</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the nine-months ended September 30, 2017 is presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No. of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding at December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304,788</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.22</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,736</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding at September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,302,052</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at September 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,302,052</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> For the three-months and nine-months ended September 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> At September 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> The Company’s principal supplier is CPM (see Note 8) and provided 10% or greater of the Company’s goods purchased for the periods presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Nine-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplier 1 - related party</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplier 2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplier 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

5000000

400000

4000000

320000

64609

655391

604788

250000

231498

421636

29290

5047

6347

6728

1580

6627

43945

4598

35014

3665

300

-3365

150000

0.10

0.18

principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share.

0.08

117500

6806

1750

20194

5250

25290

5096

January 27, 2014

M. Richard Cutler and Cutler Law Group, P.C.

Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc.

2014-04-21

43308

32052

11256

1500000

2500000

1304788

2736

1302052

0.22

0.20

P4Y3M18D

P3Y6M

35000

3277000

325000

0.01

65000

0.78

253500

each RSA will fully vest upon the one year anniversary of the date of grant or September 21, 2018

P1Y

21124

232376

2000000

1000000

0.78

1560000

2325000

1813500 1813500

0.78

0.82

0.405

0.000

0.393

0.000

0.225

0.000

0.236

0.000

0.221

0.000

0.152

0.000

0.139

0.000

0.190

0.000

0.990

0.000

0.971

0.000

0.483

0.000

0.210

0.000

0.204

0.103

0.897

0.103

0.996

0.883

0.989

0.381

0.000

0.117

0.009

0.333

0.000

0.286

0.996

1.000

0.998

1.000

2012-08-02 P1Y

169799

35420

327381

48420

173456

39600

331564

52800

110626

77178

150000

371

7248

4000

2017-07-14 2017-12-31

4500000

EX-101.SCH 6 fzmd-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - CONDENSED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Nature of Operations link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Notes Payable - Related Parties link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Concentrations link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Concentrations (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Nature of Operations (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Significant Accounting Policies (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Property and Equipment (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Notes Payable - Related Parties (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Commitments and Contingencies (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Stockholders' Equity (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stockholders' Equity - Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Stockholders' Equity - Summary of Restricted Common Stock Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Concentrations - Concentration of Accounts Receivable With Significant Customers Representing 10% or Greater of Accounts Receivable (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Concentrations - Company Principal Supplier is CPM and Provided 10% or Greater of the Company Goods Purchased (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Related Party Transactions (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Subsequent Events (Details Narrative) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 fzmd-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 fzmd-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 fzmd-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document And Entity Information Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Is Entity a Voluntary Filer Entity Voluntary Filers Is Entity's Reporting Status Current Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Trading Symbol Trading Symbol Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Inventories Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Security deposit Deposits Assets Noncurrent Total assets Assets Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accounts payable - related parties Accounts Payable Related Parties Current Accrued expenses Accrued Liabilities Current Note payable - related parties Notes Payable Related Parties Classified Current Deferred rent - short term Deferred Rent Credit Current Total current liabilities Liabilities Current Deferred rent - long term Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Stockholders' equity: Stockholders Equity [Abstract] Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding Preferred Stock Value Common stock, $0.01 par value; 100,000,000 shares authorized, 18,215,808 and 15,890,808 shares issued and outstanding Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity Preferred Stock Par Value Preferred Stock Par Or Stated Value Per Share Preferred Stock Shares Authorized Preferred Stock Shares Authorized Preferred Stock Shares Issued Preferred Stock Shares Issued Preferred Stock Shares Outstanding Preferred Stock Shares Outstanding Common Stock Par Value Common Stock Par Or Stated Value Per Share Common Stock Shares Authorized Common Stock Shares Authorized Common Stock Shares Issued Common Stock Shares Issued Common Stock Shares Outstanding Common Stock Shares Outstanding Income Statement [Abstract] Revenues Revenues Cost of revenues (primarily from related party, see note 8) Cost Of Revenue Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] General, administrative and other Other General And Administrative Expense Loss on disposal of property and equipment Gain Loss On Sale Of Property Plant Equipment Depreciation Depreciation Total operating expenses Operating Expenses Operating income (loss) Operating Income Loss Interest expense Interest Expense Extinguishment of debt Gains Losses On Extinguishment Of Debt Net income (loss) Net Income Loss Net income (loss) per common share - basic Earnings Per Share Basic Net income (loss) per common share - diluted Earnings Per Share Diluted Weighted average number of common shares outstanding - basic Weighted Average Number Of Shares Outstanding Basic Weighted average number of common shares outstanding - diluted Weighted Average Number Of Diluted Shares Outstanding Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Beginning Balance, Amount Beginning Balance, Shares Shares Issued Issuance of restricted stock for services Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Issuance of restricted stock for services, Shares Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Net loss Ending Balance, Amount Ending Balance, Shares Proceeds from issuance of promissory notes to related parties. Consolidated Statements Of Cash Flows Statement Condensed Consolidated Statements Of Cash Flows Unaudited [Abstract] Cash flows from operating activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Amortization of debt discount Amortization Of Debt Discount Premium Extinguishment of debt Stock-based compensation Share Based Compensation Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventories Increase Decrease In Inventories Prepaid expenses and other receivables Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accounts payable - related parties Increase Decrease In Accounts Payable Related Parties Accrued expenses Increase Decrease In Accrued Liabilities Deferred revenues Increase Decrease In Deferred Revenue Deferred rent Increase Decrease In Deferred Charges Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Proceeds from the disposal of property and equipment Proceeds From Sale Of Property Plant And Equipment Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from issuance of promissory notes to related parties Proceeds From Issuance Of Promissory Notes To Related Parties Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net (decrease) increase in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Interest Paid Interest Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Operations Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] Notes payable related party. Debt Disclosure [Abstract] Notes Payable - Related Parties Notes Payable Related Party [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Stockholders Equity Stockholders Equity Deficit [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Nature of operations and going concern. Nature Of Operations And Going Concern [Abstract] Concentrations Concentration Risk Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Notes to Financial Statements Notes To Financial Statements [Abstract] Subsequent Events Subsequent Events [Text Block] Use of Estimates Use Of Estimates Net Income (Loss) Per Common Share Earnings Per Share Policy [Text Block] Fair Value Measurements Fair Value Of Financial Instruments Policy Reclassifications Prior Period Reclassification Adjustment Description Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Accounts Receivable and Allowance for Doubtful Accounts Receivable Trade And Other Accounts Receivable Policy Inventories Inventory Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Property and Equipment Property Plant And Equipment [Text Block] Stockholders Equity Tables Stockholders Equity Deficit Tables [Abstract] Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Restricted Common Stock Activity Nonvested Restricted Stock Shares Activity Table [Text Block] Concentrations details. Concentrations Details [Abstract] Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenues [Member] Sales Revenue Net [Member] Accounts Receivable [Member] Accounts Receivable [Member] Goods Purchased [Member] Cost Of Goods Total [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration of Revenues, Accounts Receivable and Suppliers Schedules Of Concentration Of Risk By Risk Factor [Text Block] Proceeds from issuance of common stock, net of offering costs. Nature of operations and going concern. Nature of operations and going concern. Nature Of Operations And Going Concern [Table] Nature Of Operations And Going Concern [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] NC 143 Family Holdings, Limited Partnership. NC 143 Family Holdings, LP [Member] N C143 Family Holdings Limited Partnership [Member] Reeg Medical Industries, Incorporation. RMI [Member] Reeg Medical Industries Incorporation [Member] Mark W. Brooks and Christopher C. Reeg [Member] Investor [Member] Nature Of Operations And Going Concern [Line Items] Nature Of Operations And Going Concern [Line Items] Sale of common shares Stock Issued During Period Shares New Issues Gross proceeds from sale of common shares Proceeds From Issuance Of Common Stock Direct offering costs Payments Of Stock Issuance Costs Net proceeds from sale of common stock Proceeds From Issuance Of Common Stock Net Of Offering Costs Net cash (used in) provided by operating activities Anti-dilutive securities excluded from diluted net loss per common share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Cash equivalents Cash Equivalents At Carrying Value FDIC insurance limit Cash F D I C Insured Amount Deposits greater than federally insured limit Cash Uninsured Amount Allowance for doubtful accounts receivable Allowance For Doubtful Accounts Receivable Current Liabilities for uncertain tax positions, current Liability For Uncertain Tax Positions Current Liabilities for uncertain tax positions, noncurrent Liability For Uncertain Tax Positions Noncurrent Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Computer equipment [Member] Computer Equipment [Member] Furniture and fixtures [Member] Furniture And Fixtures [Member] Leasehold improvements [Member] Leasehold Improvements [Member] Office equipment [Member] Office Equipment [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less: accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Depreciation expense Sale of property and equipment Property Plant And Equipment Disposals Gain (loss) on disposals of property and equipment Debt Instrument [Table] Debt Instrument [Table] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Ten percent promissory notes. 10% Promissory Notes [Member] Ten Percent Promissory Notes [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Accrued expenses [Member] Accounts Payable And Accrued Liabilities [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Convertible notes payable - related parties Convertible Notes Payable Current Interest rate of promissory notes Debt Conversion Original Debt Interest Rate Of Debt Debt Instrument, description Debt Instrument Call Feature Conversion price of common stock Debt Instrument Convertible Conversion Price1 Recognition of beneficial conversion feature on convertible promissory notes issued to related parties Debt Instrument Convertible Beneficial Conversion Feature Interest expense on notes payable - related parties Interest Expense Related Party Accrued interest payable Interest Payable Current Commitments and contingencies. EX-101.PRE 10 fzmd-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 06, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Fuse Medical, Inc.
Entity Central Index Key	0000319016
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		18,215,808
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017
Trading Symbol	FZMD

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 472,246	$ 667,475
Accounts receivable	285,463	58,065
Inventories	8,493	25,326
Prepaid expenses and other current assets	24,704	3,528
Total current assets	790,906	754,394
Property and equipment, net	2,029	8,931
Security deposit	3,822	3,822
Total assets	796,757	767,147
Current liabilities:
Accounts payable	61,764	83,410
Accounts payable - related parties	110,626	77,178
Accrued expenses	95,104	5,097
Note payable - related parties	150,000	150,000
Deferred rent - short term		160
Total current liabilities	417,494	315,845
Deferred rent - long term		687
Total liabilities	417,494	316,532
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value; 100,000,000 shares authorized, 18,215,808 and 15,890,808 shares issued and outstanding	162,158	158,908
Additional paid-in capital	3,210,560	3,192,686
Accumulated deficit	(2,993,455)	(2,900,979)
Total stockholders' equity	379,263	450,615
Total liabilities and stockholders' equity	$ 796,757	$ 767,147

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred Stock Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	20,000,000	20,000,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	100,000,000	100,000,000
Common Stock Shares Issued	18,215,808	15,890,808
Common Stock Shares Outstanding	18,215,808	15,890,808

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenues	$ 428,204	$ 107,584	$ 911,033	$ 421,170
Cost of revenues (primarily from related party, see note 8)	169,817	42,536	333,119	144,654
Gross profit	258,387	65,048	577,914	276,516
Operating expenses:
General, administrative and other	216,874	178,633	686,902	590,147
Loss on disposal of property and equipment	3,058		3,365	1,580
Depreciation	384	3,501	3,237	10,666
Total operating expenses	220,316	182,134	693,504	602,393
Operating income (loss)	38,071	(117,086)	(115,590)	(325,877)
Interest expense	(6,806)	(31,824)	(20,194)	(35,324)
Extinguishment of debt		35,517	43,308	35,517
Net income (loss)	$ 31,265	$ (113,393)	$ (92,476)	$ (325,684)
Net income (loss) per common share - basic	$ 0.00	$ (0.02)	$ (0.01)	$ (0.05)
Net income (loss) per common share - diluted	$ 0.00
Weighted average number of common shares outstanding - basic	15,890,808	6,890,808	15,890,808	6,890,808
Weighted average number of common shares outstanding - diluted	17,047,291

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance, Amount at Dec. 31, 2016	$ 450,615	$ 158,908	$ 3,192,686	$ (2,900,979)
Beginning Balance, Shares at Dec. 31, 2016		15,890,808
Issuance of restricted stock for services	21,124	$ 3,250	17,874
Issuance of restricted stock for services, Shares		2,325,000
Net loss	(92,476)			(92,476)
Ending Balance, Amount at Sep. 30, 2017	$ 379,263	$ 162,158	$ 3,210,560	$ (2,993,455)
Ending Balance, Shares at Sep. 30, 2017		18,215,808

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net loss	$ (92,476)	$ (325,684)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt discount		28,499
Depreciation	3,237	10,666
Loss on disposal of property and equipment	3,365	1,580
Extinguishment of debt	(43,308)	(35,517)
Stock-based compensation	21,124
Changes in operating assets and liabilities
Accounts receivable	(227,398)	275,683
Inventories	16,833	49,618
Prepaid expenses and other receivables	(21,176)	13,604
Accounts payable	21,662	(146,096)
Accounts payable - related parties	33,448	(13,604)
Accrued expenses	88,312	2,170
Deferred revenues		91,534
Deferred rent	848	824
Net cash (used in) provided by operating activities	(195,529)	(46,723)
Cash flows from investing activities
Proceeds from the disposal of property and equipment	300	300
Net cash provided by investing activities	300	300
Cash flows from financing activities
Proceeds from issuance of promissory notes to related parties		100,000
Net cash provided by financing activities		100,000
Net (decrease) increase in cash and cash equivalents	(195,229)	53,577
Cash and cash equivalents - beginning of period	667,475	8,157
Cash and cash equivalents - end of period	$ 472,246	61,734
Supplemental disclosure of cash flow information:
Interest Paid		$ 5,250

XML 17 R7.htm IDEA: XBRL DOCUMENT

Nature of Operations	9 Months Ended
Nature of Operations	Sep. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Operations	Note 1. Nature of Operations Overview The Company was initially incorporated in 1968 as Golf Rounds.com, Inc., a Delaware corporation. Effective May 28, 2014, the Company amended its certificate of incorporation to change its name from “GolfRounds.com, Inc.” to “Fuse Medical, Inc.” (the “Company”). Then, also on May 28, 2014, the Company merged with and into Fuse Medical, LLC, with Fuse Medical, LLC surviving as a wholly owned subsidiary of Fuse Medical, Inc (“Legacy Fuse”). The transaction was accounted for as a reverse merger with Fuse Medical, Inc. deemed the legal acquirer, and Fuse Medical, LLC deemed the accounting acquirer. During 2015, Certificates of Termination were filed for Fuse Medical, LLC and its two subsidiaries. On December 19, 2016 (the “Closing Date”), the Company entered into a definitive Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), and Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg (“RMI” and, together with NC 143, the “Investors”), pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. The closing of the Purchase Agreement resulted in a change in control of the Company whereby the Investors acquired a majority interest in the Company. Effective as of the Closing Date, Mark W. Brooks became the Chairman of the Board of Directors and Christopher C. Reeg became the Chief Executive Officer of the Company. The Company distributes a broad portfolio of orthopedic implants including internal and external fixation products, upper and lower extremity plating and total joint reconstruction, soft tissue fixation and augmentation for sports medicine procedures, and full spinal implants for trauma, degenerative disc disease and deformity indications (“Orthopedic Implants”). The Company also supports its broad portfolio of Orthopedic Implants with human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”). The Company’s principal supplier is CPM Medical Consultants, LLC (“CPM”) a company owned and controlled by the Company’s Chairman of the Board of Directors. The Company strives to provide cost savings and quality products to its customers, which include hospitals and medical facilities. Basis of Presentation The interim condensed financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading. The condensed balance sheet information as of December 31, 2016, was derived from the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 20, 2017 (“2016 Annual Report”). These condensed financial statements should be read in conjunction with the 2016 Annual Report. The results of operations for the three and nine-months ended September 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period. Going Concern The accompanying condensed financial statements have been prepared as if the Company will continue as a going concern. For the nine-month period ended September 30, 2017, the Company used cash in operations of $195,529, of which $92,476 represented a net loss. The Company’s ability to continue as a going concern is dependent upon the ability of the Company’s management to successfully execute its restructuring and rebranding strategies while increasing revenue growth and profitability. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s 2016 audited financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. The Company’s management expects to fund its future business development activities and its working capital needs largely from improved future operations and other traditional financing sources, such as a revolving line of credit facility, term notes, or additional private placements until such time sufficient funds are provided by operations. There can be no assurance the Company’s financing efforts will be successful, or if the Company’s management will be able to achieve sufficient revenue and profitability growth from operations. Additional financing, may include restrictions on the Company’s operations, or with equity financing may result in the Company’s stockholders’ ownership being diluted. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies	9 Months Ended
Significant Accounting Policies	Sep. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies	Note 2. Significant Accounting Policies Use of Estimates The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the condensed financial statements. Actual results could differ from those estimates. Significant estimates in the accompanying condensed financial statements may include allowance for doubtful accounts, valuation of inventories, the estimates of fixed assets useful lives, the valuation of property and equipment, the valuation allowance on deferred tax assets, and the fair value calculation of stock-based awards. Net Income (Loss) Per Common Share Basic net income (loss) per common share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. As of September 30, 2016, 604,788 outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive. Fair Value Measurements Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets, Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities, and Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded value of notes payable approximates their fair value based upon their effective interest rates. Reclassifications Certain amounts in the accompanying condensed financial statements as of September 30, 2016, and for the three-months and nine-months then ended, have been reclassified to conform to the presentation of September 30, 2017 condensed financial statements for the three-months and nine-months then ended. These include deferred rent and depreciation expense, previously reported as a component of accrued expenses and general, administrative and other expenses, respectively. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three-months or less at the time of purchase to be cash equivalents. There were no cash equivalents at September 30, 2017 and 2016. The Company maintains its cash in a financial institution demand deposit account that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through September 30, 2017. As of September 30, 2017, and December 31, 2016, there were deposits of $231,498 and $421,636, respectively, greater than federally insured limits. Accounts Receivable and Allowance for Doubtful Accounts Receivable Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. Payment trends and receivable amounts outstanding for an extended period beyond contractual terms are examples of these indicators. Accounts deemed uncollectible are written off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. The Company’s Management has determined that no allowance for doubtful accounts was necessary at September 30, 2017 and December 31, 2016. Inventories Inventories are stated at the lower of cost (first-in, first-out) or market. Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit. Income Taxes The Company uses the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company has deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are subject to periodic recoverability assessments. Realization of the deferred tax assets, net of deferred tax liabilities, is principally dependent upon achievement of projected future taxable income. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. As of September 30, 2017, the Company had no liabilities for uncertain tax positions. The Company's policy is to recognize interest and penalties related to income tax matters as a component of income tax expense. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Revenue Recognition The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) the fees are fixed or determinable, (iii) no significant Company obligations remain, and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs). Stock-Based Compensation The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s Statement of Operations. The Company estimates the fair value of restricted stock awards (“RSA”) to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s Statements of Operations. The Company accounts for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management do not believe that this guidance will have a material impact on its financial statements and disclosures. All other ASUs issued and not yet effective for the nine-months ended September 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position of results of operations.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Property and Equipment

9 Months Ended

Sep. 30, 2017

Property Plant And Equipment [Abstract]

Property and Equipment

Note 3. Property and Equipment

Property and equipment consisted of the following at September 30, 2017 and December 31, 2016:

	September 30, 2017			December 31, 2016
Computer equipment	$	-		$	29,290
Furniture and fixtures		5,047			6,347
Leasehold improvements		-			6,728
Office equipment		1,580			1,580
		6,627			43,945
Less: accumulated depreciation		(4,598	)		(35,014	)
Property and equipment, net	$	2,029		$	8,931

XML 20 R10.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Parties	9 Months Ended
Notes Payable - Related Parties	Sep. 30, 2017
Debt Disclosure [Abstract]
Notes Payable - Related Parties	Note 4. Notes Payable – Related Parties During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. This resulted in a beneficial conversion feature in the aggregate amount of $117,500, which was treated as a discount to each of the promissory notes and amortized over the term of each respective promissory note, maturing on December 31, 2016, the date in which the beneficial conversion feature was fully amortized. During the three-months ended September 30, 2017 and 2016, interest expense of $6,806 and $1,750, respectively, was recognized on outstanding notes payable – related parties and are reflected within interest expense on the accompanying condensed statements of operations. During the nine-months ended September 30, 2017 and 2016, interest expense of $20,194 and $5,250, respectively, was recognized on outstanding notes payable – related parties and are reflected within interest expense on the accompanying condensed statements of operations. As of September 30, 2017, and December 31, 2016, accrued interest payable was $25,290 and $5,096, respectively, which is included in accrued expenses on the accompanying condensed balance sheets.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 5. Commitments and Contingencies Legal Matters On January 27, 2014, M. Richard Cutler and Cutler Law Group, P.C. (the “Plaintiffs”) filed a complaint in the District Court of Harris County, Texas, 2014-03355, against Legacy Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc. (the “Defendants”). On April 21, 2014, the complaint was dismissed for “want of prosecution.” On September 18, 2015, Plaintiffs refiled a complaint in the District Court of Harris County, Texas, Cause No. 2015-55652 and added PH Squared, LLC as an additional Plaintiff, as more fully described in “Legal Matters” included in Note 6 in the Company’s 2016 Annual Report, which is herein incorporated by reference. During April 2017, one of the named individuals in the complaint filed for bankruptcy protection. There is currently no trial date set. The Company’s management continues to believe that the lawsuit is completely without merit and will vigorously contest it and protect the Company’s interests. Accounts Payable During the nine-months ended September 30, 2017, the Company recorded a gain of $43,308 on extinguishment of long-aged outstanding payables owed to a former law firm for $32,052 and liabilities aggregating $11,256 owed to the Company’s beneficial owners for services provided to the Company and is reflected within extinguishment of debt on the accompanying condensed statements of operations. The Company’s management believes if these items were contested, the probable outcome would be favorable primarily due to statute of limitations.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Stockholders Equity Deficit [Abstract]

Stockholders' Equity

Note 6. Stockholders' Equity

Stock Incentive Plans

The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the nine-months ended September 30, 2017 is presented below:

	No. of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Balance outstanding at December 31, 2016		1,304,788		$	0.22		4.3	$	35,000
Granted		-			-		-		-
Exercised		-			-		-		-
Forfeited		-			-		-		-
Expired		(2,736	)		-		-		-
Balance outstanding at September 30, 2017		1,302,052		$	0.20		3.5	$	3,277,000
Exercisable at September 30, 2017		1,302,052		$	0.20		3.5	$	3,277,000

Restricted Common Stock

The following table summarizes restricted common stock activity:

	Number of Shares		Fair Value		Weighted Average Grant Date Fair Value
Non-vested, December 31, 2016		-	$	-	$	-
Granted		2,325,000		1,813,500		0.78
Vested		-		-		-
Forfeited		-		-		-
Non-vested, September 30, 2017		2,325,000	$	1,813,500	$	0.82

XML 23 R13.htm IDEA: XBRL DOCUMENT

Concentrations

9 Months Ended

Sep. 30, 2017

Nature Of Operations And Going Concern [Abstract]

Concentrations

Note 7. Concentrations

Concentration of Revenues, Accounts Receivable and Suppliers

For the three-months and nine-months ended September 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:

	For the Three-months Ended September 30, 2017			For the Three-months Ended September 30, 2016			For the Nine-months Ended September 30, 2017			For the Nine-months Ended September 30, 2016
Customer 1		40.5	%		0.0	%		39.3	%		0.0	%
Customer 2		22.5	%		0.0	%		23.6	%		0.0	%
Customer 3		22.1	%		0.0	%		15.2	%		0.0	%
Customer 4		13.9	%		0.0	%		19.0	%		0.0	%
Totals		99.0	%		0.0	%		97.1	%		0.0	%

At September 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:

	September 30, 2017			December 31, 2016
Customer 1		48.3	%		0.0	%
Customer 2		21.0	%		0.0	%
Customer 3		20.4	%		10.3	%
Totals		89.7	%		10.3	%

The Company’s principal supplier is CPM (see Note 8) and provided 10% or greater of the Company’s goods purchased for the periods presented below:

	For the Three-months Ended September 30, 2017			For the Three-months Ended September 30, 2016			For the Nine-months Ended September 30, 2017			For the Nine-months Ended September 30, 2016
Supplier 1 - related party		99.6	%		88.3	%		98.9	%		38.1	%
Supplier 2		0.0	%		11.7	%		0.9	%		33.3	%
Supplier 3		0.0	%		0.0	%		0.0	%		28.6	%
Totals		99.6	%		100.0	%		99.8	%		100.0	%

XML 24 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 8. Related Party Transactions The Company entered into a distributor agreement with CPM effective August 2, 2012, pursuant to which the Company acts as a non-exclusive distributor of certain amniotic membrane products. The term of the agreement is one year and renews on each annual anniversary date for successive one-year terms unless it is terminated in writing by either party. Effective January 1, 2017, this agreement was amended to expand and include Orthopedic Implants and a broader assortment of Biologics. (See Note 1) During the three-months ended September 30, 2017 and 2016 the Company sold $169,799 and $35,420, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the nine-months ended September 30, 2017 and 2016 the Company sold $327,381 and $48,420, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the three-months ended September 30, 2017 and 2016 the Company purchased $173,456 and $39,600, respectively, of its products from CPM. During the nine-months ended September 30, 2017 and 2016 the Company purchased $331,564 and $52,800, respectively, of its products from CPM. The balance due to CPM at September 30, 2017 and December 31, 2016 was $110,626 and $77,178, respectively, and are reflected within accounts payable – related parties on the accompanying condensed balance sheets. During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. The balance of the notes payable at September 30, 2017 and December 31, 2016 was $150,000. On December 19, 2016, the Company entered into the Purchase Agreement by and among the Company, NC 143, and RMI, pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. (See Note 1) During the three-months and nine-months ended September 30, 2017, CPM provided shared services for back-office functions such as accounting, finance, supply chain management, and sales support. In addition, the Company’s Chief Executive Officer and Interim Chief Financial Officer provided services at no charge to the Company. The financial statements do not reflect an estimate of fair value of these services. Effective January 1, 2017 the Company engaged AmBio Staffing, LLC, a Texas licensed professional employment organization to provide payroll processing, employee benefit administration, and related human capital services. AmBio Staffing, LLC is controlled by the Company’s Chairman of the Board of Directors. There was no balance due to AmBio Staffing at September 30, 2017 and December 31, 2016. For the three-months and nine-months ended September 30, 2017, $371 and $7,248 of fees were paid to AmBio Staffing, LLC for such services, respectively and are reflected within general, administrative and other expenses on the accompanying condensed statements of operations. On July 19, 2017, the Company entered into a commercial property lease agreement for its new office space located at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080, dated to be effective July 14, 2017, by and between the Company and 1565 North Central Expressway, LP—an entity controlled by the Company’s Chairman of the Board of Directors. The Lease provides that the Company will pay rent of $4,000 per month and the initial term of the Lease begins on July 14, 2017 and ends December 31, 2017.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2017
Notes To Financial Statements [Abstract]
Subsequent Events	Note 9. Subsequent Events On October 4, 2017, the Board approved an additional amendment to the 2017 Plan to increase the number of shares of common stock authorized for issuance under the 2017 Plan from 2,500,000 shares of common stock to 4,500,000 shares of common stock. F-1

XML 26 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the condensed financial statements. Actual results could differ from those estimates. Significant estimates in the accompanying condensed financial statements may include allowance for doubtful accounts, valuation of inventories, the estimates of fixed assets useful lives, the valuation of property and equipment, the valuation allowance on deferred tax assets, and the fair value calculation of stock-based awards.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic net income (loss) per common share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. As of September 30, 2016, 604,788 outstanding common stock equivalents have been excluded from diluted net loss per common share because their inclusion would be anti-dilutive.
Fair Value Measurements	Fair Value Measurements Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets, Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities, and Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded value of notes payable approximates their fair value based upon their effective interest rates.
Reclassifications	Reclassifications Certain amounts in the accompanying condensed financial statements as of September 30, 2016, and for the three-months and nine-months then ended, have been reclassified to conform to the presentation of September 30, 2017 condensed financial statements for the three-months and nine-months then ended. These include deferred rent and depreciation expense, previously reported as a component of accrued expenses and general, administrative and other expenses, respectively.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three-months or less at the time of purchase to be cash equivalents. There were no cash equivalents at September 30, 2017 and 2016. The Company maintains its cash in a financial institution demand deposit account that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through September 30, 2017. As of September 30, 2017, and December 31, 2016, there were deposits of $231,498 and $421,636, respectively, greater than federally insured limits.
Accounts Receivable and Allowance for Doubtful Accounts Receivable	Accounts Receivable and Allowance for Doubtful Accounts Receivable Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. Payment trends and receivable amounts outstanding for an extended period beyond contractual terms are examples of these indicators. Accounts deemed uncollectible are written off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. The Company’s Management has determined that no allowance for doubtful accounts was necessary at September 30, 2017 and December 31, 2016.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out) or market. Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit.
Income Taxes	Income Taxes The Company uses the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company has deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are subject to periodic recoverability assessments. Realization of the deferred tax assets, net of deferred tax liabilities, is principally dependent upon achievement of projected future taxable income. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. As of September 30, 2017, the Company had no liabilities for uncertain tax positions. The Company's policy is to recognize interest and penalties related to income tax matters as a component of income tax expense. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) the fees are fixed or determinable, (iii) no significant Company obligations remain, and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs).
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s Statement of Operations. The Company estimates the fair value of restricted stock awards (“RSA”) to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s Statements of Operations. The Company accounts for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management do not believe that this guidance will have a material impact on its financial statements and disclosures. All other ASUs issued and not yet effective for the nine-months ended September 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position of results of operations.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2017

Property Plant And Equipment [Abstract]

Property and Equipment

Property and equipment consisted of the following at September 30, 2017 and December 31, 2016:

	September 30, 2017			December 31, 2016
Computer equipment	$	-		$	29,290
Furniture and fixtures		5,047			6,347
Leasehold improvements		-			6,728
Office equipment		1,580			1,580
		6,627			43,945
Less: accumulated depreciation		(4,598	)		(35,014	)
Property and equipment, net	$	2,029		$	8,931

XML 28 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2017

Stockholders Equity Deficit Tables [Abstract]

Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity

The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the nine-months ended September 30, 2017 is presented below:

	No. of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Balance outstanding at December 31, 2016		1,304,788		$	0.22		4.3	$	35,000
Granted		-			-		-		-
Exercised		-			-		-		-
Forfeited		-			-		-		-
Expired		(2,736	)		-		-		-
Balance outstanding at September 30, 2017		1,302,052		$	0.20		3.5	$	3,277,000
Exercisable at September 30, 2017		1,302,052		$	0.20		3.5	$	3,277,000

Summary of Restricted Common Stock Activity

The following table summarizes restricted common stock activity:

	Number of Shares		Fair Value		Weighted Average Grant Date Fair Value
Non-vested, December 31, 2016		-	$	-	$	-
Granted		2,325,000		1,813,500		0.78
Vested		-		-		-
Forfeited		-		-		-
Non-vested, September 30, 2017		2,325,000	$	1,813,500	$	0.82

XML 29 R19.htm IDEA: XBRL DOCUMENT

Concentrations (Tables)

9 Months Ended

Sep. 30, 2017

Revenues [Member]

Concentration Risk [Line Items]

Concentration of Revenues, Accounts Receivable and Suppliers

For the three-months and nine-months ended September 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:

	For the Three-months Ended September 30, 2017			For the Three-months Ended September 30, 2016			For the Nine-months Ended September 30, 2017			For the Nine-months Ended September 30, 2016
Customer 1		40.5	%		0.0	%		39.3	%		0.0	%
Customer 2		22.5	%		0.0	%		23.6	%		0.0	%
Customer 3		22.1	%		0.0	%		15.2	%		0.0	%
Customer 4		13.9	%		0.0	%		19.0	%		0.0	%
Totals		99.0	%		0.0	%		97.1	%		0.0	%

Accounts Receivable [Member]

Concentration Risk [Line Items]

Concentration of Revenues, Accounts Receivable and Suppliers

At September 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:

	September 30, 2017			December 31, 2016
Customer 1		48.3	%		0.0	%
Customer 2		21.0	%		0.0	%
Customer 3		20.4	%		10.3	%
Totals		89.7	%		10.3	%

Goods Purchased [Member]

Concentration Risk [Line Items]

Concentration of Revenues, Accounts Receivable and Suppliers

The Company’s principal supplier is CPM (see Note 8) and provided 10% or greater of the Company’s goods purchased for the periods presented below:

	For the Three-months Ended September 30, 2017			For the Three-months Ended September 30, 2016			For the Nine-months Ended September 30, 2017			For the Nine-months Ended September 30, 2016
Supplier 1 - related party		99.6	%		88.3	%		98.9	%		38.1	%
Supplier 2		0.0	%		11.7	%		0.9	%		33.3	%
Supplier 3		0.0	%		0.0	%		0.0	%		28.6	%
Totals		99.6	%		100.0	%		99.8	%		100.0	%

XML 30 R20.htm IDEA: XBRL DOCUMENT

Nature of Operations (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
Nature of Operations (Details Narrative) - USD ($)	Dec. 19, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Nature Of Operations And Going Concern [Line Items]
Net loss		$ 31,265	$ (113,393)	$ (92,476)	$ (325,684)
Net cash (used in) provided by operating activities				$ (195,529)	$ (46,723)
NC 143 Family Holdings, LP [Member]
Nature Of Operations And Going Concern [Line Items]
Sale of common shares	5,000,000
Gross proceeds from sale of common shares	$ 400,000
RMI [Member]
Nature Of Operations And Going Concern [Line Items]
Sale of common shares	4,000,000
Gross proceeds from sale of common shares	$ 320,000
Mark W. Brooks and Christopher C. Reeg [Member]
Nature Of Operations And Going Concern [Line Items]
Direct offering costs	64,609
Net proceeds from sale of common stock	$ 655,391

XML 31 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Anti-dilutive securities excluded from diluted net loss per common share	604,788
Cash equivalents	$ 0	$ 0
FDIC insurance limit		250,000
Deposits greater than federally insured limit		231,498	$ 421,636
Allowance for doubtful accounts receivable		0	$ 0
Liabilities for uncertain tax positions, current		0
Liabilities for uncertain tax positions, noncurrent		$ 0

XML 32 R22.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 6,627	$ 43,945
Less: accumulated depreciation	(4,598)	(35,014)
Property and equipment, net	2,029	8,931
Computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		29,290
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	5,047	6,347
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		6,728
Office equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,580	$ 1,580

XML 33 R23.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Property Plant And Equipment [Line Items]
Depreciation expense	$ 384	$ 3,501	$ 3,237	$ 10,666
Proceeds from the disposal of property and equipment			300	300
Gain (loss) on disposals of property and equipment	$ (3,058)		(3,365)	$ (1,580)
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Sale of property and equipment			3,665
Proceeds from the disposal of property and equipment			300
Gain (loss) on disposals of property and equipment			$ (3,365)

XML 34 R24.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Parties (Details Narrative) - USD ($)	3 Months Ended		4 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Oct. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Interest expense on notes payable - related parties	$ 6,806	$ 1,750		$ 20,194	$ 5,250
Accrued expenses [Member]
Debt Instrument [Line Items]
Accrued interest payable	$ 25,290			25,290		$ 5,096
Mark W. Brooks and Christopher C. Reeg [Member]
Debt Instrument [Line Items]
Recognition of beneficial conversion feature on convertible promissory notes issued to related parties				$ 117,500
10% Promissory Notes [Member] \| Mark W. Brooks and Christopher C. Reeg [Member]
Debt Instrument [Line Items]
Convertible notes payable - related parties			$ 150,000
Interest rate of promissory notes			10.00%	18.00%
Debt Instrument, description				principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share.
Conversion price of common stock	$ 0.08			$ 0.08

XML 35 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Commitments And Contingencies [Line Items]
Loss contingency, complaint filing date		January 27, 2014
Loss contingency, name of plaintiff		M. Richard Cutler and Cutler Law Group, P.C.
Loss contingency, name of defendants		Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc.
Loss contingency, date of complaint dismissal		Apr. 21, 2014
Gain on extinguishment of debt	$ 35,517	$ 43,308	$ 35,517
Accounts Payable [Member]
Commitments And Contingencies [Line Items]
Gain on extinguishment of debt		43,308
Accounts Payable [Member] \| Former Law Firm [Member]
Commitments And Contingencies [Line Items]
Amount of debt extinguished		32,052
Accounts Payable [Member] \| Beneficial Owners [Member]
Commitments And Contingencies [Line Items]
Amount of debt extinguished		$ 11,256

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD ($)		9 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Sep. 21, 2017	Sep. 30, 2017	Jun. 30, 2017	Apr. 05, 2017	Dec. 31, 2016
Class Of Stock [Line Items]
Common stock par value per share			$ 0.01		$ 0.01
Restricted Stock Award [Member]
Class Of Stock [Line Items]
Number of common stock granted		2,325,000
Fair market value of each common stock		$ 0.78
2017 Plan [Member] \| Common Stock [Member]
Class Of Stock [Line Items]
Number of shares of common stock authorized for issuance	2,500,000			1,500,000
2017 Plan [Member] \| Common Stock [Member] \| Restricted Stock Award [Member]
Class Of Stock [Line Items]
Number of shares of common stock authorized for issuance	325,000
Common stock par value per share	$ 0.01
Number of common stock granted	2,000,000
2017 Plan [Member] \| Common Stock [Member] \| Each Member of Board [Member] \| Restricted Stock Award [Member]
Class Of Stock [Line Items]
Number of common stock granted	65,000
Fair market value of each common stock	$ 0.78
Aggregate fair market value of common stock	$ 253,500
Vesting description		each RSA will fully vest upon the one year anniversary of the date of grant or September 21, 2018
Vesting period of RSA	1 year
Unrecognized compensation expenses		$ 232,376
2017 Plan [Member] \| Common Stock [Member] \| Each Member of Board [Member] \| Restricted Stock Award [Member] \| General and Administrative Expenses [Member]
Class Of Stock [Line Items]
Share-based compensation expense		21,124
2017 Plan [Member] \| Common Stock [Member] \| Independent Members [Member] \| Restricted Stock Award [Member]
Class Of Stock [Line Items]
Number of common stock granted	1,000,000
Fair market value of each common stock	$ 0.78
Aggregate fair market value of common stock	$ 1,560,000
Share-based compensation expense		$ 0

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
No. of shares, Abstract
No. of Shares, Beginning Balance	1,304,788
Expired, No. Of Shares	(2,736)
No. of Shares, Ending Balance	1,302,052	1,304,788
Exercisable, No. Of Shares	1,302,052
Weighted average exercise price, Abstract
Weighted Average Exercise Price, Beginning Balance	$ 0.22
Weighted Average Exercise Price, Ending Balance	0.20	$ 0.22
Exercisable, Weighted Average Exercise Price	$ 0.20
Weighted average remaining contractual term, Abstract
Weighted Average Remaining Contractual Term, Balance outstanding	3 years 6 months	4 years 3 months 18 days
Weighted Average Remaining Contractual Term, Exercisable	3 years 6 months
Aggregate intrinsic value, Abstract
Aggregate Intrinsic Value, Balance outstanding	$ 3,277,000	$ 35,000
Aggregate Intrinsic Value, Exercisable	$ 3,277,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Restricted Common Stock Activity (Details) - Restricted Stock Award [Member]	9 Months Ended
	Sep. 30, 2017 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of common stock granted \| shares	2,325,000
Number of Shares, Non-vested, Ending Balance \| shares	2,325,000
Share-based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value [Abstract]
Fair Value,Granted \| $	$ 1,813,500
Fair Value, Non-vested, Ending Balance \| $	$ 1,813,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value,Granted \| $ / shares	$ 0.78
Weighted Average Grant Date Fair Value, Non-vested, Ending Balance \| $ / shares	$ 0.82

XML 39 R29.htm IDEA: XBRL DOCUMENT

Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) - Customer Concentration Risk [Member] - Revenues [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	99.00%	0.00%	97.10%	0.00%
Customer 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	40.50%	0.00%	39.30%	0.00%
Customer 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	22.50%	0.00%	23.60%	0.00%
Customer 3 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	22.10%	0.00%	15.20%	0.00%
Customer 4 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	13.90%	0.00%	19.00%	0.00%

XML 40 R30.htm IDEA: XBRL DOCUMENT

Concentrations - Concentration of Accounts Receivable With Significant Customers Representing 10% or Greater of Accounts Receivable (Details) - Credit Concentration Risk [Member] - Accounts Receivable [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	89.70%	10.30%
Customer 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	48.30%	0.00%
Customer 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	21.00%	0.00%
Customer 3 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	20.40%	10.30%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Concentrations - Company Principal Supplier is CPM and Provided 10% or Greater of the Company Goods Purchased (Details) - Supplier Concentration Risk [Member] - Goods Purchased [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	99.60%	100.00%	99.80%	100.00%
Supplier 1 [Member] \| CPM [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	99.60%	88.30%	98.90%	38.10%
Supplier 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%	11.70%	0.90%	33.30%
Supplier 3 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%	0.00%	0.00%	28.60%

XML 42 R32.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)			3 Months Ended		4 Months Ended	9 Months Ended
	Jul. 19, 2017	Dec. 19, 2016	Sep. 30, 2017	Sep. 30, 2016	Oct. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Accounts payable - related parties			$ 110,626			$ 110,626		$ 77,178
Notes payable to related party			150,000			$ 150,000		150,000
Rent paid	$ 4,000
Lease term begins	Jul. 14, 2017
Lease term ends	Dec. 31, 2017
CPM [Member]
Related Party Transaction [Line Items]
Distributor agreement effective date						Aug. 02, 2012
Distributor agreement term						1 year
Amount of transaction related to sale of products reflected in cost of sales			169,799	$ 35,420		$ 327,381	$ 48,420
Purchases from supplier			173,456	$ 39,600		331,564	$ 52,800
Accounts payable - related parties			$ 110,626			$ 110,626		77,178
Mark W. Brooks and Christopher C. Reeg [Member]
Related Party Transaction [Line Items]
Direct offering costs		$ 64,609
Net proceeds from sale of common stock		$ 655,391
Mark W. Brooks and Christopher C. Reeg [Member] \| 10% Promissory Notes [Member]
Related Party Transaction [Line Items]
Convertible notes payable - related parties					$ 150,000
Interest rate of promissory notes					10.00%	18.00%
Debt Instrument, description						principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share.
Conversion price of common stock			$ 0.08			$ 0.08
Notes payable to related party			$ 150,000			$ 150,000		150,000
NC 143 [Member]
Related Party Transaction [Line Items]
Sale of common shares		5,000,000
Gross proceeds from sale of common shares		$ 400,000
RMI [Member]
Related Party Transaction [Line Items]
Sale of common shares		4,000,000
Gross proceeds from sale of common shares		$ 320,000
AmBio Staffing, LLC [Member] \| Payroll Processing, Employee Benefit Administration, and Related Human Capital Services [Member]
Related Party Transaction [Line Items]
Due to related parties			0			0		$ 0
Fees paid for services			$ 371			$ 7,248

XML 43 R33.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - Common Stock [Member] - 2017 Plan [Member] - shares	Oct. 04, 2017	Sep. 21, 2017	Apr. 05, 2017
Subsequent Event [Line Items]
Number of shares of common stock authorized for issuance		2,500,000	1,500,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares of common stock authorized for issuance	4,500,000

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 113 161 1 false 37 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.fusemedical.com/20170930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.fusemedical.com/20170930/taxonomy/role/StatementCONDENSEDBALANCESHEETS CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 100020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://www.fusemedical.com/20170930/taxonomy/role/StatementCONDENSEDBALANCESHEETSParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.fusemedical.com/20170930/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUnaudited CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 100040 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.fusemedical.com/20170930/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.fusemedical.com/20170930/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Nature of Operations Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureNatureOfOperations Nature of Operations Notes 7 false false R8.htm 100070 - Disclosure - Significant Accounting Policies Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Property and Equipment Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 100090 - Disclosure - Notes Payable - Related Parties Notes http://www.fusemedical.com/20170930/taxonomy/role/DisclosureNotesPayableRelatedParties Notes Payable - Related Parties Notes 10 false false R11.htm 100100 - Disclosure - Commitments and Contingencies Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 100110 - Disclosure - Stockholders' Equity Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 100120 - Disclosure - Concentrations Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureConcentrations Concentrations Notes 13 false false R14.htm 100130 - Disclosure - Related Party Transactions Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 100140 - Disclosure - Subsequent Events Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 15 false false R16.htm 100150 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.fusemedical.com/20170930/taxonomy/role/DisclosureSignificantAccountingPolicies 16 false false R17.htm 100160 - Disclosure - Property and Equipment (Tables) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.fusemedical.com/20170930/taxonomy/role/DisclosurePropertyAndEquipment 17 false false R18.htm 100170 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.fusemedical.com/20170930/taxonomy/role/DisclosureStockholdersEquity 18 false false R19.htm 100180 - Disclosure - Concentrations (Tables) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureConcentrationsTables Concentrations (Tables) Tables http://www.fusemedical.com/20170930/taxonomy/role/DisclosureConcentrations 19 false false R20.htm 100190 - Disclosure - Nature of Operations (Details Narrative) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureNatureOfOperationsDetailsNarrative Nature of Operations (Details Narrative) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosureNatureOfOperations 20 false false R21.htm 100200 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureSignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies 21 false false R22.htm 100210 - Disclosure - Property and Equipment (Details) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosurePropertyAndEquipmentTables 22 false false R23.htm 100220 - Disclosure - Property and Equipment (Details Narrative) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosurePropertyAndEquipmentTables 23 false false R24.htm 100230 - Disclosure - Notes Payable - Related Parties (Details Narrative) Notes http://www.fusemedical.com/20170930/taxonomy/role/DisclosureNotesPayableRelatedPartiesDetailsNarrative Notes Payable - Related Parties (Details Narrative) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosureNotesPayableRelatedParties 24 false false R25.htm 100240 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosureCommitmentsAndContingencies 25 false false R26.htm 100250 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureStockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosureStockholdersEquityTables 26 false false R27.htm 100260 - Disclosure - Stockholders' Equity - Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity (Details) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquityAwardsGrantedPriorTo2017PlanAndStockOptionActivityDetails Stockholders' Equity - Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity (Details) Details 27 false false R28.htm 100270 - Disclosure - Stockholders' Equity - Summary of Restricted Common Stock Activity (Details) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedCommonStockActivityDetails Stockholders' Equity - Summary of Restricted Common Stock Activity (Details) Details 28 false false R29.htm 100280 - Disclosure - Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureConcentrationsSignificantCustomersWithIndividualPercentageOfTotalRevenuesEqualing10OrGreaterDetails Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) Details 29 false false R30.htm 100290 - Disclosure - Concentrations - Concentration of Accounts Receivable With Significant Customers Representing 10% or Greater of Accounts Receivable (Details) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureConcentrationsConcentrationOfAccountsReceivableWithSignificantCustomersRepresenting10OrGreaterOfAccountsReceivableDetails Concentrations - Concentration of Accounts Receivable With Significant Customers Representing 10% or Greater of Accounts Receivable (Details) Details 30 false false R31.htm 100300 - Disclosure - Concentrations - Company Principal Supplier is CPM and Provided 10% or Greater of the Company Goods Purchased (Details) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureConcentrationsCompanyPrincipalSupplierIsCPMAndProvided10OrGreaterOfCompanyGoodsPurchasedDetails Concentrations - Company Principal Supplier is CPM and Provided 10% or Greater of the Company Goods Purchased (Details) Details 31 false false R32.htm 100310 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureRelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosureRelatedPartyTransactions 32 false false R33.htm 100320 - Disclosure - Subsequent Events (Details Narrative) Sheet http://www.fusemedical.com/20170930/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://www.fusemedical.com/20170930/taxonomy/role/DisclosureSubsequentEvents 33 false false All Reports Book All Reports fzmd-20170930.xml fzmd-20170930.xsd fzmd-20170930_cal.xml fzmd-20170930_def.xml fzmd-20170930_lab.xml fzmd-20170930_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 50 0001564590-17-022672-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-022672-xbrl.zip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
]>GT_[P $*9G+>CG J>A,#VL+(SLIO'# MX"%MA;/KENSKS,09US(MSCC2#)%>7_BZ"X4;H,"H5+9L%\1(%[O,IG#MS.V^ M:DQ-\R9IJH1:G=-+C5-L9);/B'I>"]^AP?[H?;#VAIT Q16^N!(BR1@G, M5@)7R0/ /D\% (S44=&U@] UU,3U%5^0R;\M8Q?ZXW:&^MZZO"[=-\$O4!M MEB.%Q(C ?HB"*:U #"G/;LT.^62IW929R.R,YQ7L?I; G#3* MN CB?XSR]#&EE-"E?MFA83&"J_"$/3<]VD/E3VD4:9A'A2_HJ*I%ZFE>KYUV MYI@Z*U$=%#EW+OE M/V8L./.XRB67I9_T<96-JG6K'WN7X6RGIU0>3!AO9Q[IES9Q,B\[SS$[<&6- MGN&Y1[(<;&.V8DOZ6QX,UJ-#A.A::)?YO@ 9AE5FGT>8&%"?2>O^^LHEU_)5 MNA8YP 66Q)V18._2/]Z#4?#BP;L.P/\JGS3*_Z0-PC2D1,0KJ_= &;]?7_WU MAO[))E%@R+,#<)GI%W?$#+5JIZ5]^0.Q*+^2,+3;UP(EVCVETB7X5=<2\@6Z6A9,%8 MK.#5GB *T$*60\7\_/YIP&-V@68.%_,4.2.C2HY+S9^VK!C%?RJ4U,.!L]7[ M[7+H'*/W9]/@K1Z/K1B:7=_*:I?3%=5R;2_51:BM4+/M*65-,\!JJM[\)A*!,9 M+TI+QA?T(N39J7=+2RDC0Z6L M>^YJ[^6)D>T[G-,)7 G(9RU9.\AC+=IK4,Y;-6+;S%3Y3ZBT[A4SJW5#";%8Z M;M*974MK)>_;]4W;QDSR_GR%S%BJLE#"6*JC)9VQ5&O0L]FH7#9;I:6E,56F MSGP\9/O"A'B'=Q#*.WH8'O0^BIC+)VZS-;GYTI#L"+*[)C=_S-0SN?GU2/JZ M66E=;MKX9I+S+TFJ-^6@DK%HQZ83C44[9NH9B[:F16NT*C6[60YE:4S:IB;M MD&7F1?&V%R9XJU"]>GZF;O954A4K8(<^UGF!:W+&]#J"Y/$*B>-%]#QKW^7H MC]S<'65/W:>I5VKURW+HV-45[%D*96ETKC&)I2:/,8G&)!J3N 6INY7+AET. M'7L<)E%2(R7&(KH=MKC^EJ[MS9[2+_0]_/7"+P'!'FCP4:N+T_WF@N[_=\K@8A4)>A-V?>8RW]<3C@>5@G@,$/?P3 M-4M"]\X#9.UVBY8VBD*7,4_(KVNUBKKV'>'B ;SMAT+]6&G .X 9.;/CX[>C MF;F5I9?$KW/AN[PJOO_OH?<.+SX7M\X8)>V.4>_$K0/#9,_JE\/7S_AR^&;5 M(EQ9"ED6:8:_=NNV_=Y2F+,0=5P_[7VN)?XC$3'OCW5=8==71L3AU(<4K_]* M_+&42E 98?(PL+Z[<8B"A5]6"E(5]F(')-&3VL42@S"""5DT!#F 6:U^% [I MA<_!(Q-Q& F4$OS">7B(V ,@UG*&81+$)#-VJU8!KL-GV+,[<(('EDK=D L1 M1F, &.G48P[!:M=^AH=A0AC< A$!N0J2887$R^[.^LUR^GA3W=0=]Q4+K+8[ M@*EXX/(1B*L8.+X/,UE>(A7%2#)'Q4I&*-9LB%\"V+@<^(W!+TYL(5IBH)V: M"'\$8'T.?X?]=]9K_F;6Y+#(UQQ^HJ$=2ZT=\( R&85^.H]"//$KZBL1 Q" MB0IJ&AA$3OI?3I X@"P<&466 ,/7\?1(%F7HH-V*HR"O:<]8 MU#)^)-?2BD.$YA$4D868P=E@K2,@.1H !2#\&UA),'+ Z\UQB9C*:-%S0(VY MN#H8$;",NK>XO * ;C@$10]BA@H+$:R@$#@K3.%*'5VKUKI$9AJQ:OT8<*&4 M,_.D;NZQ@/4Y6"Q?'Z+/'+(%"QD3<-A";2^9!,U5'#%2"_"G0_BCAV%%S($G M4K:89%Q$!(P+*/LWVJ)'Q2$D,O .O9L;O-VXF'[B@]!G@%775W('=-(6:][C4;SK>VF57*A2_PNYM5WIUMK*D:IT M6K6B'U4ABH/G%CX$D@M!>),XU22*44O[,#K\@BH) M6&\:*B5;KBL%'.'&&;O"K:JE(8ZH7T#=DD@95]HN^T*_@'WWK:].#&POK,W,RNJ+ M/-P!;4'F"-8[)//-BO6U:MV!V#H1T#6)?7*+LS^_.$_6;^#SCRK6;?6Z:KU& MR4V56KWV'N)/T!6\WQ?9E_;[-Q!!^^@(H:*] 2UE?&_F11 MQ;H#:HRM^P'S8_17_RL,G!C\9>M#%#[!YSN,56+K/ZO61\#/ !".*_PM]/MW M,*LGJ@!F!0(2=WI]'UD?[(B#IZIKZZM:@,DK\#1]JVZG>,0W\_6BP@0?$'TU MP 2&+-JH3X[T(L&9$\Q-4%M7M?%Q]%QIVUV: 1"1(QMMQK8HOG8 D1 U5> MBU:KW:I+F^2AYK[]3^O^7\ JS*M87[YD]I?6W5!R/3EZM:"5$X[7!P64,6 M\9@8]HE#\/G('T)05 *>(%,-"D/]K$@REZ%29P<(PF+">4'\J:48[I!(H/0I) .D "80F8>)[F)7K.X^@\?$G4.G MJ!QM4<)PV0A=$I-R]SFXLBELR]+LZT4,Q6CC'M-3,FTF,#T?C]&V+0DTFF<< M:+2KEHZSOSFC4+RW).I.(:25+.3*]B@X!>M'9>^HW3.>"*Q*.&8,Q M/ XO8Q&C@F*+F64GC9$=[Y$+^.4]+8,23Y*5)S@ %X8A#00S'G<=?TX@0@/@ M\WH?'0]6)KW=>7;B0XA!'LSW,05[:AIZI!#*A6FDTY(V4RKT%%.@GT72 M^X/<*S1U6--!B@AWP+P$5#% !EXNDC,>6.29IQXUF+J(29-QPDYP(913P:+R M.R0YD '#1_0Z@/\ &QY91&6J,ZKC%\#;$5[X)=V;A$8$8N;UDF)=) $W.:(, M)JM4G:HKK ;W0%!7X6J @G> 9I;%E1J]N8?:?E0CU:^O:N ,=_'5BE8=?99-6'19]7>A4J415DS ME^K$2\TFG)+,UW]+;:%EL/6&'M_>!J0O3\[[6_L^*E0TMCQL[7C=VSH\ D MYCR7CT7XR''CQ/'/$P$_6#0LAQ$MX2%GI:&2<7B.B K&X2D]):_237CGJ?0_ M@]'C@>#N>2[_'[CQOAR*U!B][=1M*:^15(7YTS\HZ8/:7:=W+#OQ]%; #67M M!:[NFN/'G!B=3N.\LK,\BZS\I+LLN)GFYJXEEU@W:LU*I[OI71GF\JZSE3-C MK$I#"6.LCNS@3&.CUJ!B#11-60EIS%-I*6/,4UDH8\/K-7*2DICH'9;4]Q[-\>.:HIVH]HI/9%^ MDQO<#URA-RY$69K.C!8[.LI(5\%X KC:B[(2R8A/:2EC3$Q9*&%DI*24,2;& MF)C2$J3\XF-,3&DH862DI)0Q)L:8F-(2I/SB8TQ,:2AA9*2DE#$FQIB8TA+D MW'?@'46U+#V):]-ZF6FY*8NQ,57_LZ6,<0.V=P.,^)RM^!@34QI*&!DI*66, MB3$FIK0$*;_X&!-3&DH8&2DI98R),2:FM 0IO_@8$U,:2A@9*2EEC(DQ)J:T M!#&[RXZ@7G831GW&S?ZR@Q.B_,T91H^5E3+!M,Z4E2/G%QYB8TE#"R$A) M*6-,C#$QI25(^<7'F)C24,+(2$DI8TR,,3&E)4CYQ<>8F-)0PLA(22EC3(PQ M,:4E2-GWEQ6*8ZM>U'<61;1/SR,>'7S+F>X&O!1Y3D.J#MX?L,JUM$8GEI)Z MERO?*VS<#ESMZWJETSCT'9CEO6^V3*1Z4PXJ&8-V9"K1&+1CIIXQ:,?5=VIL MV5')G3%JI2:/,6HG23UCU(Q1,W)GC-IYDL<8M9.DGC%JQJB=I]P=I<8U!K'4Y#$&\3S):RSC MCDG>J+;*H6F-83P.T32&L=3D,8;11(K&'FYA#ROU3J<"<)1#S1JK>+)[9\_8 M6JK;&AU<_RZ+Q2_0UW;&5"M_9]2$CS/3S!D?YVC).^WL[)G"I^[L;%LLWG>' MG'%V2BF@QCR6FCS&/)8I!6"LXK%1>HMBL3&(9ZEQC4$L-7F,03Q/\AK+6)IB ML3&,9RF:QC"6FCS&,)I(T=C#PQ6+S](J2HJD!%E$N\/6BM_&6)_,GO+XXP88 M*B#DYW78=2[,Q>Z'MK2]465+EC(HZX&S// MN@Z'PS"P[N/0_7/ORSV8SO@>:/7NNBWKW14K'C#K0^A$H"Y"1$8<6LX3?G0" MRWEXB-B#$S,K[%N->@LUCB4&(,H"OW$EW@3B#3_C4(#+D1.,*Q8(/"J@A%D_ MU:HUVQK!K/0J3AF%R<. GG\ \&/)9 9(0@@AOD"X(^+Q@ <6P_EP ML($S@?B^PR,+..M/%BMTPJ" T4XWQZ@%PR&(GJ(4 6B]_JG>:E1: V7/V># MOH$IO'S.)^[[5C_Q_;'U"$)A)2,U'O"3-69 1\ L?P3$.-$X14=Q+L#R%&]U MJ]85H6"ZRZ)20#^M>1A&,7"_9_T$K]OU)A#+=PBEBE@(FN(3^"A8BF.P*+ . M+F"5KI]X, (L]X$%+ )>P'4ZWI ''(0=AGMD%GM&[F"B0C_^5&_4*XU.6PU# MJ.@QF-P-'P*"AQ@K?0O'[B=Q C@'[//0$_@[@J>@02BKIZM#KGP1(K?M4>_2D60_6J_?X.$%B/FPEV5M4> MBU3&+$51 4UA5UIM.?>FN@+4A,^EMG0L=^ $#R0LL,(X"OT)ZX#Z8A[%?*[D M')C'"@BSA'$WB7C, 2WL60Z_CGH)PEA3,:3SAV$2Q&)E->,!&M4C2>"R*'9X M$),V'#(F!Z#'03!A!) B<<)J !FQ'_I^^$0+IW8ZD0P!:I@5<9JY5@5V=5S0 MP#P>ORL)9A9[NKK?+962[S?8QB8/W99Q4?T6<5>;D %(NR.$L% M21";^,Y(L'?I'^\M%2?7] NU#G304+=JMP]]JMY1I,D _X %($G]U4'W5]C5 MRR4$2\/@Q9D2R:R[2)5,Q77SHO'N*M'X%I3\EB@7?@6-<@B<47J' MIP$IO=))@E%F1IDMH>3_$ P01%\]LLAY8-9OE&O]B,F;\BFZTITQ7!HZEGVO MZ%SA5*F TV^<^!8&%YCX8U[%^LAU#7QVXU;D*9]D&['+H8_072: 1L')29I[3;RAAK%0Y2%?:9DUCG(QQ.F*"'(%*-,:I+)0P MQLD8)V.7&V] MHC:,E)9:1H[*2AD3()6%$D9&RDH98VOTXR2[-FUU*RVUC!R5E3+&UI2%$D9& MRDH98VOT0QH[W=(2RHC067;8'45:[1_48&[":,^X^5N6%ME?[\1NW)2K[;R"0W&M&UCVD[_1(8R4:DT@K>CH[D,>8Q5 M,]0S5LU8-6/52B!XQJJ5FCS&JITF]8Q5,U;M/ 7OD.U]BW*39WS;I'ZJWO0E M'24N "P]7<#<0'GL5;@7)/&IV]!M-_J>Y5V41D(71(AG;#-+0QYC'_=!WJ,_ M5\F8Q9?:DVS,XEGJ76,62TT>8Q:-631F<:OMT]UZ.53L<5A$28R4%HO(=MB< MZUNZ(C5[2K\\M737N^H0_O(V$1UAGU9L]O_Q+QHS:[9\H_+1NW5WQ%6!>I__&4FPQ'N MNBOC3K\19UU5L%4R.&96IVH5T*5=37G$2RLLB:XK9X\L2/"*^2O7E==,WS&7 M\4>Z11COT[Y/1B.\+GL5!+1W+!9[4!8WZC[O>! Q=C&$YP:"UAGP(/N,EZ)[ M,PH!]"!>M#-];;< 5<'[W,5KKUS0&.&0KE/G\0 O=N>/W$L.WX0\2<&&9WA+K!6LR]C7JI0M^#:OJ+)N_2 M(K[,S=/=,MP\;5?M>OGN)SV.T*/AFSZR;#$AJ-8R.6,1]E)Z0Q M'[LT'YO>ZFG,QTF:C[/3)L8LG @AYYN%;WGNQ5B%(PLJ2M<.7AHJ&NMQ/$0P MUJ/LA#36XQ1C"F,]=E75+L]!X;(VJS&?9I>T),I?&'FN3WJ7N"&Q) MO%-OU&K6JJVRTO%<#^G[N;0$F1,&G1C^RZ_AC'$Z6M(9X[1.%_&AM]48VV1L M4ZGP7WX%9VS3T9+.V*;5J=D 9)65CL8XE8T@QCB5A!#&.!TKZ8QQ,H'3$9-D M@6TZY(4;IA25E:(VW;!L[GLNJTW:.V7()AF3@ZNMUSM#2JAV[G-@)D3$NI M\%]^!7:NDE%^RAC38H*6\I)DQR48LQMHYR48TU%3,LH<25N ,3FJ!%/F[71G M*4"F)/EHE0AVYAV\V-.2=&E/*K0V/,CIEZQI@=67^'H%8JUCUFMVQG,"S/C)7 M?6O3M^V*Y8:!"U!'3LS#P K[EN.Z81+$PHK@8?Z(Y+&>>#RP!,@5[W,7YK-< MM9,/GQI%3, (("667?O9"B/K(6).#+/,&\T1%ORO'_I^^"3>'0#IB\FN,R&Q MIQ+T7U_57EDN\WT495AN]EDI"?JLU _BE$69LE&: @34=T:"O4O_>&]);=*M MZ><0'&:[:KN[91^99GKD\G=A>X[#P0"* &* 2/57!VTL:U9KW=6:DUZ*?CI- M>J'OS3)21,%N2L"%M-Z.#T,Q79J32'+K-LE2(^RR13 M^=._=J-@F;2=_;!]\\;$2K9L2\F)"J] M"CM3R3@"RACC4J:S68P$'=,Q+%NWB)T8L8[BHFESU-BII.>VI^"I&[1ZK;KI MW2+[WAY@3ALK4U5I-SUP)T:4(U"(QIP=,_6,.5OS(.C:P?LAC#D[XC+4@JCM MC/>$;W5VYDL>#FWV@Y]L_M'L"-\9S;N7U=+L:C);PDM<-IL?\YVQ,3P"C6D, MXDF3UQC$\D2-QB"6Q"":,U+V' ,.F'4=#D=.,*:E_;5;MSOOA36*>.#RD>-; M(AF-?,XBBPOK^O:K]5HP9GT+8V9UW]!A*J,H?.0>\V:<>A+/&?TA##V8(XG< M@2/@38"4GAVQB-,O\B@5^*7'_/#)'(U2DJ-19E\_/-TTVFC*CM%)L<&'B>3 M?3!'K)1]K_UY7*16(\S1+FQ%64GI+$5IQA!&%NQC>(JY6DEJNYQ^I78 M^[389UL75L1\!VMPP*_QN+1M$^;0K9([9G-)M]J50*:7!5=[>5D]M($S6]1+ MUL;#Y<<7&.!GC=)+X+[^&,\;I:$EGC-,: MD5.W>EE6.AKC5#:"&.-4$D(8XW2LI#/&:75J-KK536];,L;IY8U3*>\G.[_B MU*9GZ9O;)\IJE/9.&3)*QN;@:LWM+:4CR:%/@33Q4-GUU[E*1ODI8RQ+?N"& MO?$)5$: C&DY2?R77X&=JV24GS+&M&A!RZ9%'",_QK*<)/[+K[_.53+*3QEC M6?(23./@9\L; 3JF8^2W/P3MQ*B5U67*W 1JKDLYC8:"[>EWZ@;M\)=9EG>$^(N7ZR#$?V[5;-FNLGR]W(.#_@.V-36'Y]:WBD1"F_PC3V\*3):^SASL/#;CD4K3&'QAP>&U'*KR^-.3QI\AIS M:,+#\Y3-%4N*;V,'D)8]Y?''#3!30,3/ZRQ\L1I1T/SR-A$7#XXS>G<=!GAM M7N3$/ SNN/CS(Q>N'XHD8C\ A@]^Z/[Y]__XBV7]DKYQ)V_'NL7+L7X@[AP7 MWQ4S7K2X]^NKFW\"Z>Q.^Y7E J3PTQWK__KJ&K^M->S+FMW^)]YX6K-KMOSC MLE%[]7>$5@'['W^9B3Q$57Q*'E6!X7<<1[ M21Q&EO,0,3:$!ZPG'@^LZ]NO%NOW&:#GD5E7R0,LWJI7+. -^/]1$HD$9K)@ M&-!"[L"*M5D I\)RX'\ 1W#!GET_$3B*/EW8MUP6Q0X/+&<8\##FKC5DPQZL MBEFC*/02&*1J(? \A"?QRER*+FP8-W6F#D >^!9H!'9$WYG,0?@<8(@<7S\ M#\P<"2<:6Q[0W@*,62)Q728()!CB@H; 2825!#[\8'$:'K_B 3$,0/D4\1@4 MMM4#+ *"6"0OIJM:GS(L_9<#<\)$-J&I4P&(81@-L8@3^,N#$0%Q['F$@.._ M/ <>B 30"TBC"*:3A R0<.FOF!NX"I MU_>,6<3H]IO39>:/281$0%:(!X!7=4NI)9&:W=-I-6J2!H0]O)ZSP*#@+'G6 M3W;[LM*YO*1'?FJT*LTZO!0Q,9+D],<51#$'$J3\B'SO#AP!4_6C<$A"$@^< MV )[#&_V?7A3]EI5U; M2LZ4B#MB*PV81L.NM-I-"4RK7NFN PPJ^9X#VLX%&Y$PU(W(:[MNM MV_;[PE6D?"ESITL1 \;B,V#I_TK\<?#+2H%EPAZ:?+1_ M* . (C!F%V3@_1!FE4R!+WP.'ID 1T&@=I&6'^SH YIP9XB40G[ZR6[5*N# MXC/@9@R&"R(4=+.0: 8T!+#VP\PFK7?D;G!YP@T%2[MU'4!P/#U 5B.]-IKD(7.>X'&A%PY-V*H MLRO:O; MM64W&U(\[[Y^GA5XR$= %_\KX3A1"U%.2F%-3D&]X60V36.4IAI/ 9%/U=SY M5(TZC5?10B\G'Q;B>M1A'T$)5JTK 4(8P4/PIF2%XZ>\+EBZB">@%[S8:E4:E_:YQQ5(\U45#]G(#_FR(N))LB+-HY M$H)'E:Z !>BQ@?0[D\H8\P#R.(SE-IEZD>SQ( %F6ZXQXC"1/J38+ M7,RO*$_%1Y=YO(!E@2-P7*4%/X1.1%[41])^X"$2KX'.0IL+_#@1210G7\>( M5ZV;,-I&)?S4Z*AHNU.I-[O$WBS5L.3P3,$GD:.25(,,A\4P9GX4\P!4BAR_ M4B#3H_1&0TI:L><11YR"1M3 ,#V 1RAA1 0GB+Y>$& 3$;K5;8/(C3 -35<('DS$" M#A1/#CAE]PD'75W'[-$=1^WO"=0$4OMT6K4N_. YR@.!<"CW9>12FNE2E-_7 M8_$38T$QA8SQV&(POMQF>J+^'JT(6$]8\$ZUBO6%20>--*20R2\=SB>."M,9 M8_I9AJ3D%%)<0?J!5H)O@#C&2!D]FRU'[S%@/Q+( G[H35 N8DHS=:IR+7:[ M]MY:5EI:HU!4K##=)SW!_I7 NCX]HB*864_J[+J>=$!EL1$$AZQH75:MG$@Y M2TAR[7251BE/*.4TP]74U;)4(LX(U05JTMPCQXP&%GY(!2M/F63\%GP5_((' M;D3*@-(."4D[*(D\KBPF-9)X$$:P1$_JCP)/!4!BD?G(*]>J4U%:D6 M1@00FDN>F>M]'Q?Q-/Y<^)=E[>')HQ!*E]R*>1'4L414-Q>35YM.F<:Y%JYH M"'\7['O_DXI1A6[]NOOHIFB7O9L"\(&Z(Z!LAPB"$S'YB#SA7'E3-P-P7]..R ]*ANZCQA]%1=IJB*&JBH MG3XY40 X%K[?1OZW!W/=-8OC;.>*\SM>AJW<=U9;'T.0#J8]?I+*,0; M"TB'J@$]+2+AALUH*VG4,K5R?G $=ZDTP14^?,('!L^IYTGXP&2A$B(9U@-; MM E29S632TO MKQ0 G#ST*J3MX1$4+L$]EEN+@HN-2@44@E3 ]YF+C17.B%,23SGWN&"I#;U4 MF_8(4RF\UCKP9L4>JC'#'V,+*^M5ZR/W$QQL1?R#-D\.@7T=;\6%J>2LI )H M8]FO!R F(JOE8%"51&.%VB$#0GEZ]N2*:#"5O&U7K':M6>ETNX4IY]'3&L : MK!XFL:C;T4L;ICP-QXB@:=3VF.LD,NX#@T%TISKU$YGD'J9N8WY!XX#EJBY- M]RPQ!T7;<0-&ZA]HH[[WLWK/YP#X,2'#+-_5+$BWM@^'URY]_S#BR2)$65^) MH:3C]]%'?HTYVV>N):YH[#>ISLN;04+,I0JL/3T"J* JP@2=QNA/%F=:()LS MGP"[NK#'!92./Y8PR-QGFG'.9U:#47\7SHDZ>I;+J_=2NS[,"?XONNG2Q43? M+YT>OP:\X.R44]?\P3Q+HWTYX* $(W$SMYPQ;I M,V30$2,NM4281%2:>AIP'U<53D\ WO*,\:FQ)P!?&DP)_H(=S^FD6K2C ?^C MB*RA)H1D+S-:>#IV0_3646]GR'VWQYSD#,^*A+2=RN@B<=Y#CHL0M\OUZON$ MFM56\^?UY,D^MI%3LDB.)BF&YLV*Y^B*6JZ@J/'!>,)/C*GE_O=IE(IN\0%4B]P7Y M)WUH4G=RG)'OJ-Q)SJK83< !*4XTAVLK*2R*[:G;B+@W!P=[=B1G4_.I7(9H0+1U!J^:$E7KT)^J2;_/+$+\\#S(I*=%!L[0C9 M+$%_:,%U)=^;(0,-V5,_M6&#N$#CGL*2"G2CB7, MJXBTDY\*M\\J?2SC\7PM(HO4E1[2MBX$3IQ$6K^BML*Y4406&V28FF@V7P2, MC!&L-#2 K_,>FZQK/I*)^R7Y@I52 ,6LP6W$P^B6LBYW+/6\70H]KLA9PC<_ M,N%&G!QY/8%@[RR!L"NI.5!*81)SIYM,N,ZV^19*5.L4B)RY63H4^OXJ79JT MS81:-2M:MBYB6N0HMZO@DE)3@\UF $"6SYW1.;H$\C5AHZ8SD>5_\Q(3M9?A M>Q!_ ]!<@J347 4!?>1A(ORQ5A(4LB40E(3J39O6CC#@ZBVCQ2;4I9IE7351 M5#+78 6N @__\RFW!?.+6]WZ"VF6\FH<'V)&V?_]4UWML\3RQ?BK@IP10 MN%!+@D>:EUVU&[YN5]H-.B\=N2P5C'GY%=M.O?N*+,C@3ZDFG#\ O:'KT#7> MG3EYX7WK(6).G"87YI%SJ=I>2?$6=?6/R/$8O/,=<7VEB'J7^>K39:2&T=5* M%=I@/J9M,#,>/UFE?C4=]0F5B0HN\KW!:F-WNB6&?"^*]1XB M++B"V@^Q8I5ZGU*O!\OZC+1)BZI-:W1"];UD%#PL1M5E $84?/2!\M^?2#EQ MTCT#NU&X<8FH>X#4/VCLD#:=QK?"11>D6?+6Q7&>A-'GYQ %2&E!2B*7^KLLC-QDB M2MQTRT=*E>D-(&) 55"G![.%RJXIF J,4^CY^YKW_"$ 6NL"C0^.PC+&HKUN M#+?IX5[!=3:U+=/_*RGSHO[_K+KPQ@O<\Z91^4JO?D,U?TH*S_2J]?')X8=QL-H1X>Y(ZOR$2'8 M,SZ$H5)\RX[8RH_26E;XQU@;CQK+BRYY$D]K2"7MQ1XQ@'YDZ2Q%W3*M5C!7 M21F1F2.B$4"_6O9&E)V(12DG*/N.S9(,N7GM/D<0&^L#IH0U). M&4S<-E)VI#.2%7V7*#9<4^I>JP!-%N+31NQTTE)=$&DO^;>4L5D?0=IB><1$6ASX$VF '^\7E9-9".&QN.PHB.29R#]$PU M97[C7-RCSY+C6V8D\I(CJ-T_Y%9^I;IA.%5$18R<\-$71=.*53%1Z!-$MH"@0541B#,P MBT/[84@0Y6F=@,">[#JF#)=LMT4)H40_8#$A*A4Y+VU1P#;A$*(J/P_P9HO? M_/13,4Q!HSHE$G-6L4S._^; HQ UC%0>14A]XX8/ = E+_C1D6,L<'S5?.BG M>_ UH8*5Q1A.3A<'M(=4PG]Y!V2(!]8DQ-UI$(7QV8A32(Y.7Z*VXE#R28:E M%$=(%/LONCE$^]FA&HT1 MB4,G##,\.4*=*8=YIRA"]B:USYXA;@&.IX/\J+6%*6]#[ES#R%^E!F3/ SP( M3X)FT=MB\J,5L\P/0(3% ID3?\T?WZ2Y$.,!4?::R?T-5/9XE@DJW*^,^T?2Q@R(>=[(.=!$JQ:/U\I+-4= M2[7"Q)D9N.7B S9G(,) B1(]OE-9XRKP/M,I[\ 5N#-_QO:*G9^F<1PZY)YV M1!+:+!UOFRF2YG'ID=1-E;4:D#D\U(TV&(4C92^?2&G$J9Q,[!?#D\35*5VJ MM0 /7<^^H;;*[!@IGI_/%3E<[I/2I#=OJ%#N>WJJ8%$+Y(6[4!V?J?:SCF3" M66A=^ \)]RB1"6(LY(:->)#F>4E>%.739/6/< 1.>\?NI@)]6,5OJ]<@4N._/6I?:KPM>E,<* M>*^HLY0B^,M+3Q"2R,3T5.)C4VNAW2T[6&V"UG*^,)C94"?FU2*F^R+U80D. MQ43I$J:X)@,[/1G,4R?R/=!KA(2\PIX3?#$./^?FV9_WDOLF37FEF ME4\'#O$E\.@[/H]DZ - 89%>&B)E7JF1):4-QG'*>JDS.!5KIQ4#7J@7%)+N M]VE7#L+S73O1;%643N_4E*A\G4Y3K[V_N[_*/MGOWRQ"<[Y+4>\ 7_D,T5E4 M.BXZB$6$6*YBXG!"TZE3O".I;JC'0^J25JVUOBZ!F$IM5"W@4B*_H#BXF.C' M+*@=(E"QR .(5\W]SIN*SGI9 MIG?2PI ^$+(B.$\R40Q4HQUR6:-GNL?79WBX[+UV1L'LM:)6D>R_B($H\2Y4 MIQR::<*0Z4AXC%X@+O196D=TEZ<$NBA]A M>=C^1H5+;=K%1UXL.SUF?5^OZ"R"QY%SXFT4!B$F"+2VVP4!Z%Y.GBF_IXAU M2""J)L!%O,WIH;FYR?MOIAMV3C+S_CFPOCIT+']3YJ;R WUGJC]Y=IENRE!5 M%FP9.:?>[-=_'Y$:TM^_NO^]\/JWL$K@7.!YU+K)5-&SO ]"=1BH'KWKM/]! M&ZEJPG=4D81>.WWZGU5'O8CM9+<@L7514I.F@3V4PM&K?UX1U%?"_#G MS%E<+,&M3.[_W]ZU[;:-).W[ /,.A'?GQPP@*SSHF)D$\"'*9I'8ANV9Q5P% M--FR.*%(+0]VO$__=S=)B90EBI1(L4C68C=K6Q+575]7?57=U57!3((Q7:6IZ.Q $$(ZO?34%VCLXM5$^*@! S-!J2:KIT<3:S2 MG;ZL+"FH#ZPN!NB$^Z[=I@YC])VEMNBP;7F:/C+NR!3TWYFI!"$*WR9 M1'DQRZ$E?.OX[LC?OOXX7QV_KO86DR^$1P@Q;R?X'EY1?;EY3&DMN _-9#;U MS2F3@!J3S]K*7-W*",XV@@+;0=,GWIXJ8B=> C38UTAVFY#Z4>+CQV"-ZJ%+ M;_!:$G.6.<,P-L/K[I:?/'#)^/Q!7'S1.*,/\PQ*@R[%CZS"*C_9#D^JHBH? M?$T943WIP$T*]2UT=!SB.7:L@C&+L;CF^G->&NF)G ;"$M1E;GBL]'WDY4;3 M3_J*QO)205BZFKTUEG?%7C'H6WFM_ 1&]IJ;&FRT;[Z#P)WW:&4WN18YI8X) M>7!X%?)50P?N.6>@@-#,#TY%.6'F>:W;N!U_%;"K/$6!D.AX@]72##N)4-C8 MU:O5R;'*;Y42EWKJ L-+@;"5SD[%,MEWZ$-'N:J#WO*+*WZ$F<;># MQJC1PEDJ@\Z[1X;59,+ER1#/86'79 M F=-)S/P_G(_=IV4PX+_0= :?V:@)0$XLA^R!WR\U7UF4@)@7 MB3_P>HAIYFE;DFNLL&78\N.!F"SE(M30!92CJHIIGK)<6]ZKH"G0CA0QV_CVZ"+P-2S);PXI@]S"X?!-WNSA6 M ;%U@JLT01)-^+7Q_.6@XG_@]/&2$6R=:5%%B"!=?+5)Q!%GT<\\ ?>VKJU)0CDWUK+:?**CK$FXP'%1"#1N[O3UC=/&*:K-,&G>7R M][ )//\];"\?%-]>-I,/.\&SXWMUX9)WT0^_"4&W^"$=_ZKG>ZS_>6K'^@G_ M3U$=ZP>#[GCTJFN]2]5'%X(W)KK6;VA1O[7X^"%-ZRM>^YM6"?\IUK#^B"!) MW8%\$$8%(/)JYWC;%<=1EOI5Y6-#AT<%0L&13XZ 4_2G\Y6$0^B4[FB'?B5N MF!Y!M\ @F2"+W+T-&B$"QI P3,S/OSW/#(^<\H92=-C/CKI 4U(O,]]L74'# MWQ0DX^% :^W^ (;-0;N_&8.W\7@L8VAV,9F(DXL2C4H8K94##Z3BE!?!14)G MM?&PI[:4#DE VLU'Y&!?J7PD5FS+1+R1:H]FZR!!]T^PB,D)'^E U&(> S]X M+L)A@ 3C*5@8C^A#0 *D!B81R0D*$DA.2$X-)B=YW)''(E@LD:$*#71+WSUK M3: [\1V+WV<)DH6,'_QN2\5;0^A/0#D80(M6/V0"OP'= C;;?D?L57W B3I4 M/QU"GH&"!.H(5&209U9P#3H*\@PT4/"8%3I"_%X?:^W.\O<=^VF]-3:P71ST M"J @@18-*C+H%>")*5A :J _R#%0D$ =@8H,J$CA%OOB 1>5JHW='AK*=?F_4#> M-VT,-^_;JV3(5%"00*:J+73(5#GP["F=<:\/%DND*CQGK@]L7XCKOF/]!H,& M-H1505\X1#/6.M?BWCP8R&JPNXM[\W5&#_?F\T'Z2Z_3'^^;^(:;\\>$ZE<8 M*"&CU,T/%OMN]2^Y&9QR#;=IY$[HCR&86.S&]A6 M*B48FXN4"!H>I$2D1*3$ Z >=<:*!,/&UH,2 S0B,-)PJ_9P_2UOV[M\5[RA M;Z7MA>.C6;6PWMV$.MFT^DZ;$=TWR?7T;D;7Q+GJ$IUU22*6RT^M[SSZD6O> MX]T]8_W##>_EG@ED^;Q84^NQ6%A3ZYBYJ&E+]OM$$VO7G]/QO@@.F9I$\UR^ M7\&V+IY51W>%1_I4EC"P< S6G=WF+;!YGVL&9-B$G5#A,(';' Y!#>$0=-]A M7Y&UI[M@N/1[B$OX-SX0.D+LFTWMYAA W^R^V%5Z\)IUUMU++OK(4<:&J@>C MI0%IJ"IV)6RHNAG)*[LKV--MW-#LN7-WJ.J.&=A,%6U^D]!"FP\>R?_P,1"] MG5;_[(DXZB-IY^0__B".9K@MG?V-8V@$!M<@WU>/ >?[UEE_Y/&F((D\WEH> MOR5SU;"HQK1S^A?T%4?5/%\UVRF >^+,89 HP'1C,"BAPU,C%-#A 8_DV>.C M0QY5KZ6D_YF2GF&YAM;.Z?^IFCZ8Z!U)KZCD&S %'<.#^>:G+)ZKIFII1+!] MS_54BTE#4#WADFAA%HG$LT@&8#,;M_DQ#<.I&9G#K6D M%;'7&8ZP71,P8.#K&9(5&"20K&IVA04Y*@>*(C4T4(%$>@*+#-(3%"20GNH* M'?)4GGK$704JCDA38)%!FH*"!-(41E'-92=6R4_N/,?871[6"S_47N#)6J>V#"[3<+ M":I?8:"$A%8SDXB$5F?TD-#JE7>*7%8KO4-2 PT/DEHCT4-20U)#O4-2:R<\ M2&J-1 ])#4FMG7I7Y;7!M&-0W?8?3"+(W?:1W;EJJI9&!-OW7$^UF-0$U1/N MR,(C\P?B"(K8$611&E:<=I#BJK08/?BI.UD:Y*;AB;X,:'@S=M,M#N&F.SM2 M1Q'ECMB78=C;[,86%10 7$B/,.%!>BP#WGU[S",KU@UIL2OOVX4>";&5%A<) M$30\2(CMA!>9L6#(E6X?AJ5%8JR':B(Q@H8'B1$C1>3# _BP(P^''3H.&&86 M6;&Q=V=;S)9AMT:5S;_(P^(CY+6UXF5%K/LY&FD,?I[;POG9V2D:XZ<[. MH8?%96?(H;,#4D&1'D'#@_0(:0L 6;%N2!]P6(R$V$J+BX0(&AXDQ';"B\P( MYK 8B;&5JHG$"!H>)$:,%)$/JSLL;B4K!HA$@*1A5^U9\5N/G4\NWZ4;3WM( M*"&0G_,LU_0QAZ/Y_:WOGCZJZN+=G38CNF^2Z^G=C&)\KKI$O[#G"V*YJF?8 MUIUG:]^O%^Q']TSSC"?#>[EG$[RG(SPWZ8L??GHC"+]'S[NRK2?B>D2_I?\Z MAD9_XH_@3]_R!,'0WY],OE&DI;%T(FAT0O2E6S)]?W+!_BHJTEB4!M_8":\H MB5+PPU@13SZP285S^NG-5B/RM^]ZQO0E+F1)7FPR*_O+O825=S\CPM0V3?N9 MW8[FRTIP_3D=-?U65W"6$J8BF\]MB\Z<25,-A?QNA7VEDMFZ(M_$T N,'I]B M8(O>GXAT*1#39-:&SG_Y>VC'^.^AA=3HH(BSM(>A,:,VQ%07+GD7_?";$/*9 M&&]\45%!@%%7&E1=_:86[BR5/Y4"A40^J30/4NJ.=P 6T56Z1Q,LUB)31!UM6_0.L^S5 M:HNT[F-?T*$\. ;:>[3W(9(3U7"$/U73)S 4#HU>]1APHP=.$]"8H3';@>1_ M^!AH$'WV1!SUD0B?Z"<]X5+UB #/T(&K!0@&1^AW.K8J9[@5T/P#CBO;.@TV M!SO")='"JQL2O[I1=8N?@^X_MO*XJ@:GD6*"]0Z$K^F'4E67NTW30%0PF,AL M<_H1"60I&-"!3:I H0!$A0D4$>@(H-< M$R_[-)*43A^Y!AHP-= CY!HH2*".0$4&N29>3&DX @L4JE K,^QJL:WV)T^P MPQUI6*C4X) .V0=/=, "4@/]P0@'"A*H(U"108Y!C@$+2 WT!SD&"A*H(U"1 M08Y!C@$+"/3,M$J*4]5B7VUB.U-BP$Y8RW*_']4.)GIBY@H-2&V'4%OS*S) M0@F,XA54F@OA059#])#5D-60U0 H'K(::'B0U9J)'K(:LEH[%:_*]+ZTO&M?5PEI\5AWDI$66VEWD19!PX.TB+2(M'C0]>F1#,/$UH,1 ML;EP&R'X4;ONU/I*&[)$[%\C-#_.82#9'OV;$XB??NM_Z5NHO1$D\6>!#O/1(:I'OUUUPX;)[M;FQU5HQYO8F@@, M\'$:'8\@-#J6NI(,KQUF/3QM*.WCQ*Z"W>.V&4F.Y3^D@?@;M72K7^YC9G/U MUX_,7FZS3Q1UB JG+G5P-M+\S).+\)A/D,"FH&"/TKKFA(WCCL"!X#4]+Z@G=OM0 M<6QK3;B?P0*R)0QJF/SA6S@DI]I"A^24)VFUZELDEG-\N.0RY#+:@H*?&N(7%9G])#+\@5F8R2S6@"%9 80%/CF$,FLSN@A MF6%@UD#% WJ;*>TH3;?]!Y,(ZKI CZ.WEE9,PU+9$#X.2%'!+CI M%#G>/]XKULR^YLBM)K:5JEEU(N/V>*_%5 C?7B(=-AI>I$,H$2.R(;(ALB%P M&N[W\Q?V[T35/-NYIT,Z-VWM^X>?W@C"[P<\0##T]R>3;Q11::R<"!J= M 'WIEDS?GURPOXJ*-!:EP;?P*Q*/#1YZ3BQM1D7V_>R'X4;O.],TV[<\]Y9H MQ'AB('PE\P?B?)-%:2A*HA3\,%;$DP],&*$L?GIS-&Q*6)1GGG!'%AZ?J*"( M'8'-45 M7;BD8@C^*O&_#CI,TBM)"O944$.1"^A^>2_AX:9R90X2S,:OX>SK-=3]0'409OG MK=Q^@[\Q+BD)9CX0OJ9O>_=&76QF @R3J@]\MP/" ICFR[\&-@[IJ;;0(3W5 MZE06V:D>I5$QJ(J"JGW+U&,_1ZBD5#XR 2DAY_#-.ZGRR@*H0L *XF!(!-Z$ MM50S:H ,D@NDJC6H074J4'-PBEC#P*I%"VXLPM:4[;G#$6PZH963CVDZ$3?4,U M&&_+TQ^9B(6%[V@SU:6?I"/E[UT0Q^"O!"5FZ"L/Q+2?L60,D)(QFQO65%Y% MH!X^%Y3: 6+63E^M*QTPL9W 3$D#\3=JCU:_W,\<0D[G]),S=_77CW02^C;; MU&Q1+:OKK*3!RNPL?\'2,]!K$+2KE6?=H$&R@ XDDD619($%:Z!;I*.21>NL M"=)"0X#<3@M7AH6L4-,0 EPR%!@4:\(>+10Y<@5T()$KFAA!(%<<8KA 5G$) MSSV:?T)]%QWV2<*IX!!396=P=+UZ+V#32; 8&7#';"MTV9I(88X/F^UXW*V: MX/#J/K#\UNV M*/F&'P+A^146^B0G'+S;UK[#J7U[ M#&!7#JBD5#HRG)20<]ALL:L-.$BJKHZ)\1!T^]56S8"/##++JA")M'=E+E0@ MI)9&RA^^ 6NK9L!'!JDE%K3L>XB#^H/,TDCYP[=?;=4,^,@@LZR.8)3*:^ZC M M6IO/[A1= :AM;R7 9R$BBVD6E&0L'A^#6=T*IO\@GW*BPDG*I.@@-3FPT2 M*/"M(7)9G=%#+D,N:Z#B(9)$/"P\/ M1S ,+=(ATF'=0(%O+Y$.&PTOTB&&A^W4S8Q'BF\]E0IM^2[=>-I#,@E!_)QG MXNEF)!S-[V]]]_1151?O[K09T7V3N-?3"]MB'?0B,(OR\?X-$_?79=G^B7OD,7U@UQ#%N_F]&5XM)1\I=< MP=#?GTR^41"E-NR?3]R07[JZA(8U$:? N?>AMTX+IA#;CN&3YT M!'10+AU/[)6S'X;[;?J_N7YU(?64"1?/OVR3K6[WBS$WPO=9Q'%GQN(K[Z/W MC77,DV1IO/SA1-")9E"4W?7$@#N$(2$R(R7+LG2\,_[BY//O36I+1S MQH1 M(A^TB&[4ESFU8M2>+67+/G%ANUYBZ8P+%4SXB<_6$W&IK3Q, H/>0!S'!) R MHV#N#);=CHE;)VMR8/*'+ \^GUE+/W^=M]I)A?(F>49NF'ZGO%$ M[HA&M>+SY;K.T1_O5QZ!0I4[B=M MY<8O?SV^/^CZV#*Z-.=LT^BV:ZVL2+WQ*#FVM2_.-;(TCRBP)XJ4T4V1I8$R MR#&R,].TGYFAF=C.)8V)O*EOGFD:>Z-[2S1"%P9U^2]\AP5'\3&G^2<'*$^N M\10TE31'8I/XRY_*%T-],$S#>Z$?_8,^P?%4P[I7?]S8KL%Y:<,LTEC_ $"R M#B7G!*YH1/9J#E(:4Y9ST-E,FL^_$TT@T_\0G/B5X MCQHK^K:)\8/]Y*[FGL-$]ZFC4?;4TRBYZ*GG@'V@E#_U-*;//_4O1'7)C$;N MG^<+QWXB/";8;^Y#>53VW#-L\N28.W7G#8UL4/0?[_A4A?'G_L\:+XD"X=^&0_>Z,\F83_0 MCU-'U/&,__&_;WUT?&)Y?9N4B?7CCGM18RU= O(.SR@'M$I?E'IEBV#KVRX- M=V&[=(CQR17K/.WR(<(]BQR+1AD,LBC#X[,O6NYUWQ/KACCL5(R.:&ZXKNV\\"\+9U_H MQJB8G=/7=GU2)9&4&IMH\'Z7;18ZQJ-AJ68P?1I+T4'=T@%?3]E?XC+,X,\! MD*$X#+=:UX6Y'@,OZ!*FT6]7BHDQCVB*$6H&=[%ZH6Y7[ZU"'14EU-7,+U33 MG!"5F9ZX!#,< (*3X(>%8UB:L5!-P9W1:0D/1-!](JB6+BP"U>T(_L*VJ*CG M[(_V5/!FA+U&Z"NJ1]_Y(GC&G'YD2F7(7R2JPTO1VM-WPB_&K\(ET?CW"XK4 M$9A&= 3;H:_0E_BC54&;J=8C%:;%)>C89O0];%^%?D-7H.)X-KR9Z]%!&-8C M?8+%'A)\Z;]5RU>=%X$]F4V-#XQ]G(6HQ/F_?XRHN?K-%5S;I-,S7,WAGE(G M]AYAIKK\5Y[8(W@V&PFS9 *3"OLF.L\%#H_^SZ)I;J 85UE*.3$I& MN)Z$!]5D&XKL#[80G*FL36TY.(T?&PDN/S5E@@U'P-8J>SQ]"OWD/\6N.!(H M(05/ZR97]\8UFKJ45^9ZI1DW[,ND^-+.<'(+86EGWFQ<'F\Q:6X5X7;99!3I M.;$(#9L-U5P]8(/A.-+Q[SZ^D20-^Z*804(I4TT**S*U'W\LB.62^/!C,E%V M;BP/<\]E,!)C!RTIX]AKP#M/7H=;3EY3A$]E7]Z =QZFYE\M]-WC7GDCWGFB MNNUP.V7763Y(Q%O]?"6#GW\><,/=C!#OBZWQ:#VNP='14_@E+*[7-,G0Z M8NRYU2[W$\<,FR>3=\(9G/)B)YQC!Z4OCC=H?MI\60!(#9E'70UB:2]?U&?7 M-[P)'83U>$D717SF.PZ#USVNR%F1A]Q9B>G+KB]-'>*5.F?!JDFC5\^83N,# MW+DGFAS@UZYP:U"/S-&%"]\SB<-=FO!'.BCADV/[BXYPT[WH;AW\VG R#/V2 M3(FEJ\E5M6.#='WH$]^E7ND976;"5T*^$Z\_C^;5NJ1[U- MX=RQG^GOM_8#<_+^U14N;8O,R#.?["?;G-[2M:B[7>J6=83/EK9KJLOAIT[U M,@@P#)>Y0M19C$UUYY9IO0Q[G/O-.;]+QQSI MB>W,B4/5;V(X\P,W F6Q+Z^DMUT<^X@MPR[HL<06T<[2-;U^MLC!#K'<'^27 M'4]^.U==HK.PCSH7 ?DY#HM[@XW.U5O"),NS9VJ"KWPVVNMID(5[YGLSVS'^ M1_2XR+-LL%*3R.S4*BY[IM_P>Z/\1&J/1UY-ROO.H,-DPV):G]\*&30TD MRSA+ICU$J8YQL?98ZM;NW,)@[S">@5RTE(X(0I8#]J.",)93=QTC$.2Z@'"] MX'I^[7O1)E#PA7$0=F0,[DP,6ZY,92WMM?!1%RL4&K 80;Z[^]D*TO;C8LGG MH699-,-XSF()HS_BFCDT+S*V9I*\"G[-$$_LCGR[CU)N9Q5E#:CJL78SYM)FD6,1;!: ME6*,+?:L8MRQ#5FU&#/.:(,8'W9_Z4-N[&[)G(:._&X.NVRJ>;YJWA-G+L=% MNF.C=+7MR#7]PTWO+^6K-+I<$]IQQP]*@#OV;==W-FZ4OP9?&R2][6M^VP#B M9V_]G7=T2I7>'H,OC4H^T^\Q+-?0UN]:]?/Z_:G)=H4$0[M&7X&0=D8!.3:0 MAL/*Q%3,8DY^34+ABDLAWBRG4B9PO)V.?H9D /ZL]NP MB.W;HD$]UEK[DP)/]&A8O*7)QH65X;2N70LK+6M&Z1_'/*6!5] "XO^P[Z$> M-Z_(%K_>,\APH-C,59$,I8FJS83;NS/AV3!-8>J;YHO DBJ#K&66PTN'([P0 ME67(6 ;+>F2)/6%^K\[2A.C/C\P(L SB.[+P@CQH.HS6>Z>/CXDV"Y>-RGHB_SNI-7=G>7X0.4K,?+19PKIX4?&B=>N)+ M*,.-H(:J>/:R0K(RC&<#505;]4%NALM/@!?+7N$JKPW8GH UCG:]MP!WF@;Z M)T(ER2K>]-S/+7E&XW5'(=L>PX5NQ!ZZR MM%O^@V-9KNR;'[F#HF'#MU$SPI\UV3.E2F+>>*8"'V58[-;F?FFRA1T@ B7\ M92SS*H-T6.P>(E"IK\T_5@'[6$AOI+EB-^?VO2DSDH(-\VKD<10LEOAOA*'8 M/3B8TG\M ?C!QK#8G:U4_4#//>/ZR05@L;M->^(V*B)+OT !O2I)MNJ@PSKG MA&58Z$?C!SG##%LYKQYU_G).+&TV5YWO<>FR>FGN+?-[?7)%O*3;NN$AKXHH M^ZYGSXGSZJW))WU5_[:=Z+WNTON-_B+%4=U6)4396"RJ)_;CN47;!;B?J#/L M<=16U-OKFVP6M;A6-*Y848\R!/JU%?5VLMDL:F6LE"GJ#$%U;46]O:1,):LZ M0TA;+U'+^]MJ62[35H\RA*^U%34P6YTA6JVMJ//::CG1"Z9P46>(2&LK:F"V M.D.,62]1*X?8:JE,46>(!FLK:F"VNG'1HK*_K9;B=0V*%W7CHD4%JJT>-RY: M[.UOJR5E7*:H&Q ;9Z7*JH&QUJCB&X/"SD>EAFCC6L4H\&S>05&7:_[V>:7GT-TPZOL.*,W*O,X8UQ@ MV 5/UFNUJJI=UXI88-P%1-:';/U*IL"(R\@LCY@FTP6>V7* MNL#0"YZL\ZYK22R1&Q6QP-BK=%GOL5)'XV&9TBLP^#J&]("MO0*C+W;#]GKZ MR;;#V[>Y97?G+Q:LP]T./<_9X>'BYNM7BHG&6VBYONFQA,TO7R[6+H\LTPCY M!,XL_X-FY]P'&I5X_J.(!8;7"/8&S\3"A)948(4H'[!O7&)2]IB6*9I"45N,=0;UQR\XM2INRAEZ4M>?BD5EQIN=Y2E+_GX11Z5 MN0TEU6EG MPFGE2G4#_55J\7&@GD)Y5L%>0Z1<_[;#2-1V5*KTXQ;JKE*VCU M\3H@EZP>K_'@>[9S]NB0H C5=$HT5J(WV==>D3-$H\5NC6THP4U_DD_%T:DH MAY5,=LY@QVQ9AZKX)#.$=J5/DA>13AUQ4@5B7VL0-V@W_=D*5BE/CHM/,$., M5,($MQ%12L&:P7@XCD7Q.R=Y@$PRQ">%RV0[O:0U(^O%FR^6*9(,H4'9>I"U MI59BT[I,F61PRTM8)MMX8+M,>J."EDE\"C>^H\VH?^].''L>?T]<0AD<9!C& M9:CT^H.-(LHTY^(DEL$IAF%ZQ@-Q\YHZKL"4#%XP#,.D2/U!#X+$,GB^(,Q6 M7QX5M\2BC*@;]86E0R5MX(7O.-23B@NI&N80*IPA'/T M91T.I7B=O/SRN+(]LN7MINJZQM0@^@:Q9'"?+\F#MRK@MIS^/;'"(.R&KES# M=6WGA0]B[^R"\!.?>4$XV]EO8;'2J#&MRR&60N29P?6N7IXYUF5A\KSTR;V] M4TOW=].7ZB3@?>(5)7X9:]-1"\M. F@9Z<@F6+X!(N\_M;8MN870MUAZE)1J6O>.7DT+(L*96WWMI<6 M!81#&ZW&R#9:AZ?B\%3JA5N1V[]EVU ^\O[MZ^-(<[2WC4.23Q5ITSA67W&T M?N=*+X-G?.P>$'?^@TO^Z[./LV]X?=Z0>#FF+)+(+O'LKJ'?XVY-R:W/?W_[ MX\$Q/_P_4$L#!!0 ( /AZ:$L&64L+] P &Y[ 1 9GIM9"TR,#$W M,#DS,"YXW''_[ZEYN_U>N@=S\#'5/@)]3#W+0I=QDZ MF3U\!WZ]FP[!S%PA!X(>-5T'$0'J8"7$^KK1>'Y^/K46W*2G)G4:"TP@,3&T MZQRQ)VPBW@#U>M!%ER$H)!K0@P(!_>\:M)K&1=TPZLV+N?'I^NSRNG5V>GG5 MNKPTSO_9;%XWFR$%/WO6@- _J>#T_+1Y>A42FT#S*UPB,.B%Q RC=?_IXN+\ M_*)U9YQ=?FI?G9WU^U>]R\MVM]_JWM>;\E_;N&H:G^2A<6&$.^[2]8;AY4J M$_,[#5D.!2'(MM$&W =&?P^&P^XIZ-@VF"IA#J9(C0.R3GU=W!M&R0SAUT1J M<)W;6F@D7QZ9?4K9LF$)UA";-6I(H;J40@R;M:!==J-H TFVNLRWK1:0/^H6 MP9V&9J%IU-M&T(B+-=LVT%UP9)XNZ5-#W5$-C&@# K')DUOH6PE]+/[G6!%3 M%BY'#K*P"6WM3ZI)\ZK=#!I@\H2X2.[$NZ>:M*.]*"EKKY$ROM5LGC>\FZ&1 M6D*X3APH=2/!!@OA9#SRAA(_BX/!R?1)/&UI!1?2FU @;U*7"+9)[L*_F8#* MQN3K@5[4[4?(M[V\Q.2?VUK:N+JZ:NB[6T N8S*.I"'R[R9 0B_F*KF1NI/D M@=A,<4!L1OP/"L'PHRO0/65.#RV@:TNZ7?*["VV\P,B2D<]&*FY%!$*W!61+ M)$;007P-353$)Y-&38ZQT?CU8>A%S9J<^0#<8&=-F0!>"!A24X?" QRILWK@ M#G5UJ6ZTI+VG+UPB)HE8TWRI\08(@:^\"L+.T5X%(9B?JN_SM%Z3)W2N_G33 MQ$G>0+;@P97ZSCG30!R,%/FQ[ (XU$GJE*#@4\=6EN!_L M+VO*&:Z4(QJ?]!?JJ/"O>_G]WZ " A5.A>];FZLEYCLJ#^J;R@%KMK M1FTTE],<8)G:SI&SMF6Q,]0)E+KUTW20*[MH*.%&M'VQU&Z+*T!F(5F>86V! MJG5D?1.NYX*N@.KKIK'?8E^9A&V-R0_Z>,UDF4.\P0FU]D4.M916FZ[]BH8[ M9.GM_*L!(7L\!>,T10N@$]QKR$PE>S@-;JP972,FL%S60EFT5K!B:'%;4T5- M/:#Q-\6KY"T0B740)4^3OCCNA#1C_'L [6TW:IVYK7$Y:6ST MGB5!XV,&5;)?=%"C#I,\IKVM3.:0?I#A-GPL:KAL@NQTFX?J=EG-E8&EJ+G[ ML2C9ZDE(JK#QVPA?*)X+^$()=38>S"#P!O_O$*M/)+C-0*XHS-' :GH)F4KQ MWW*)'PKX1D+$WQY"8@%/'0CI*[8&O#J2OW[Q>/L:< PF9Q*ZWEOHCD>]_FC6 M[]UUAIU1MS_[TN_/9R$2LR2S^%,[DF"K1!YO]0!?$? T5S7XBT+6P M4'N!!XC.:IO%=CN=[9UJ,+X'.^7@9*N^XOP8G'>_=$:?^[/!:#8?=__]93SL M]:>S_G]^&LS_FYO[0SJR?. LKP_XG8#!"(2[^0=<4_XOX/56><0Q/*(S^W(_ M'/_RBB"0T#2+__/<_$O=0"NO8D#Q_'K[#'L$A?SO>#&6A8!6/I$H9\+7)!7;T\\#3*8*9_&8L"N3EHI65!XG)SU 8Z)@%H7QC9FHFHJWX^UI M]Y" V.8CR-2%)Y1SCSO6+(O3A)V:A#UO<.(K!EO-%,QRL5_^_[R"67 Q1IG^4!\0VL@X]D*O[?I4[.E[1E M-\MB.V%K*[UVKIA^!Z9GKN- MADOO-/.,V06_\QDHBRC.,.4S:G2.K$AD7-; MMQ^OE4'Z"QP[SG-ZR-&ZR_*L^.Y:NF>I37(-2]6&_C4/&?"A 8T-".I]44/! MT[%(ZP0>0A! K)+.]_#/*>*"85.2H18$2K3H&YTPE\XL3RNR_Q?QM%WOP.O> M=Z?*CXZ\71BJ_KLN%]21O/R"Q6I +#G0E@OM"6)*'B[1>#&G MI3](2(BY3# M0(EO:33'[+/Z*!!BAWSM6_2;Y8^9FYG1[9 M,O LH8$=-K #I[Q5PP,!/A M!$;S[T"&1A]DY;-'\MG(V7CA;UKQ*3(1?E*UD'*D) >;(G](HMZ3I"*_)W]+ M-%G^'=_8C?EWY()RWJ WL.L.*,@I,R&,>M_!4[15?G\LOW?6D&QDOB7KNS6T M9^YZ;6/$!KP[>9 IX811&9Z0%7$FO]%G2BT^<9FY@M*<(MY][#XS?+B=].)A MS(>U?K!%!0)8 ',@@>D$-("6X*5BA;9*-$JPA5EYZ]'?O,I5,>=NG.4_\?WO M]#>SJL+Y'=[6RK=!DM4HB^;X+GCL;:X_&;LWC?"W;.19]%LW-_[7\S0;Z@L- MOQWZ#D'G419@63]3ZYH+^.>*T*.+(<".0HC#7 )3VRH:M:?&;4 M70>"6(K4@'>\1@Q3:Z[56"[SOZ! L&VK3.*V)I@K54&_P^"\D6*@7 %,A"Q^ MSZ@SX-Q5G]$;+^15!W-.V49OH,_I_I]%>!:_LG%X"&3=*AV0;=YY$!;0UE_@ MT(T?H:V0RI;H$8OTL=G]220E%B):]ZG8:Q%<_S9ND>X \2UJF>UC$6D9%AZS.5L'0JR6+1K4"#LIGJ1:'MUXMWDRUF8P[)DAF7ZGG>*V>Y M'75?O&1F1NL;/V?9-RY#J&0F)2^>H9WD$1)RNBT6B.E)QD7&NIO1](^RZF8& M&IGT(06YC;4EWZ%D9:X7LG[S'0?]5"]D[E=XZQ]#QUL M;[[(("2!\2%VL)\.$!F45GC]@)Q'Q+8V%VD222(LZD!,/I3>*4++!Z]0'!#+ M55P@/B F96OJZ8X:FU^^;);.$?$W_/?2_ZB!F6)EL^O RRFQ.)1/MF01Z #H M2.S)EBMMU%$?PT=L")_O,7.B_IAXJVP^.'^6IYN9>G8FD)Q YA5C4,YU)7JWV8G(>EYO=ZE77;QW6'AGN61H*8NF 5$!@&/S9VB[ M*%:%O'MM#8H78? 6)/Q+Z!2.9(4PTWGN(F1Z)-P_T MZSO^HY09[S;T")H\^$X+4>(YK"UHS[]CE\N*NY6,N[3^'0!L)^,NKW]/'OR=2?7@VK55L.7# M87?/W3.DRF95#W/O)Q4IZ\B:4M_M+Q;(^WU866%N7^[(%@PO:.JI_L<^NTX" M/$?,.620=S]BAP_D8VWI.'>8S@1<+&1:%O.YM+ME\S69,3%JV_KA'><2:]]9 MVW2#T!TB:(%%QW(P4:QX:1>Q_#&UL M[5U=<_*V$KX_,_T//O2FG5.#33[)).T0("TSO(&!O#V]ZRCVDFA>6^)(=A+Z MZX_D ,;!!LM@B&AS0^)(JWT>K:25=F6N?WGS/>,%&,>4W%3LJE4Q@#C4Q>3I MIA)R$W$'X\HO/W_WK^M_FZ;1OAL932? +]#&W/$H#QG\,/KRH_''[;!G]##Y M]H@X&&WJA#Z0P#"-YR"87-5JKZ^O57?,'5IUJ%\;8X*(@Y%G,TQS MWDB+ 0J$/D8;!6!$/U=&W;(O3-LVK8L'^_SJ]/*J?EJ];-0O+^VS_UC6E64M M"?C]'8^Q]",$5,^J5K6Q5&R G&_H"8QN>ZF8;=?OSB\NSLXNZK?VZ>7Y2>/T MM--IM"\O3UJ=>NO.M,3/B=VP['/QJWUA+S?JVHT/<\8RL+<&(+D =SJ3)8W)U+T#N$WE242WQZ95Z7LJ587 M:M3F!2OO):_>.$Z4?CV9E[5K?WSIC9QG\)&)"0^$*G$M*2:MGMUH-&K1?T51 MCJ]X5+]'G:A_$WI1YTEHB:+P%@!QP9T+D J7@3'2 M1.CB42V8QW\\>_SE@,$'8 M[;Q-@'!H$K""IH<@HL&58;)I1CT6YDMO>4..K]DBVC9.4'C$Z !=.! MAT@@N)0\3N3THC@:ULLI>W04G7_V.].\MZ:NWQXL> R" GKJ%$,^/4+(JPY$C/?L"/'F\?=B!LZ/D($\+GS,P(56#*2Y'>EK MVF+[%4.]/":HZS?),>B&KJ _[K[IYO.-!6J!^^A19QQ.Q1QHZ\FMYR#KJ#$& MKJWGM@:XTJ%Q3(5>3EP^*M8$!&+@>KER'R(X].-_4@#JY;ME UP?X(OQZN6I M9>/-CLC&6/7RR=*CI,M;D'SA]!B_7H[:1OSKDR-BV'JY:AMA)Q-9%C#K>OEF M&V'FRC6*T1?TRJYK'Y+ 2DQN&STT'SI?.OT<(=4U,\KL61@T43X*Q!@R!/S8M/U M,<$\8$@FHL_F2Q58^>25#4HPB63$8-:@DN&G5"[;N)BP ]'_8[4T@$2U/=@_ ME^8*PF [;Y*>$/-G::+]<1L>E4U_@[#2\WX#8,"# @:^4G5?MMPE8F$$25LA M:UZN7G9.'@3%E/U0\: ^93H(NH%976.T&]&NF'VA(*RI ]0ZBJAZ9K^#47!7E][T(16&T,(;F!TC4$F^8\ MT[1MK*[AU@T /YPD% JOFI_A%*O5'/UVU^O_=Z>'6-E"/^D95HK"96^%' :( M0QO>/[MD'KMK/2/VI+9WSB&L])U=E@8%3NER"-L[G-7H^G:(TN0= E1VVL36 M^-:)/C34G8([ )Q99&4^+E(C+-MAS-?"WH'/(V=;&VA"T,',,8Y[[L8BE^65 M?;5$+"UP*UIW6]27QJ$<2LB2\,^AZC\Q$ETB5$V?BB7MKZBQ]PZ7KQ&28U%, MH#X.?17- MDQJCNT:A>#8[1*%$U?ZV:NDP1$@GA ?[(")W2XUC5J6!)ON:<(72^"EL1;[C5&U_#ECE9QNIVK MHFM =$=+/RWHINIZI75'C@+-W*+H&FK=/3$YMIVZ7HK=/5G'$;[=/2_JP7V% M>/!G".Z70UG>C*?"<>6C82OKM%C76[V[9RA?6*#09>#C-*D-4:%"=X7_+DSE MBP\6NG7\=Z%P)8RLZQ7F Y"5N3O4[#;TGJA;R371]4;U/OA:R3;2]?KU/LE: M9)H5NK2]IU3(^"M>YMN3Y<.2MGP[E+? O3;_44G2P9(>\VE9^CN;XW=LQ7MG M\;L'T6@@[O(!Q$X"N;MK\U#?!1"E'RO&KM=*.JXO-3C$;)H+8I[7M\QZ1-?P MDRH/NQN,VU]^2UM:KA??[?3S_P%02P,$% @ ^'IH2X1CTL/>&@ +,L! M !4 !F>FUD+3(P,3%]VZZQM MR7;B.#79+5FV,ZY5+!_+,[O[-$63D(03DM" I!W-KU^ NH"2>$%#! G*RL-, M(@F-_AI H]$7X*>___# M15;(^&G=6"%JQ7\^M\[:GX??G<^?CYXM/GLXN33U?GGSYUSOZWW?[< M;B<(_#K'TTK\801./IRT3ZX2/WNT[._6&+7N;Q(_ZW3.[CY>7G[X<'EVW;GX M]/'\ZN+B]O;JYM.G\][M6>_NN,W^G'>NVIV/[*^=RTZRXQZ9SB@>3\+6G^V_ MQ"PS4?@^_W3EI=UVT]\1\'K2?$Y8"L;8.%W^\&C^R\\_ KSVZ[?SY6\[I__ZUA_:$^19Q]@/0L:* M:,7)I+7K7%U=G<;?KG[*NG?"U6^3W'PXG7_)?AK@ST'<59_8\5!*0&AE_H+_ MZWCYLV/^T7'G[/B\<_(C<(Z8N%JMGRQJ4^*B)S1JQ>Q^#F=3].4HP-[4Y3#C MSR84C3(967+/Z7_@E/]DN>Y1:T'XEZ?[;;TQV&C"C?@GJ#AYO;A^'MS?"Y^WS[[?;A M>3BXZ_WO_X>="_N7T:WO[?+_?/_RX"_,2H_[8S]741+V"S M98E]S-4EE\;:+]&/$/D.-I-[*"EWCN,<-A;%G3 MF(M3Y(;!\I-8EL?MSD)[_VGQ\6\/*+QG9H>'^B0(UH7D\BV$T.6'KO6"W-@T M26MXJI?-84CL[_=!$"'G)J+,1GI$%!-G.+$H"M@F'E)LA\B)?]9]LZC#V!N, M[@@=(1PR4PD$K83.ZA''KY8;H8JD >A+MS#B<9ES" *VUJZ*$9L0UV$6\NWO M$0YGX#'8:*V9X2<4L@T6.;<6]=F@!]\6.ZT\TUD4-#/>=9Q8E5ONHX6=>[]G M37%HN7#^"PAIAM$CGD?\>.#AK*$-^+EE4QRBQ$=,_^JB;D1.L5P\+Z M[%)[C2@[02P)+@X3DF?A>9L1)5X^#XO.2+98"65[SI>C3KO=:9^TVT>M*=O\ M*9LH7X[8)&>V[Y.I2MH9^T]@+:S*V$ECO/]%0?$SR3D<=9\>6RX%%?8+J2Q_72Z M[LHMS:LM@JX]XML,"(VC:T%L,Z[ Y+JNY4C4Y9\NX$[SX("=B_0Q&:[T/ M1D\X^'X]X_^]LVQVOGIF>*\9$]]!IR\5\MK=.P%;RU\)<8)GHN2>RJ*@V[UF MVR1BUO,3LA%^Y;-#P;.624/W*=YRN69]17Z$F+:!,XBWYYX M%OT.=U@5T]HC,!4XXK99F*V8@/KBBFE5#0;LELNB4#7C2FZZ/"I5N^LD$)%B ML>^_^ZY@RN;):&MU-/FD-U%2:+LTQ.FG@CC; MSFR(2TP%=-:Y0'B2)+8"@R#GNU!4CG9"$M)JO@+'PH/%?3J#T8!M?/.S]PWW MY[K!@T7Y!Z^%*8$;;@9Y@O4['21XU9X'U[."R2,EKY@ANY[]PFR<>W_!CS^. M<^^9-%# YAG[(&*?"6:!B7,[]:39DM:>$+@];_DGOS%YV @YP1W3!MPGRM/D M^:)>!:EBY^=@-$+<4\J5G!1WZK0UR_G1FG&KFBFNE1N8LR4-3(Z.;A!%@@4A M*2969Y;I WJ+ORHOE31!43.P>_\5!8Q+N,-KLR5T63\A-/XVWPGN?2?B,0T4 M<#U!IV2NTN1Y A*$LOK0ZUR=F<_$Y<78@5][.$0.8\6#7U$@PF> KD% MT=2>T..9W!76UKKAC%<@3DSM?R V9Y\VV:6:.(;J%\00A4\Z[<9(IA"7,B*^_P?%]UXJXN M:"$A:3.@@@ *@\-X9':<[_#$\"E?YXLH C!R(D&I_I!)'I/:O;YQSX^NY8?) M[MF\ CI\<^CHSV.,O"BVF6[0E"(;Q[.;_=U%\2KVG:Y':(C_B#_/Y!68]UA2 MG_K]^ND]?Z7 J% 1)T^L@+$BUSNO2E3TK'#1:$" M/Y>,9@AW$?7C*@4VZ'?X1URO $>01T5_ ?XT"A'=8?)DDJAK^3XSIN&>="ER M>P>I@FA!)A?7,\X'-$P@14YW"'61D#,898L87.HO3;.N\0(%'R#4JLXZ!B!, MR<(J'B#A0)1PIC4J[J"\ AP 0L1?C3![9X7=8#H-QDQK"MG(WSP4O$'?7)H MC$L>LG\3"0M*.*Z-SF95A)UG]C8D'J&(//?(TI"L;47H&4=-PT,TNUD.1>Z! MAEQ_H :^/'>0*)7?0S'ENPD%=).2^7. M^;1ACROY;V4I5IAUG<*(JG<:1+:NDS:;85,26)N!&,63=H*:9D!)!0]A?;W= MP6=KFI?PX",\^ @//D)-/L)]RTVNP4=H1&9R[:ZQ9IZ<2_ 1-=0IF*M)UDTB MX1ZIT1U>^=$W8;@:GK.YLP#DSR2&9RKN)@G9LZ>"*ZB*RPU(B()':\9WM42F M.D8[7W( )ER_;P3 L^ZRX!"Q72-<\-*+* 7Z#+(H:*]GGG=[^V/*;(RD$$'/ MJN22T>X0> GO_8 9I/&K4,1_9:L9,QE>(Y]-1OY0E@CFT:#F:] &:YW#9W=::TK M91@<4TEM7BG+2C&33!)5!TJ*L) "4>]_("1O@F9*Q\@01UX:=([>R 2YKMB: M<]7*;E@;$[,IW,F(K+U@0JBF[/6J=(E2G6]WU7V+D-E7,N]XMF;TOE8#;^;A" YRGEFGP9GY_"U1_U[\^YIG>1 M&U?A&3K#$=&P%_H/1521E@,\-@@HY[,N* MSPUT"[A&[VD*<#-5^4=I>Z62%T4]#X=QH2/;>N'*- N?[L& C3 M>GV1MS]XUQ$.)IR;^7[8];BI!'%'YE'1[$SE.6,!3QI#PC78& MDJ!4+9"^]19$.+QCAQ]_S&?'#E!2:.D.VJ^,F\&;CQ3"WQD$H#'7.T(]1!G^ M.TP]8)PUM>TA#-^8,+R6'*>=TYDJFDAINZ-:!6(1I3T!4D'P/M4, ZZ,;!I0 MU9ACY,+>6RDF5")KVX>N'=CKU_2Z"@@?D1;S_@;K81.6R"R7!@7O"_5& >"L M.\M,CYB4A[LQ07W)W2X[7E8T\X#05V(X.@96+?\OPV MX04@5>P2'GPC,GHTP<\+Q"CD]500&8S?9.*7H2(:\!)_MH/M%A"4)UA_'%"" M5\T>(X:=S! :(OJ*>3*51=&UQ0[D_%)B9E'&654/)$Y[1$[WS:).\$Q"GE(@ MON>/:#V0\-\H?$(V&?OX#^0(2O-&@W""Z//$\@?Q%(.YI.IC4K?OUXV1)SE) M\KQ(90 Y@R4IZK[^++7W+IO43(W-KSX2/UF\5Q>/0?R?7]E KEXQ!-7)E]MO M$X3TA,>3$+2<2NW65!'-M:G(I=E:V[_&RN+>GP]VK"[N+$Q_M=P(=BE?31PV M5O!?&8DP6,+Z)^(3B2G@5T2M,8J_Y :K86,!9GI/AL=$Z5?Q*M;RL=!'BP[H M,.0;:CRPC(,8 T0N4N1,G2\/$3^A#$;SMX2[43AA1X8_4#43([MS:,#OGMGM M4VZ\L\X(H\S/PQ39C&=H<;P$)=T9;\AG:L?E)0R.Q\XJ;-G$1X6%;0=/() D MJ/TF"_X\;;PXXN17YPRD7GP'6]T1"Z(<^74C 8Q9LH M< ].;ZQ94L\XY'>2LOT?OV(GLMQ_XG 21]ZXB3K!TV=RZX=8):T23/K=0*U@ M!6QQ!%T)&02J.Z0H/=J[V5AW:F)\QN.JD?A,\2DD5Z83T+VK+.V6C>X#Z"0I M( 2^ZNN-M9T-T2O['T(^WS:@EWQE4]#]>H3R'ENQ25$6HU6\LKSH$/Q4REJ[ MRMY$B37/]:SG6H%\+K 4&=U:EW>UZ'@[$"NC>=,)5'UM5SZ.U"=-4H2]O_G MD"E+LI93@S* 4_5'"K F9OG"L#4FDS=C=R+%^WLC4G<55V"!G242.FM,?9*: MM7*6)RDTD!ORE'+^^8#D'EU,>#)9UWS..%R*7"XC;I3+VUKRS]=Y4(M= T;< MU"2UG'5)(7F=CY'YV[OZE$BNST^ ;\ %?,"EO^%A74&]-'[)ISN5D[NT)F>Y MD)'I^J 6$24$],EH9:$UF+-6TI0:WQ-2VC^MDAN/70)GUK$)ZR=/Q\B$IXMA M;ZN.CHPOHU;542;R)&ZCSP=R:17)0A"YI!8!W\ABD+*L)XFLI94DSHR6A+SG MLORLLY6(/AI]::*TB*0R$U>@+XTV&?3/"W":JI"-*28#<9QW7G;)5D^#1D;,-.-'9Y#':C1P[/:\1LR,A!^W\&@,"O# M97J>4VW:^*RQ#DV,UKYK(@^U9@DO$S.S!'> M2MN8)+%!\ULJ<T+(Q_0> ]#LNE($H_<&_F>RWL8DA3?Z6I4/AJ]GQ3NQS5Z^$VHQVND"!.B MNVJV-5A72%/4AQE]YJA;?IGQ])7\:KR;HP'R2\OC$ 5YS=9ZQN86K01\870Y MGW%R,W-H$^/YX;T?2 )!]\%BZ!W"?/I M0)- E^*[ -[YO=5.M>-SQ8[/=^WX3+'CLUT[[BAVW*DH$V;^P/4WZ_\)778- M3V?)(=)H]BNX@'VM5_#K &FM=:?76"X*%OKU 87PC*\, MJ?O=A0I-?(MR>> M1;_#YTLQK=)BDA5/2X\)Z.$^94DTW@(%2C5 ME#FMDK>82Z;R<8 F,&91J)KQ;=^N"O/]&K,8BQ&18K'O?Q9CP93-DU%R81F6 MSIAWEZB,GLF=&FM*L3DO8Y2'NS')F3+[(@%8(B9D6U:SLC>L2?'H@A'7D<-F M>;J5G8M_\V@@TD3-OOY,]KQ$"D]V G$#;L66G^II9V_QKD2-D6&YO2O'\4 D M72,";8V)!E)+>4>P2:A&IZ,4N\-(EI]1(#1Z'X8C/-M&:'1*&QSA^19"LY]T M@2.\V$9H=F[3;D?&M2"/@"R=R%!YA'3M7X-1U[9)Y(?,%K 1?N4;*(_7I<7Q MGM"4HH U70_2I9$H(VY: Y^F15.K%,%[CK$>0IV'4.?[CA1NZP5X1">;QB%> M^%[CA91M?F$9T<)\0HT/M!W";(SQ58DW9!P,3 FQ5AYO.3(^EEAB V3/7=DH QFC7=BD!F#T+HFT' M8,P.HND)3TA?L51#>,*;6O[LD6+?QE/+'4;3J8L1O0]ZC]_XG6F4O&('.6MN M[46CKX0XP6-$[0FOA"LG"*&)&_-"#64#?90T7Y1L,O?2'RTZ-9;TU*W!&^WKI#A9VKY@67'D_IZEOP&ZNN"4 4_\;!8 M7M#(TU8[U8ZAD:>M=JH=0R-/6^TJNVXZ5FM,]3T0'ZV_GQDDIL.2OUTNEE;K MZ2"(JFI4H Q>SY8L0G7.KCUI]V0'X6 4LQ;7;BL$#/0T3 M[GK8,RRDF%?!5M()>@?A;3L-A/AJ7$A2BL0TZ34FQ%N2#XMD^2(;$@?6)(:F M!8LUB<&HB+*&;0H2!Q$B,&)+RM&I"C&C#)ELZ42S*SISHGM$,OYXJ.PT)'4B M:Q(O8O /%N5P7E?+6C(' DJV_F0&:8Z!4P/^:7(DM' M+S/;0\.G:X2NT1C[_DZ\;)#07UY&(^0$5ZC2NG<$R?MTDQKK9GAQ2W:_(+L M.X1 #MBMIII9O8G0,TG,?XP"!1GG48'.U4=*;(2@G%HP4]_HP"XX0Q-O\K-^T?*3NK@1+] $2KA6>Y[AVR^!L,.\!) M$JF ?2&S <7,D+#<.3\A8FLA?&*S9S#BGT 1R=/5'XM=SH_DRE!86$64*BKL M3U_:2K:8!+UZ\CV7*>QVODLZ-RV'4\=EX.%@Z(KN\LQNKGR+/\GC7%H>4NG93 '%H= M7=>SQ'=+1T\AM!B_I)QZM23ZKG>-R3"T1B,VI>%5%EG-H6P\(31> MN$OO?2?BB@,%][Y-Z)3,5Q20,7F"4%8?>IV+\SO+P^[L9^)R;U30QQY>C(C/ M3*$G@*Y!='4/$OOXQ?7"(7GCFZVA$KV&?D+?S'3LAX. D)GL;T'E&8AG4H/ M)[R\$JZKLFE4RCQ4-Z6U/A2 '0K =BL *\F=94^0$[GL^"O'%#CG6;&#>L9U M.XZG/IK]^M*CI=&1G<=I_W.H=ULANZ8[&)]QK3'=P>R\ZS+3'9J0:EW:.D@S MAYKS($B.*9B),6FIFI!R+#&["\UU(GNN,.'ECYV7<]9ISH3,O')T%>BTO8+] MP>A)+ %;WB4B,!N=BRJ!.0R 4J&LLD:\$=5X:YTH*=3[PJ4<*H&Q=(8<:G79ZY""; MD[T2P<7>&082J?8"O=$W1BBASRV96 %OCB](ROY7*H(1PMB[-9!7O+2"_7'O M=H&M2C.!=>\T?5H-X KNY=Y8N86%FBO,>^;2R"R4%8!-*KP>1B\!^CWB+J=7 MO@1W++B6)5=_H74AIU7=Q,OOGD=L7LTG-9MBX]@-=CT3/UGHQ^Z;19V'B$]6 M9B;$IF$W"B=L$OTA) .[G+>TSL%IIF^,YFR(N.P1\A]="YI<0:33[5=Q[O]TW>-YGD:B8 M=7 ^=&K[:IG>MI;AC/?K2V\N1$.*Q/T.LI;SIFF.?$R]\SGW#M ";9(/-R7C MI5VC5T_NWLX2$#?U\VYQ[V%//\RFX&G;#>H8_A10[>AI2W R(,OW MS0DI29M6*9[GGTXYKR^LV[_]!U!+ P04 " #X>FA+?MC!"@%$ #1,@0 M%0 &9Z;60M,C Q-S Y,S!?;&%B+GAM;.U]>W/DQI'G_Q=QWZ%.>[)"C[XS='K]Y\ V"V0'&2/?[QFTUQ&!6+ M)/D&%&64Q5&*,OC';[:P^.8___0__\'J(#@#"TV*YB5X! \E>7ZQ]>O/W_^_"I>%@OT:H%6 MKY=)%F6+)$H/"Y@_)PM8O :'AQ63TQQ&)180G$4E!/1_/X*W;XZ^/SPZ.GSS M_?W1[W]\_\./;]^_^N'#NQ]^.'K[?]^\^?'-FQ:!O[('!*W_80*O?O?JS:L/ MK8_=1(M?HT<(+L]:'SLZ>GOQ^^^__]WOOG][O[V].+P#?[?NZ,/;XY^CW\\^OZHS?@4K;=Y\OA4@F\7WU&1L2JR#*8IW(*+ MZJ$/P-75Z2MPG*;@EGRX +>0Z '&KSBMM%(DABLK_OA-2XE?'O+T%_3ZOSY>W2V> MX"HZ3#)B.@O"H$A^+.@OK]""PBDA%Q!^@OS78?6Q0_*KPZ.WA^^.7GTIXF^P MR@#X0XY2> N7@/S[Y]M+(;L/K\DG7F?P$9M7?!4]P!2+2VC_^)3#Y?#WTCSO M?(V(\(&(& M53M,UKC<=V64&]:UB+!!V>]QQ(-FI=XE:5)>5$:I87EW2)J15\,8RET1)9!/ MR2?(*Y1_B! ;B9F4%X_0+:+P2PFS&/*@2,BBQ9#LE%@!%Z\>T?/K&":8Z-%[ M\L,A^>'PS1$/KO^&?_7W\ZQ,RNTI?J/G47J)R7_Y"]QV^:8DRJ.\^B5]F#]^ M,_+EU[6 Y*/D+8._1-(0F!W^?"=+Y^_I0T^K.2S0)J>O(&DUEHVM_XFQ 9P/ MH(P YO2'UU26CM3'^:+#.\H7%5O\XP1G_HG7"X1?F.OR,&U;R#)'JU'U<;9H M4C>O18:P_&U%?.GH^SPL>$\,C*3]$*JL7'_G5_^,ZA5)'K\ #38C_5# MRC-H;?6:D^Q$J9I=[\O:VNO0L6B(C ]^=<9TX\VW30[K'DWJ)B0]]\UU0L4& M+/<8\XD)KXLT>I2UV-Z7E#78^;YY"ZW) T+?EUT.:Q8)-1""%E,9!1JPNM-- MGA/!DV(1I?\-HUPQ9(J_KZQ%$2GS9LDY <8*$%[>@^%=&Y4;1A$4T M=(\O!LE9-.A_C]:H^ ]28L Y L82<$D\'VN,(X1D51<@&KT],IZ\]&&P9OO4 MM4YQ:O2(XIPF)?;TI:?H9]1#%2CU+2C1 C1.V=/5.F@'(] (PO:#'V'+-E$$-J M2@P6G50(C 0N!G>BV:*7[1]>X-])9S$C!+1W2G=H6=R5YJM]OG-*N?G>F19C M@:3T%)K>^[O4$BHW;MED-V>&7;>^/E.[-27[-DUWL *RZ%T,!NVYIZ&P]"VP M9;&J#5CR?1Z1Z'^W73V@5-9^>U]2UF+G^^9ME9,'C+XO^QS6+!)J( 0MIC(* M'+&Z950\4)*;XO QBM;$]+Y_#=.RJ'Y#B_9:-LA__7>RHH3$ZJ^7]5V#&U0D MJI5[:O24=*Y"VB@<-4-PO6QN8H"*YTAUF M;UT(0Z:A36 UJQ@2/BP*6A8ZQ M];^I959=(A9.HBE]GQ8B4# :UT$PRDS;>M0KR9QKG'PG3M]&=PC,T&Z/EKU# MZHBR^]&_Z8K4OV/!@ZH)3=5=>ZZ4[=BN3Z/BZ3B+R;_._[E)GJ,4"U$H08@8@LH7S?OBL4";3#[6[B 6)2'%'Z")?=OI5?&*!V]<#9"TD+* MP[F!O&;G]24B@PM245:@&*0]]3>< &8E.KVUX@N7V3-FA?(M9JQB^]WO:>FY M3<+"(3FGGD"OKX%!_:(Q)02BR[2KQBVQ3"<6>9/#=93$YU_6,"L@?FU#G+A<[@FNST%\P?/V&4U".XF(86 ")RYAWA#F+2I#(G9BQ] M6O\D$$A60P$JO3I7YTRJ_*1AXS!%4<]-9KT\;64CH60AXO1C=MYA(>%P8F=7 M2?20I$F9P ('=5KN]X32& <>$M_+K<[AD3Q-+87+DCCVTE(!GV M%7,'N+;5/^ /GHYRJ^W^FVA+MOIG'#CU*287I67(:PJ@^[/#O( M!!9(6DGD9%D2P3&&LX@1)9+7@4.)AW%,(\S/>* M#IYHAE;W [NT@6WD35/S=NJ!9W ),;?X%C,\Q?].=$KC1HAH;H +Z%FXR<=9 M ;I&/ 3%$\I+@#^Q\GL ,84*DM96B BD/>43-H#Q<6K]\W(M8TF6M>Q*6#?1 MVI(*:T=*;B?*Z Z4[9TG3W%<]_QXC(ZA6&+S'+D?T%.4/088SZ<.E:=4%B@2 M8X'=\0ESRQ,U@_K\"&,KC(<7OB?BMIF ;2M2N[G;A5:KI%S1ZS=9?(HRTCL, M9@M%^QPEHW=%2$S1PIE8PXQ=XFJS\WJ#2P(>I*"T,*%(=U&@5[7&4+#4X@X+M;0/&.N3Y^[2;JL=H/J=]YWO:K^+VV3L MY$(H$SK#T9M1;SCZX>#MT>\.?GCS _4#\N.'-_0_@W42(:IH2NT!(9AVP'/M M&,=Q3'L!1>E-E,27V6FT3O"*L/6H2J?%$M3TCB\G"5LX/ZYY G(5[S#)P(*Q M]7J2+ \84M=?T."D.[@0?N R YQCIPNK$_>YA6649# ^C_(,!\/B>+'8K#;T M).X,+I-%HK3\D*&FA= T82OE%Q4/$#,F/OU& 2FDKKB@4>%^4[$#%3_0ANAL M&")'B_5YBW1CZT);^ZN%:&D>ULI<;D5N="5N>P4>Q*4@S?," 2TKUT@\V$H1+?K;K)K$3KA_-:[&X'$2['(1B*YSP-@RL$@'?38EPH-OL>D4 MQ_76C[Y/[5(R@%&?J'T?XN,Z&I;A^)(0*Z$/#:LO6%P$/C,)B3,_H4,49_M( M1<48#HR@,]]@[$+SBQXV$S[15EF0.(S[PC $SOQ X"TCIXLF%BY2Y.:>8+E;LG1.MH)8KZC@-7R4:&&E MX@R;H0-'_VN4G8%]>@N443)S<;&_-!D:(QC&ND0&GV%?,;@BL8[%D&_X68OL M/*KZ0D1(PHSN;2U!AI3O?_TQA<>8[<]>>5C5_8C-.UQSS)WV*T?'C/:M+C44 M)\EZ]8&)18;AZ;[N\!AQ"==KB\ML@5:P'N.F4]4N)*$Y+&"0FN&Y 80':$;S MA3&$;PH+)*DERZ/V;N$SS#9JUX":[VB6LK"OFP^'%66_M4,]A2+1DP>@O'1< M;Y9>WD5YO>0LU=[6G2]JO@Y:-&R\CXL2H"7(N4+!M^L\645YDFX!,9-.OY3M M 2@@!!GIJ/+#=W[?U4.0H%&UA:+^M*7YZR7@M)U8\D\Y*HJ;'"W5*C<[7]-2 M8XN"^5H<2ARL*76?1CFD732B@S TF;:5>#.H1"NV>+V&>43N4?(A,%K3( M:&E72,]\Y*U9U2W(1=*R06DZ.E!(D':O&-PA@<@ZO!KIGEY=1,5])".*@-'JO(C.JV+ ME7NY26NB)+O"KZ_K["Y*X?6R,PBGGDRCE/%(4M1[A4L1GPG7!P97 M!A])^LY=BW %* -Q4JQ1@8'#F?]Z<*:2USQ*#4ZDI]EPH>LE9I@EH,!=9X!P M)8N&W@2F1"P?("P:T%LZUU$N^U;+C]]7G: M;2B9M^-&R0D["_DVQ7R\[BB. 3!DR'WUA*7L'6/F9TZ$@Z.#/?QBA46IL:#= M^:KF05Z'BHULNF)1A6&_AW?#^D83&@E M_W#4:Y4UPO(@O@&Q)G]^1?B,9ND M>"(9]?7R##XHKQTGB&FO/4;IFD^(NUS(:C'&?'RO#>600LJ:"QF5UF*P (P= M60_V ,(KP[,!@.Q,HX"E7J[2^Z+>5((V#?/Y"28?3F8RK&@TJHQ0E)HV^G2= M@51]0*KR\I.H2!8J=BH@H*7:05H69IWT[1;@!! L>.[M31*K\+% EKX:/$ MP[P/5>Q!Q/B#C I DOZV(Q7M]I@AO$WT,$>S]+XO^*8]:#EKP'B3Y<)NW;?# M%Y9 (SQBS+HHH4S:)*0B+L$X;0"O0EWLIQUW7/O[@_.T\W+^OBYOU/7_.(@9 M&E @15"S.9\$;MWQ38%*[=HI\Y%3M%JCC(ZO^9(H;:%. M$)JG[2&:%HX66 QLV 1AU*/ #-FX6%FA@K#C 3M(X!<3YN;&)7K/>8964:)4 M5"8@H+=#,D3+ONE[W9$:U3^2TDUHNDZ'U0Q^84S<&';K&O='2!)V%:,>^/+< MN^2,CN4+_;\P+EX3%+'BA^_NMQ43DI)3!?VZ')ZB;LT3A$Q.Y;!EY;VI'(>M MJ1PAV+P<5-,34V;[@@-8TD%$@ 0B3F:DJ+N'B(*1J1O6'&)WN$80GC !Q\CP MD]FV;U/UW.AWAYPXM?5ZS7"%A;C$/^HM6EO?GK=(J@E9W7,A7 !E$\;&RZ[R MAQ:F/=T$I>C=39@)'7L>P+*&>8)B+&Y>N%9:X#GON<=]4;&[VR38SAO*-*T_>HM M+,H\692\C_+QYRB//\'R>GF!\B5,RDVN=H=K/B_]B4\SV)I_;Q%AB,NPGCZ5 M!&PP$5BB'!0P?TX6GGW)E&7T)WG-AF*/K:!^J1*DF32 B0.8/+SQ<2,1WU2@ M,@%20G>]!"VQ? 8)%JT<10D59B8-1)ZOQS@1Q+O7F)%,!PQ54/;9(*9#!L\: MM&.&@DYL7.GHE0BG WG&?5O<+SJ@YO=&410-(N%GDX9O3>(,O?5C%] M+[SY\.X-?2N0W_S])D<+"./B L> *DS13ANKI"A0OOV$2EC1L7318H^%S]G MT29.2&6A0KF<06;J9FV"KQ4K;XO1]%8NR N*2 *H*-Z,V:AM(.-8[+,=[.PF MUA(!*9L M5RN6P'BG(2(@8/1@%A'T.C.0/ZH%/]=A;H7P"NTW&F-9?Y6S MI%B0_9&;'*Z2S4HI9DT3TS.'*;H6HDF+9=6GA[1Y78BVCIQ%!&G D+("0P8G M'<"%M^$2&&HE\;(=!2<&IOUTL R@.YP%5M0\>VFG'5QM]M\PYBW/C[.8CIF MYYAF,?.\1(Z#(?1DF-GP*\ZW'HO0C(QJO9L"(Y7[R)MN:2Q9J8X5R$T[5R7Y E'FO&(2PG%&$DE1YV=!8R M'E*)X!L5/>-N14X[-?O!>UHXMJ]61K>'RQ57!)P <#- M,++N7#3?X)2KV4^;[9<[],P!V"-MQ0,)CR!&<2F!->5D@YH+')@)=Z) 78DW M@AUY4)6I]L?7:[G/#C%#$/7HVABVR//UG'$(S'-$((VZS:#20@9DS&%J@#A' MS]YR^A3ECW-?-CO$#(/#Z=K8W&CYB]^*#GF(I'REH[(@X5#Q%@#*GAX[G(B@#?,N[>[M[">$65P'M MW/]EO=+-O\J]O<)#?'7[C H7219E"Y>YOS)'DU:BR-Q^[K^L! H[4.B:R73 MT$)D[TU")H#4@LW)_27TX[LYD3@_5NQ,M(?//IA)UJWX6#99/385@UW6=7_L M/\]YW+TVO,0&1TGERWI7F']'>'LWA/A.<#/3",N)%[CD7V2-^XR7P*0\BO8" M[!_"J<0 -;IZ0WH46-CQ[V]C3OX[,JJ>G1PF&7-[L@%$?X"-;%YG*.D C>9H M>T] 35MI/=GJH3^T>%=]4W<.B6=<\1]^RF,MLJQ?_J<@\R>CW MND\_2=CH5_?I,9ONI6,/"@W!IW3.@1?,U MNU='MGU-S(4A6Y;VA$J>NT# MA03-]@VLV8"*3R#O$0E5E*>HMPZ2(6UA( M-WS!@.5Y73:K(8CTE!D\6JD44.ZCM+#T3B=82Q#3K1@X);#*! MI&&N$O0%DZMHKIB84>^M.[U77AK$FW\"!R2GHF!=N+-%1?WWIFZ, M-%%'%]B3I$,/T7Z$K?MD_Q2M5@F;(D).ZFD=TB/,R,ICGF\K$M8K%E'A8;9: MI.',BD;:O,,+$7HHHUF:MOSVD9)(:]F@2MF>Z5J,I&T#COH&'+RICJXA=%2[ M-Q@JQY_9"XG=$=EG<)DL$J7M(%E*.D-+)XA:64BTN0+&UN,<6EF D)K.@@6C MVCG=!0%P?J[+C'8?G&1Y,U]$"D3U-KMEZ5L:?L19_WNT1L5_>/0B?1"1MC+W M ; 1-R-\#>]7T>J#ZV7KOEX6_X3(A!J"7*Y4)*M*46/Q*TOM^1E@U^W:&IJX4.%BE A73T%C@LZ0 B@'#4? V9\:#.;F$>906Y MUZG9;6&:EA9$4V2-PM/=S6RS"V0G3!HPI*I!R_M=(B%FAFPELD;MSTD %]MC MB$8H&=.5-;H?N$V'$/,'Y/=HYA4+:5*:YVNC5"V>D9=H\.*#WT-R.;20HO[" M1:9S8'@_C(CSG:[-0P'_N<&LS\F(/C?1BU0 M-1K71C!J31N-7H]HU(J5GDTB%RMY$^:E);")ZA:J!B")>G< M@580?'N%BN([TLX#D.-3E $J@D]3E\4+*6HP7&RX=U2\*!J4&[OPX*$"ZB)* M=SGWU%E?N78[N#R4H9TV3;N$BC8J"7F^BEV'C?VP*6K;2NJ&JXEOJ MM#7O!ZBQL;%QU67KU=>T$45S5;I'Z'%GI,RKGF%]]J#AW[ZC[;/3GWZ&*$G0 M9!LXV]EBW36LWP0NP,Y]TZFB@A)#!REMX3/C_QCAYGP<_ M@0&254Z ^DZ[JMYZ>\NP':S[Z,LL2Q?1T)W0.DC.AJ73[3O,RK>I3X" 9+43 MH,+3OJZ]V3H?38U?*>@Q2\CR:(;12Q#3+(Z8H&MC1X"R!"V>?FM89&%"RFH+ M&9)4B(8WCZ'[YR=1 >-3M%K#K&"]&:OVT8C)YAJ3GA,9^MA9YO=-D=4Z6 MKJ8<4BE 6PROY_PS$$8&]+M?:%95 _18:1=(<-TT1JR%H U9G&Z3?X*?6RW& MP=48PX[6G3EMSYHH:&RO;Y+#7-ZTCAM_A.IH H[D:WB,PT^J8_K,8 MQ.K%ZNO]*NP69;8KF;5>9/_J0#8,EDS?,:O=QCST&+/8#^">[/^I%T]+TS-X M';U+VE6' ,#8AMT ):9PO'G*(\+\%.. RBYBD+/ M]$L$"'8TK-+W'96U7DUP8;TN$\W9$#(/V5[;2Q4WN#BDT$JXOFS;15$;!HLK M[K/73XB.,8?Q+?YGGBSP3U1 *KZ!4*)'7V^)HL'*:KAHY*A+BBGV(02#6;@C M$TK?,XRKI6@E0!M=!BN3889'"U+J;IN!,UA&2:J>2$]044_,1@E:29J['$', M6/KK8R('#)+75Y @5,557>5S5MY[DE G4WDAB2B8:7!!B5GN-,+Z6OQ"67GN M&SH*QEB?D9:>@E/\D,&/ZMR-I9]L3V"V>,+)Q:_'7Q*E2X;3M,R T"/KQ ]J MCD%Y@@BL,9\8U%[ P(C]Y&3;P(+?$)BC+Y^II#A#JRA1NDLR35!17F]_ FAN+A'992JV[V(@N:K=8B8>9NG M', -)O%$M]U#L/<)*)"YW'%"4Y[&":IUQ<6WHO:[M*,GA9PM6\]7&+ MBIEDLB;H9F^(L .47U@;1+OHC"7W/:4%B<3(9M$("%9K!(KK94>;U:/FWUTR<--E8.!BLY '$%D'!)B-,NV+E[080Y M !E>@I*I"%P@_%G3:3DO-=Q$?ZH3U=:N+!G$Y" MP$EDZR^J)^@J5(WVT]]E8'D,0HB3#T:PDQA\(%+A7N"4#D#4'7M %B;=*='N M#MS;SZQ^Q#[T[=F@V#I&#]))Q"?E(I4$I=]!XY8\_A;ECJ='[]]=1*LDW?X9 MI3'I(GR5K!(N?88!?4K6\N$-*^F%!^ASE:\026L5@(4]0W1LAQSXP/AL0XYV6$]Y=@?Q$_Q,_Z2TQ25+47\V M_21Q"[=QH[1S#DCY>3V>5\,-Z:DP>(RJ@<;H62BMS5!1@W3EG+T+S+7GPD+(R0P:*.U-=!4'8@8H? MJVAIN@^X<:-H2WNS72_KH$)DD2YBD:.CA\D(2?-^H;Y ^H,,!R/RD,^'_Q#*D4T>K.().B5 MD^D"6S<9@269((.Y/R%>UY8K,-*+E#4@@'( M)6-1@7X"_P>I@$QI*@?S3N+F]4Z843M"5C#;=YM)&W.IK:41"50RL4C;DHI. M*=X=Q\I$NP_W.6S#'NG:]KJ[I'R<(^ M 5RC(L&QY#&'$?X#*)^B#"QAC%/[--T"SCX,BQ?!@B24%A8$;5NO&;BT\GK( MY07*JQ&7NST*3C=Y#A672FJ$]=);%1X6ECZ= :%Q-2 TJFYGYD$,"-5#&,W2 M\KZ@F?:!O)B8] HX>R>^>95$#TF:E%LLU<_DF+>,DHQ.V"OH1*]"PRWE:6IA M*$O>O#-6G,EBDKCCIN(.RN@+6%?\#\!B&$&7+JD,+-+5\!Z F';QVU(?K-GR M68^<<5CN]PDC;<$#VV3MX-=P\.B'62U$T*XX +**-_95O1^ *OGD)R&0EB>1 MB <7J?9DEJM@1 3@Y>\=W-6!G9P"(B,AO< Q-0,?FX'SIUL M[_$#JUYME2)G=K)90]G>S+D#CE-G]-P!((R#'$ W )[,!+J^*L,&*NUB-.A* M)UL*DLMKK.*(@@51O]1(Z9H82>N8@:2%K<@W$$& M(*2@MC#!2/LX7,K@8,4CKI?+9 %G9$," EJ*'Z1EWOX9F\#RH'$@D)220E-Z MVM&WI_Q'N."YTFG(+D/-[+KLRMXEZ?&-PZLP6K4KX">SB+XRT+K=%58R2VCG M][N%#T]O8AKQ)4[)+#:4J$4?(DL+V&P^/1)V0?I-%R<9GVFI+EA,9'SEIR%, M;$UXVJPVM'G<&5SG<)'0.POXYQ22'[!N@.,C+"? M:0X?F#ED\)%(4J]XBN)'4G]720CBEHB>ITZ9-11D"Y%]-HJ=*5BU';2E K58 M-&ZT!1L]8YUQH5/XP)^@J1(<,OIHXEV5P3G/T%:AC9O$'8C@ES7,"C?W6(3@ MG"7%&A51:B;;:5$S^W:M"=OK7K,>M*@@TYY=T&12GYX.@P9()@6J6- 8 DU!.6LE,E/3NP:-6RK:%O&U"QG:*L MGIK#,6-1O95(*4%I6&3#[@JGND_V*5II5$N):1A0=D/.NE$? ,(L'-,>0$-H MX'TU!:AY@;$3-C-'!MS#[ ;F9.0?3K%625&@?/L)E2KU&W)TU%M'3Y"TTN<; M\R3=80A3DN]QKB C;/UU]Y8%":EH+E! VD'FZ,W_ 0TK0'G-;AGLY"FXPQ)S MXLSD'\3*R^HD2LDET[LG",LKXL9D9TPQZQ+3T J9(G+F[8AS I05J'CY?%M- MPH%D]12@ZM,QK;O,T(8>4SU'&Z-B3/NV\K3],'UQJC:EJR !F' E\7H51^! MFVA+%O?D,&2QR#Z@CR9E@)Z0K'.Z0&IUBIBAIWL09(VKC6+G%D6TA M@#6/48<@YW,?UU$^U+/8I6=(XH;45!DL1NDN.&Q!7KU 7#9Z(4[+)"E(&]P\ M>4RR*&7A D=56)2WV$RNE^0WJB\/>;K:,4V6A?G73,4#Y)@)/Y[M;-?Y?MLK;3*$TO()V!I9^W=8@8R!U: M]!R>P30NPNQM1U\A8B#(X @?P!GYL/_F#=GXZDV>+.#1#'\8 M(VH"&S%]&Q?>ZQ"V)BQD9H]X\AD)+,4^-*73?\C2?IF(1UA96'R+UR@QXQVB",.^5#SQKY9 [QDW$F5WZ)E OTL M$B1L/E^)0EJQS3(9&3>?Q&O/S$/"^1L9VG' Y=NWRGO/V<;S+;,W,NY]J^+O MHV0T)P$+*5IR("&%%09)D!I#QO."'!.@+)RZB3ZFXLB"K,T M;V.C:NA0*JD0X,X0@NE/[Q>.:2DXM?=M76U;4%!G1V;V)27MOG&QDO* E1].JAU?@;CLG9SZ#'U M.A)/43*&@LT^Q,-NX+\!L21,$RYAI.VP"TC&W<-]K^%>S=WL2DZ319L6ZS.[ M!7\!UF=*EV*:KKIT46 I64@I6,5T) 0._ZQ1 M"U=?F@,=RB>,0OYQ))"4ED+3>CJL\-DNZ6X_4F$+XVJ\ MG#VLYY+;RQAY)#L]TE%1-")L<4@L-DEYD6!&CV=1J53=,$U+KT'W!%D++=,Q MQ]8&YO: 5!*M4[R4*''V0/B"&#/VVCI=%C>DJLB ,4I;\+2X D!<+V^HG23+Y0S7V:%D I0>41=NDY&N&*0@O&(:D,N(T!([S* "@T5& MY"RT4PF9(RC"Q)VKG,$ES.)(<7#N!"5S@-1$7;I*7#'U6DHC"=>4K_0T&"PT M4[Y2L_/A*V?LXD=2D&K(*)WA*SN43 #2(^K"5V)^SZC)RN**?4!.(\)-[#2# MJ@P6(Y'3G%57A<8P46@^6A .L+C.ADX5;-P5I9U':??A_D%/[.KVT^#)XHKL M_94S!UX4H(V<&"4*[VWX(!Q:.=L/6RFCIU;*@L2A_&S-<;)C1_\$Z_K MML*1ZD)A9U ! MU@A9F*C6G76_I]?;OD7"PG E3-U[\]I![:(Q%02BR;2G1*>#Z_G3:,RH[WUS MEC*M39X/R3!'1LD/J"$8?>Z:Y[QFR9]Q1KJ]@\_X7Q!FA*QJFV0Q!8U^O")B M=EHC4VZ@J-B1_?7,8T_D22R0G)J"TWL["! ;I$-6YK<]MBLT]S1N)#6;<=FM MO!;NDY)D99=9G#PG\29*55,6 0&MH#9(R[R94#9DSZ)AY/.M,0X!DE)/:.I. MVYJ^;FO:9@D7Q^CB*5G?H_.LQ(MF]:1(F;09A,:YV&@.T? B M71T8MZ"\11+3,3^2T>K^X#?B>X0]Z&!Z7V$Z,]EC[ZSB>GF"HCQ6S/.&OZR> M:@S1L9+=<4:T7PIAY2^Q&]4[FM1+2#KN7.")%D^ $2=*IKQF)W7V1.COA M%D2Q$'_9T1=EZ?7PPJ;A(!>HO# CJ:EW&5:?/,"Y/JV&)M/0: M.FYI%[)C(60S^W1<9C'$=&+LN73KCY3RYW"!_4)U-K0$)?5=VTFB5K;)6US9 M/CDM%*\8^]LTEP<+J>DO6&"Z;_P&E6K'>N[6NJ/'2'>?@&VTT[LLG*';A14M M+N5EK5_P=CH[KTZMB])#M2V-H?W]GG1DBB%3/"1E(W(X*28I&B8I/# MZV7["?CXA5-4E 65[*&EX$+G!MM<3GIS868Q-3LAIA:%H-VQEFK6!14'-/)4 MME($G&X&NZ7##XGI3%F64Q4GV>(O2] +EY(].WND3$K@- MR*/"6'B[HU?-J_T 5":SER]O.4LR\0:7 .G%68VQ=SF7%;2$!41:P,4->_6Q MJVF6FWB*5!5SW^;&Y#!C:6N8)RB^*Z.\[$:I.QZE3N!CDF7$;DZB=&_7&I.6 M9"=2M9%Z259C-3XQ0?_%S@8DL7!P1YC M^ "0$%4O3_LTV. MPR*3@)D\_2,7\OP+S!=)H;@EJT%=SU:4&WY-=\ 9?\ $J/R2;U2R3U3>6TNQ%ZD$7I M84+&+]>AT64J, MR^MA0!(;,8&S"2LF6+0A@^F$$*$78B^VTHF6I$U.L1?!Z?S+.LG9K6,?P6F0 MO1=C&Y#$3L*"V;RHT#1F009#DQ"?%V(MMD)32U)Q:-K_?2NVVWF>57[6V^L\ M9QM0@HW.0",S37));T3W>^,#S#WY64\.&R-):Q8O*BJ+K,=H3!Y$YR59BH5X M7,NY3_OAK;#]-Y@\/N&,YO@9YM$CK!;C-WFR@.0$/4N\= OHPH/4T+RD. M!QA\P[9J6S47$_;W+[=5BA0D"=Z*\EK$%Y$6&UDCF\R*HHF1^S5A+2 MVF;H2X^P>D9J,LAJX/S5&*3Y4%L_Q$N+M@,E$L'$6V79_!BXHICF8VZK7NDE MQUQ=4S49=;6P_HK,TGSD':R,>AFQ=Z &))C8JRR;K^1"24P;^2XOQWK)D5?7 M4,WFNQI(?T5&:2/G'2C\TK'SE[@]WB\7FSRFV>\"LE"."J5%\EU"Y&77A96@ M[?.;R+!%VBE5"_1XT*GU62UKVXOL?@*-XSA.R ]1VG0-TNI$95D0+Z8Z*I.# M@K4,'W:HUL1.\W8L8+5XQB$ ZB;851RPH?MJPE+__CBNC12XMX84::&G7HPNS&^J MU JMQ094;B_[*F9..;L >+JQUQ?"]\VHKCPV/;-G2&'N>UBU-#NW[X80?(E6 M9?6&7<\X]VT[HJMO7[L..U+X7J[U!'(:W5[>CH'(R.QL# QB]R(-RN(ROV>5 M.TMY!2V>TN%IM"_L391?YW0^X_L)K3W6.[2#$TDK%IX?@4F9RR=9=*#EOB R@_( P@O/[^HN-G;EJ=_/,.O MIXLHR=TM]LT+';0;3,IOX>8>)@U64?XK+'D>@*,TC!9/G5#]-81H>8OW$,,E M+>-?UNW]+;![#D@_ QE0!PQ$A-13@3%RS (8_&(_;.R*2;B_@07 M%AW5S\&,\?5G35P$>_&%7>4FN=?MW?'>1YB^I9@.,1TX7HA56 HR7$8G4>8X MI=$ QL/:/?]"?E1:',I2U+(!.>+F?9ZR.QRH^H2,HT_W5X00Z6DS>+BX,]8L M@= MSXH*#^A\K]A M>0L7Z#%+?FMKE'VIO^13<5F/0FJ9E3=YS0>6G[.\YCX86;P.@_)OO2@ 868$ MP#VW5!Y3JZ< _#'$H;5^%);2%'Q?IO,9\CCX@R7 #P2:)^H0Y=_>W?D)>^DU MN1%7ZX>,?[EP.*]*4[+ ]C&'A+2;[ GS^0>>SQ\.E* =B'/KI"!MJ&"C+?3EJ^C9HMZJI)U2.[*)%D5;D3+3ZG5>=[ MV)UJM@?,[E!Q,JNLE_2*%"*%E(H4(@Y%Z'"K[U]+6$BBD/L!\J1HTH MG%!1IX'8 '=Z985LAU8WUG=:\#$K%-? O6!=>*[4"MH(;6W> M"NQOM)+H96K"6X5+R&9G-RML2EQ$.:%2<4OHM92U,B<;8(9[E5--],!JX[2> MXH55-V35O$J\NZM0]G: MO),S[Z_[/FQ@#>15C>8KM_G WQQ!7H/PTM^_NX4K&9@$V[M[]LKM;L/MR7M7 M6>C I&B_.;7C9(F_O7SGZ1AT._4Q*F MLC*G>K]-BE]/MO=8!\=?$J6NUZ-DM#QXA*+YMT:'&2#< &'F\^4@ PQ24%>8 M(*1"_>-(1EB!7PBSG3,Y-[Y !#A#JRC)9OE"FXP9&!J*7Z MU/1=ICZ?HA6\7G:>3SWQ&2&BI6XAO9=IT-,8(&G=A*AO;N6$"[A>@JZURZ8W M@CO3%9DC^?QD^'OJ-S1[)*Q<#JZU=.3OJJY(Q6A,#X&H<9;3<]X.]\SWKKPC+?^/:.OXKYGO#7C&4;5.>@9;XUYAE%9>YXAEE+- M,]YI>L:[^9[QSH5GO//O&7T5]SWCG1G/,*K.0<]X9\PSC,K:\PRQE&J>\5[3 M,][/]XSW+CSCO7_/Z*NX[QGOS7B&474.>L9[8YYA5-:>9XBE='.B< -S\HOH M$2K-D1^G8V8[NT72]J%"CMD=D,ZFG&%09PM#$(T=+NSH+5 XQ,<++59NO"*' M<5*:.%H8)Z0'Q!A-"XY!V05[J""%%%+27JBHI+J V"F'W*S7:6+D &Z2E%Z% MU3A5"Y>'.<-0?446,:2HPW#12?6!L5Q"_!-"<7&ULWE-+.F48>I/8<,HX1V%N2#I:_Z6MY;>"N/;I604F$ E@:TQ &5 M/* E$"T^K6*!P[-+5<55,JH?<,[EY,0NNDSM-O%@QA%)&,%B M")V]-8MYX:*)%;..?BLRJD>_.]_3:,[;)6&G+W2E)8]'OR(5HS$]!*+.P27$ M_*-?*[+V$NJY1[\5'=6CWYWOZ4-I\^BW1M/CT:](Q7W/F'GT:T6=@YXQ_^C7 MBJP]SYA[]%O143WZW?F>/I0VCWYK-#T>_8I4W/>,F4>_5M0YZ!GSCWZMR-KS MC-E'OSJ)\$39#1.,D-F!S-49 K@! M/!_W M(2O(CGKWK[]0>?R><\XR!V0$BGV#/K6&NDR<_71Z]/[=1;1*TNV?44I:3!17 MR2KASYEALWQ*UB;3H&Z#PD^G /.?F?0!W[7'1, ( GUA*7L=C@>T/3L]89-V=-*;-"66VUU828Y$(12U8** M43):T7Z$HGG[$09SGR]J&6B0@L+"A"&=0,!E)8+@8=4+#28(F43"5IG /KF$ M^'A?0FFA@C'M&+..W6^B+6:3WN1H 8L"OWW.^6'_"&\T3D!0LF,"BXQ/X248N&ARQ#^W*,K!WI*PN[:5E8)2;@ X9H.AV:0">@LZ^VN/%'CG1/-WF.W[-6^FU4_$!&&((UXP@.Z[?' MF@6C&4_5?I1N0#U-([RD728P-OJ(O8/ESH/AEV'[R7;0DMO6O((8?*P].@JZ MGM^I5%4W1D)]!TA,SAQR9TZ)M# M^_LS;:$AY<(0(!M-$I 5#$ Q: )]/5FNECO;P'O4"X8L!*HD4F-4M%ZW8H(6 MEL";G6@L>,^XRHTD0$'RN@H2@+31_3T"_04'9^5D@<''-)%)61=0;>6^\U4M M5?>HF#=P0A6;=1*#)U%+M+R,;Q1%92V_5IKB/Z1M/J"$JWW&XY>4#5*XBVH:3\;7-@ M:1[9GF:YOLYRT(G0:5O>B@^H&^PHOEHPB$M6^I_ M]U# ?V[(@=,S>1\[P5$\"X@%\J/IZ[VTW@@605 M9?NV4I>Y^F6DP>^;,!A;5XEZ%A/$':$Q$,26,ON&CS6%"[Q3I&LGEKU5'],J M)&%$W5M;XUEWU$Y8A63??2A&3'P[>RBK5;6+#)UP<=K4;_ T)L[@:Z M-UM3NC"1<=O%?U5V&4!4^B(K;X*P-EP'81$-J] M0/G\9_S77_%_X__"/Y">MW_Z_U!+ P04 " #X>FA+XUNP2:PL );0, M%0 &9Z;60M,C Q-S Y,S!?<')E+GAM;.U=6W/DMG)^3U7^@[)Y22K1KD:K MO'!Q=7#P=3.\2OZ ('MDN"R$?_]O#UWP_^ M]^S^YN &>]^>K =7! [6B O/#@\> G#Y4_OWGW__OVM,P]L\M8FBW=S[%F> MC2WW,$#^*[91\.[@\' SR+F/K) R>'!AA>@@_N>G@^.CR:?#R>3PZ-/CY.-/ M)Y]_.CYY^_GT_>?/D^/_.#KZZ>@H0^#W9(('F7\H@; MT<'U1>;7)I/CJX^?/GWX\.GX;'+R^>/[TY.3R\O3B\^?WY]?'I]?'1[1?]Y/ M3H\F'^D?)Y\FV8'/R7+EX^>7\.#?['^/6:90>!YR7;0ZN-I,^C\/;F[.WQY, M7??@GOUR<'"/& [(>;NFY6Z I,OE!;^\R8#XX\EWWQ+_^=TQ9>/=YA??)+_Y M$_M_P*__R/W^]_?Q;T].3T_?Q7^;_FJ BWZ1DIV\^]^O-P_V"UI8A]ACHF.S M 0+\4Q#_\(;8\7(*\'50^AOL_PXWOW;(?G0X.3Y\/WG[(W#>4,@.#G[VB8ON MT?R _?>W^^NMX>91@!;(P;;EQ@+(EN;H]/W1._;+[Q[18NE26;M)YLN&^>G% M1_-?WLS_6CB'FU]F8_UKT>^&JR7=* &F?T-G_JX!.Z'U@WADL4KXVFRCS7^G MGG/IA3A<77MSXB]B5.OXO:>$_H00*IS,TJ<2ZH7Q+[*9;_TN^A$BST'.A@+C M7=ET8WXH1RZQMV:^'BZ6F@#9;Y_)ZSL'83;6"?L#0^7D\&BREIE_I3_Z\]&W MF.9[6"V>B+L]?Y<)+?$W/W2M)^3^\J;@HW=M,K29^155KI;[=V3Y5_0G@2AK MI9\K9/(.^9@X#=C<(M JHXGPG)/%@G@/(;&_/;Q85(YG41B?;W0113D6H:2 M]2OL(O^<*IMGXJ]@O.Y\J@+7R/?I(MZC)?%#MB&H=A"7@6H:"MC]G;@156!^ M@@R0S]S'"AC\@UH)?_/(=^\!60&UO)SK((B0#V.TE$BK#*^7C:N92\]AMIHH MK^7?M\KFE"H9)U8TKB6\U7<^4J(Y$Y4'!*WD8R4,/E)>H'PEWZA0-)2X;[G7 MU,3X\3<$U(.YCQ4P>(^><4!'\<);:R&,6_&WI>SE+3OVDS^K;*7I$Z-LAR(< M 8BE+&:-PJEO;XUB^?9F!/K'G$6X;=RO?^/=TF)JX=!^P6YJ3,Y]L@"QM^:" M5*%,? ?Y]/Y++R]';X_H)7A)]Y1/?_&7-\=O#JBU^LL;LF1D+9?]'9HCJK"< MFP2JTFG$5AQJ#Z-4)%"@X-# M=#I"1.KLQ12MR:C(MQ5YZ4V 0S8J]&W(-K0)_*H=K5/;%<&6\Y!RL4=UOP-J)=G"(-.CW MG]_MAIU:BZRQ\PHQ+,YGMQ>7MP^7%V?3F^GM^>7#KY>7CP]"035!&MW%T^H8 M%/&$S:W@*5ZH*#A\MJQE/-8[Y(;!YBLW.2_A>'M\2SD^LMA.=J.OIP/H>S7O2U=M0E^*X@HIC] M6Q*BX,Y:64_,$HW/P3O+CP%TK2# B?5?!JZ&,\+@,Q97$5%WP0*+R -IU-#4[58!0$*00?TY@OE MI\22!)C:+?%PLN=R&0WE)C-9(C]+.D][O+'$GD!HB#-PA?D2S,O1$[QE*Z]5SH,\5= <=G^3M.!=(]LA%_9 MB4)';7 L%=-1?<^R@A=V,Z+_87OKU7+CNU)X;OG^BMZ5X+=S,8(ZMZ[,^51" M0 O;\OQJ8S3UKL[F:67/'3MJ@)EW,'I=! ^D9DS*%X8'$8Y-B[/42'$.E-SN M2K%Y?V0V-F6*B8#U*(?L\^ AJSY(4Z1.#-]X DAMVTDKM]563#:5\T]V4ZR MAK6X!S$%\9.QZAKLHBT&LMPB_V2LKA)PSQ?8F+LQA!2HS\;:4(V *HD9I;"= M#F%KBL%6%C3D6+5O6NTE5J"(,4=OU&1U"00;K"9'QII@,*RJMB.US4PUS9I8 M%=4I02EXDR'H_28F618K8Z_43;"J3/'CV U!ZX.Q$[DU3B"&=PGL5T(\YO8X*Z M*J#;*'&#V]^I@*VX-Y)YG=V:8B=DS!G/#[.KV=WE_?3Q>G;[\)MG10X.^0T#Z'\2I-HG M)U0=RVIO$7\@]B83>T6VT>$+^;'Z!W8C^M-$='$Q:\86IA)\<(V=6 M@.T6)EI&6/$T-_&2S4F_QALRH5(2FED'KT0) =7]45!X[=$]CVY( &HLL/.A M8C:_6-@+V$A4*+W+'RQK(L+!2W)F7: GD+= @)CRDG%Z@J$@7%?N0)C/?:J8 MU=F2*@8&D9R8%'ZNB^4U1G(,\X_5]\[P$36YV-D-X73[.PT;D"W>S'NP7#2; M;U4-I25#T%TH0E&UL+"2N2_(HZON3CUGZBRP%[] PI[.E-B?8O1T[P 9IVH% M$=7"YE.YH/(PA_6^W/I,>0@KH(?%/7I%'K0AY-:'RIN+QN. -"#_1ODIR(Z$ M]%8A(Z.E)+J\3M?-BQ1A;?#[&!*X[.P2@WOP2X"SI>=4]OGN2884 )J*,XLW MGS#6CU=_[!.HH<+KOXU52R#41*U6CEM[&NLTP*VXL1$< MV&[,7SMY.7/["FN/-7O6D< +F=N/H^X?1#G7$"\C;4]Y]TX)00RG>LN* M\YXED^FSW_WIXB/W>._>T=+$]I[$LV-\DO6\B'RJE)*W()-UOJ\+'J_+-X&]%QE\2C MW0CA3;:\-+G@QNV5$HR$6@%&\TCI&Q?ATQG45J52N'RM@VK-6G4G$IR>; MY/ 8VU5(&)X:4XCGQQBKF(2A*K-Z.48&=_825MZ9>PP'QE@U5''Y$VQ I:#2 M=)EX84++#_<'HN+2R/;3\O82G,:>):TEDWL()<1ER?/]C(V1B6%9$L0_.ADX M+N4Q"IZ\U_H=)M%KEUX?,F?@*C\/4.LY#L4 =1=$G3[\>G4S^Z/5ZNYRHKT- MF>8YUE,AR:X[L(*0['>JG6G1DJX3 \URV=N'5R[Y?NW-B;^PI#M9B9(T\JE= M34%B0]\1+N8BL9RH!> C*T 7*/EO\]F5T54?X&>,W/GD%5.U=[;Z+4"4BW7? M$N]Y:H?X-7G$NZN']&?K7.'B0?-"&@T4BD0^3.#_80]Q&K*:-@VQJQ&V#86ZA!J$/,A4=2W@.3 MRVU!R4WVP4K(K$%D>[W6+6X"\(C= ).6@BC?!,(CJ:^4WCIEK[W-BT7G]';V M#$N $B#6V70D"NH%B&F?3OYAO&8S*J+7Q:3*'TEL/+\JTEU/M=7)=3"=N^2= M\,V^*'POO-D(]L1*]?K4EDEI[V2:5GZSJ6+=G^ M0YBJCJS=,\J#PV+45/K!_9S**(RMU<9&5;GZ>7'VM;8)FRX(/;/_B@=+%OP" M![&RH2?$ D<+4/YO/3'EJ#8B+'2N.H:__-IC--Q&'( WS0.;9XF!= MA$7;QXJTO_8\0\38)SQ;WI@"F1#'QB:8JL-2S='$DW:,3615N"3U]A)/_AG5 M!QC?D@Y6)\;F$ZN#$MQ&[:0]%=V[#D9J819M>/2A/8T[((3+G#8<5G.3ZJL] M7D3.3<<; QI[0DGX0BO!+'+G?M%PU6C&TC*!8'XM"VIQR- MAS871N3-+T=-*8?A;IR9(VJL2:\ T5QF H?16+]*VS#F4E9X'U)C'2&J,$RS MF#B&!A\S2KVEC7+B>+?8]L^GCKO%=A$J "=GL(9D!_,6_X: MJZS5(=TT_YR#W[ZG98!J!EP(P1LY&WL-:;E*A30KR>& &VM>MP]X.Y2SK:/; M5_4F:QM8#2%'>=3IS5'.U:&F\+8?!>Y'WY;N0=[ME#!I/TK[: M<51RIS8Q]BP*L(>"X (%MH]C6:#JCKT\$C#KE$_^D4[VC/+P#9($*T-=]6O) M_K/EK?.FN.9*&,MR-)NOS43+Y4I-ZF7E=@;L]'&[5C$CS>2#=PK5T-)*BTY[ MP,\>GM/?]$US(KU0*,@VYE2-D'U)D2K#YJNFE'%Y5M58TLI.E&*JDM8%[7+$%0C523ZH#T*^5/>FZ0X),"YDE(=,+KJ M&[ 4,R.C1P2(=:E.Q.=*9%?+/-T2NZDKFT*(WL-J"?5!SU1P":S+*Z&T ND, M44K*JY.?,O(NHQK**'2I#VIF1<3A-V_;LQ<;<%( QKRA<;3D&7D2%Q0!2GW8 M^%5LJG^*JF3DAI8&E+*&-[=JV9%1+D#"7>H<.0R(_)J:IYK*'R<4=9G4O&[8 ML9\DSYWNQQ[9B==0]0"(PAL>[)*^0/3:CT%7%E%*'8;=1&=9V?2^%'7S] +5 MA38=0BY*5/QQ'_3!#F>JC^C,8/9NTH]K2ZO)$S)9(K99Z&>8B> O2/B(YRR>J+P?';DL_[H%%RO*E^<&5[ M.+F+1SD1L)F19&@W3 L1)M6=82$^3R($M(&;O"JVK")S8^\R.#1EO8I,>OB,4FURR"5*4,>>6F5EPB MS5K.46%CG#184 %BZAMCDP5ZM'XTF$4Y#>7,)PU3FNRI6J,-;D^1Z MZ,!WBR#!;EX!DU\@08+*TU"H@9#4"U%(72L(XH,FUD1I*\I,TB@L*P5*6_%D MKRSLQV4DF?39:X]:6E'FK(',4)"@XFEMGF2G4,"J_!13*RR#$ M"VH)@[I<[WXYYG]JR__#C47-0[5>"K47,@Y5.-!(.J!X9B-FE_> M+<=1',\!26D)]B$]4<-E1$56[]6%C59@*M=)N M59C94=!<>JF4-JDCTP==4LJCXO FB1LCLE;!5/BP'7?8H9S$-D&P;E^6L"(7 MXI2BKSK,:;\@)V)=.(M-GYC#Q/YI 8(V1FLM93T1JO82UW?I]2]]O63&I-T% M,MCWVQ1>.16@U37<0;F U$%61:(/AU@A?WIT.6L'EQU]-F=)YV25ES7NI-;3E477(5J H=55)1/( AG\R^$.,$CZY_Y%2V>D ]COIB" MGNAGQKT+9[VEK: M)[-*69C^P,TV<(Z6[LD$B\)-9C"F@+4W-T^=RY0:&$7;N364.G,]A*;757M MU>/.$T]'QCXL4".352#EML\ LA.$]5$E<+M*E -G[&N5PJ<2J3T_.5K&MAN6 M0:O<3N*A)V-?HI$!K,PFYF$F8U_4:*#U,[<>#M1PCL?\U;' ,0:Z_'(437'< MY.O@US;8K>6S'[RFDB;=(;R,8!^<.@+ M8 ?.*_LA]'I5_+(0:PRU=HY3^E0^YG0KQ\TA@MVJXHI+EQ1MU=%H:[5^82+F M8,.6\,3$Z*@/J5<#"PRIUQ%3[;W:((B\!'(+HJFQ/PG<"UOT=4<-5:@- MF_D;J <60K5U+2+L; 61&]]&Z4VK##68$:! &.PSEMEG FV(BG;_ %S)$BJV M!,P!N9$K#E(B<^X/P)T]2[8,O8@;[W67O MN;N=@P5NWUJ+9/8.10&_C%9__/X!6.FBX]@95^36 #MYOVV*Y_O6-_,K\I_( MOB):XJ?G< WT$*X#JU&PAJ.KP5;NOFEDPYBE%.T^A"]AC*MU?]U@ZPF[5,2N MB/\;DW ZNA?7]0=QK7IP2^4^\MFF@3BY0&05>_AJ>3E7,+]S39.;NB[YSDXZ MRL@%B9[">>3F\Y0D9@@DK*'GWV\>]MCV<:8+Q@4HJ[?HK4TX-@N3UN#C)96S.!*2SE.%HW]VT3J?AIYR?KC.M2GE%6BZMS1F M5QVXOOC 9/,Z2EU-).],;C*9&VT9M[/Y'-LH'1B>>%M"0+4C$%D!8AUCKA=+ MG[PFZ6APYBO)J'XW(:)74!:BH M_A7^P/TG,H(J*^@?0Z84:^0V$IY1$5]OX MD3(-SSD6(M?5E,Y6C MH]K$0.6V=U,H!AC:%$*(AU912?*6X;\78 MDFWP5A#I[IG=R@-X] &B(86:HV:4^P!28R%G)A$XXKG#Q;@,QH:05=ET \@I MED2MTI8?0%_&4,S @*C5WWTJH]>]>[-V[:]ZL9ZFC1ZU8W-CM7C53?6":7216QN M+$*?ZVYX[N)*Y\BVA:\PW;C[BFM%7J3,+<[@Y@F-P1._W"LL^]]O%$4=0"I\ MP1WWU"8A"NZL%3L",AV*FM>IPPGWP;T)X%IU>UES89 M]O('>[D_AM4?LV40J A3#,^3%CRU:;O+#@ KE M%8J;9\!\?S+TNYHT9^7.QS::M#+3/%&]T[-Q65#B8 =:Z7T]C_KO7M M,#IV5@=3A796?T3>'?+9:T;TNK7 04#\5:RM@0WY:^EHU?:WUD(B@%=.0ROS M4/$H^EHKP^#P6^'G&ECF5TR9\%H9A2X]+36S(C68#R!F5B6JI? ,)AI6H7E* MP\>=F(A1[?V]!JC[\521R,OWS!6C]?Y M:;??JZ[T*'.T#.RH+X$7++"@LE1H_V2M(LS$@3*V-Z8\4%7A10Z45\ M0.8A0$QU7T(Z.)>'U45B#N* N2_9?A>?2QTEO1-A;EH&X9SN) OXODH-I2XF MB=R8WT/(AQ>83K0,Y..!E,IH 6->U>HQ/PI6A?\%B.F M.B4EM1IGWSTDD=Q10@"*[!7Q%\BG2W2%_04PBZ#PVS')9&^23)2DOS7.=-,D M2$4'N%PE>1VE#B8"%:=R&BUJ:N'$$T%"ZAL0EYKAC3)3@(2[O+#*84"$E]#@ MC!;8;B B>W$ &2ZURJP&J('5=PL>8N41OP$DNTAOQ#'M15?:B[E=0*O37LIO M40/H[BF6$51RS34X8PJLKP!.#8/SJ>!^(@+Q6!G<3:%-Y')N2XZ;<9W_V\7N\[$:@5<5P5284UJ$FI:0 M_$-([&_LL0,J\:R5"S70FD7BQ0GV(0 OP*UBERZ=/5DA](#\5\R2>:E8GUD! MO!@0MR1.ED?.]+OE.\$CZ^^=_?MS$H2W)/P["N^139X]_!=R.*7D MHUGX@OS'%\N;Q2(*\QEWQZ3JB(8;SSS+29;G=?82*,0A2%%U<];"T:=4J*D: M3+HJ\E^YLU9QE1E;@_A?O].%9*_[(JK@'%!/DW;'W0>0[O'S2PC:3JT.VU>( M$FW*4^!R>_OW6%E<>\EBQ^KBRL+^[Y8;P5H&=\3AW@+_A9((@\VT_D!,D*@" MIB:(]8SBOV2F=L_6 LRT(.?Y">@2C?'#5$N!:04#'96N6OZ^)K'DQ 6B. MPS6];BS9G8-B1"@@S 'A(YN."^W#(D!)=88L\JBV=%GEG[/ 'F:A?';#69ND M\&P>08+*FR;1FQZ*]W2<:B_=M:J&4#?3@*;W5))1GO]&)0#;[.[#MAUL0A:YI,]3]^Q4YDN7_@\"6.B#++Z@4O'\FE%V*9'%1>'K4P48&YQJ#!%54K:-!I!<7*AO"@ 94 )QR5E!Z@\Q@S.& M)?=3C0DR@!1A,6N.U!J=//O56%U=;:^3RJO$ -X/ VZ]DBOB %KC5=^NJR"J M&5+J..'#&:B_@]MQQ[VUORX\F E3L"26J_;LILI^-W;-*'?-; M!4N%80>.\+BY!8)+VUO]LXEPB<3HZN':W<$3<]T48K'9;.ZZ6$B90V>L6=S4 M8!'(-TA1/#861:""*\D:28'Z:.Q96YUP [%FX+E$'%YC.V<*PRN4JY8"]JEU M>>R^?$>?1(+3'CGNQI[8O4-=(-67+XNQYU@/EJ4Z&YZO@;$!%/5K4%3?P8$U M-OBB%]BTN"A%UEP/BC"RHE5K'+/Q!.RP*I(O@RFMP?.%N _18F'YJ]E\G0T2 M0Q$?_W1OL^D^$D:5N?>F7N*Y2_"9VB&],J>5O)NEDZY?;IN1?M8]MS9+#.Y<_D&_C@#D KKW0QUZ [=B$@5>Y*N*BZVSWLC-TS?HL"H/0 M\AQZDFZSKJ4@J9X):/IG4U:FS\\^>J9'YS8CD!0\/7SHD*MVML3.E>\>,0P-N_V#&LA9WX&N#)%TAS*$K:XA M-O88- 7:>^*Z<^*S#WN(\A9W/0<\8YHF21@=V<6;P7L.5T8"],.5&[PO5BW< M<-0K907#]QRR O-/)V2%PROO 4#L;]=!$"'G(O+38&R2$I:)*:3V&@P1">H] MEY%MB^J+3P(]G2:KAN\Y9/U2W_L$%[-IKCJUN+8X4 P<]WO.YEG&UX^5L,!\ MD/-/2_EJFX[4Z3OF[:#41A)/C;CP^A-CLX@5[W4UB[31@_RYAM;79YF<\Z'E MA^,J-3W>^2L'XSYJOD(2)BDO*FYO 4Z3!?#B# %G6$N@XIZ4KM&'<8UZL$:% MU_]TC5HL*QK7J'W/5KI.GQ09!I?>N%(-7;:\%MY8HZ#7-QWA4$2Z4*?&+E2' M\2?]BYO)]9^,]Z8^K&N;07!>@3_NUGZO*C"!)%W8\1+=\X4%)V&E2]OB]7Q< M6C5[%IC,F"YMB[?Z<6F[,YYV;Y@*&HP8>L/L<&V%$^EY9;RQN[5_=]*:NA%> MF&SLFBA&L&3)GNH'? )OZXHZJLU"'H_1U-XLI%0-8KJ0YEXQV].2>BIQTR4Q M[W*HM:1:C4&Y6U">KI9YEX).5ZL=19AKGY NEPZKL.O6*+QS<:9OH++^)Y#1 M>M[D1&@J/4W/LP[0>^NSSM+;B[+[WT =Q=GO86W'W0P"; V]]K MO,Z^#M7O-PC@44) ,=LECY"*LUU"H&NQ;O)&J]*>A57C*P:-#YU].51@MCL? MJEY;@<<319:HBLS8Y,7,)B]5:\X[M1C[B%";KZ8;"5"Q"M3W:OJ1L<_4*3V1 M :^F'QG[7EV[CPH?'1NK!7OP:F7Q%81C;ZR"[>B^J7=1<^TIWI^.-?+[NJIE MKRT?G7P:-^G^+>>N;YBWS/HP+N?^+6=!*(4WV!I/T3U%>#3K($N&]LUJ_NO;+BNP:_-+4IK1\O'WWS"ORG\@H^E59>;S3F(97 MQ8>)?5$F*6\"-FI[[9G/O%'7T:"MG=[F](_MMCHK >F96&3[<[7N$>J7@=8' MN'OB!X2(Q&VQT39DH$+"J]+$KF=G2 &\@P25"4\+.'Y_1K+SR/@I LJ*C^@<.7:\_!K]B)+)>J4_;[ M%*G9_)&$EGN/7I$7(=8MQ:+K]SPYFOE??$01].6ZR6CDJ \=9W1,5W'V='8& M]SCXQEF<@)*H*^FH3@'?'3Q_Y969PHU ,GA)0>%F_4_$\[J+OY,=^+WDP.^; M#GPL.?!QTX$GD@-/-&7.L^RZV?RK]7_$WPP-3W^O(**8_:TQ V@B>]'7JK/9 M+1<%:_UZBT)X@44) =VZ[ QY]LO"\K_!I:6>EO;)K%(6H")43TOU9-;BFV,$ M+EJUI'2O"\L";D&^LF3TBY9,A4TE&>VK "VU*:, /D.W[-BUY0EN5%!#I;.. MIV*S(_6P#J"0I48FJT#*[IP!5+2(**!*F>E(ZPD#_06NY,I!:B]'0RAR$MZ519?>[7UX8B) M%9X"(N3)X-4]QN:EU3N#2)F;BJ-CK*T 1^>O_9O.I;9/("ZEU:"/\&K]> MA<.7HN#H/5KSNAWY+"+11CBZ S[[%Z36"<(8NM[CT/4801XCR,..(.<5&SS2 M5TYCC",/-8Y,C3L]Z&N-##_ZEA=8=KPKSU;9OX'ZW"%4 MP:_!KO4#- *>^TYV8&@$//>=[,#0"'CN.VVOC\5ZF>KN6^(A>M*0%4(/R'_% M-@HRXK#AK\D[8W(C]0R(L]6&0>A&:SJ2\F,F"&?SF+6XH89$%+6$PAB?'VA\ M?B._+43H:TF-,?HQ1C_&Z,<8??>.FS%&/\;H.XC1UYZ08Y1^C-*/4?K.HO1E MMZ,Q1E_8Z53NCCR >'Y+#HL&H.]Z: :0(-"2NXR4>?L&D$6@",(AI1HH@G#, M1RC2BI"XR/:Q\]%$X"2"3R5@YHX-ZC[?8O0&7K&GM>(EQT2ZLNA_0@Y]X@UA?#9KH>$,(J^5LSP^DT1]GC,%4*@ M<%'N4\6L7D3HD63D'Z- N,J*E!9O?.)C9 37%%=?AT$D475&Q,:JHZ2I$4WQ MUI:RQ03H=9,7O,FUCX^=[.^TD!U<05O?9"G$TP6#_]I+@FMQ*V7)V941@UI[ M]!(6^O@IHH-.GWT4/\_WB/R%L$E73J -5BZI*6BSJQ_HKB1 J1L9SSM Y&7Z M1KX@@FY_>@-W8SN/6@?>\^7:*7^&/#3'X=198(]AF'B+/&?-PJ_1PO+.K24. M+7?COP>[6O/2=BR@,%UYY-_"5)!!'(F#A!**NWYY.3]U?6 KNK7XG+/%+!#5[@ M]8IXU/QZP4L@MR":BJ7T.G[@E?CPE.O=+Z'(/B)O[7&FRFF!@X#XJ]CF Z)9 M2T?K!865>\,U53D-K*^N6FN579L'D%0KH,Y!+I$4L@^M M;[Q7Y#^1?0%-W.O%$3,V^5$ KS+W98K.1V.WH&KS?C#E52)>_7JX-P5Y])^,O5@)!Y.)>/R;PZ:AY^8>PY:D,J1H?9Z, M:('R43ARQMHR#9$3S%-*@3PU]M20 5(LHVT#WL1'79C2ELDZ'YPRMA M@^6ZDL.9.O[=K\57U65 M;0K:Q_'$+=BR:3DUQZGU4W6?<2HJDD^A^C3>OHA %P2.UWC1*L0KV\$B!>NS M*?U4'J*G /TC8J[N5Z9R&O91$277A_XIM;SJ>I."O9V$J%0F6X(*Z'/L1#]; M\5]9GPC3[Y;OW$8L(D;-N?CJ,(W"%RJ"?W%D8,]4M#:X\F<&ME8KOWF%WA_E.OU\]($8&(>_.M:#%3A445'>]H$/)%;CL?JF)46C]PO9WRJOFTVN! MS&,JN8\5LWOYCX@>5VS3$X]*'EP&2@@H;VU"S]\X(+L]? !^GZ>:D%XE)O-" M2B$!O6S+O8I2040_^V"Q*2.AF75P>5/A]WJ9EJI:*J?1:89.W;/ .J%Q"Q)4FOP\@=0C%7D MU7<%4GF-X? 8&U<2W7/;U]$!9-<7WML+ !G06T(E/A=2[PP:0'VBI,%X4Y#. M;FY=8JW_L_"MG]:\NQQA#39Y8>3CYW=LGD^4Y?_Z?U!+ 0(4 Q0 ( /AZ M:$N*C30UV9, 'HG"@ 1 " 0 !F>FUD+3(P,3FUD+3(P,3FUD+3(P,3FA+A&/2P]X: LRP$ %0 @ $/J@ M9GIM9"TR,#$W,#DS,%]D968N>&UL4$L! A0#% @ ^'IH2W[8P0H!1 MT3($ !4 ( !(,4 &9Z;60M,C Q-S Y,S!?;&%B+GAM;%!+ M 0(4 Q0 ( /AZ:$OC6[!)K"P EM P 5 " 50) 0!F J>FUD+3(P,3